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Abstract 
Background and Aims: A woman’s cardiovascular and metabolic systems undergo considerable 
adaptations during pregnancy, which can affect a woman’s physiology long term. This research 
aimed to investigate whether parity increases the risk of future cardiovascular disease (CVD).  
Methods: The systematic review identified cohort and case-control studies assessing the 
relationship between parity and morbidity and/or mortality from coronary heart disease (CHD) and 
stroke. Two separate meta-analyses for the outcomes of CHD and stroke were performed. The 
cohort study was conducted using data from general practices across North Staffordshire, 
contained within the Consultations in Primary Care Archive (CiPCA). Due to the short follow up time 
available from the database, the study was conducted as a feasibility study, to test the potential 
methods for future research using electronic health records.   
Results: The systematic review included 18 studies (2,869,391 participants), comprised of 13 cohort 
and 5 case-control studies. The adjusted ever parous versus nulliparous risk estimate from the 
cohort studies showed no association between parity and risk of CHD or stroke. However, cohort 
studies with a longer follow up and the case-control studies were more likely to find an increased 
risk in ever parous women. In the parity level analysis, the risk of CHD and stroke was not equivalent 
for each parity level, with para 5+ women having a statistically significant increased risk of stroke 
(risk ratio 1.21 (95% CI 1.06 – 1.39), after adjustment for several CVD risk factors. The risk of CHD 
was also increased in para 5+ women, however, after adjustment this estimate did not reach 
statistical significance. The CiPCA cohort study comprised 20,513 women, aged 15-45 years at 
baseline, with a median follow up length of 3.8 years. No association between parity and risk of 
future composite CVD was found.   
Conclusion: Parity may be considered as a risk factor for CVD during CVD risk assessment by 
healthcare professionals. Grand multiparous women should be informed of their increased 
cardiovascular risk to encourage healthy lifestyle behaviours.   Further research is needed to assess 
the association of parity with CVD with a longer follow up of participants.
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1 Introduction 
This research explores the association of parity with cardiovascular disease (CVD) and was 
conducted as part of an MPhil degree during an intercalated year of the author’s undergraduate 
medical training, at Keele University. This chapter gives a brief rationale for this research on the 
association of parity with CVD, presents the aims and objectives for the research and provides a 
summary of the thesis. 
1.1 Rationale 
CVD is the leading cause of mortality worldwide and coronary heart disease (CHD) and stroke cause 
85% of these CVD deaths (GBD 2016 Mortality Contributors, 2017). These diseases pose a 
substantial burden not only on individuals but also on society due to the cost of caring for patients 
and working days lost. Substantial research has focussed on the risk factors for CVD, which can be 
used to reduce an individual’s risk of disease. This research has found that the established risk 
factors for CVD, such as smoking and obesity are not responsible for all of the CVD incidence 
(Newton et al., 2015). Further research is now concentrating on other potential risk factors for CVD, 
including life experiences which may be attributed with the unexplained incidence in CVD. 
Pregnancy causes considerable changes in a woman’s physiology, especially the cardiovascular and 
metabolic systems (Blackburn, 2017). These changes have been shown to affect the cardiovascular 
system long term, which may increase the risk of CVD (Aggarwal et al., 2017; Harris et al., 2018). As 
82% of women in the United Kingdom (UK) have at least one child (Office for National Statistics, 
2017b), it would be beneficial to determine the relationship between parity and CVD. As highlighted 
in chapter 2, a systematic review by Lv et al. (2015) attempted to synthesise the published research 
on this relationship, with conflicting results from individual studies. However, this review did not 
include morbidity from CVD (only mortality) and only investigated composite CVD. This did not 
account for the large proportion of CVD burden caused by CHD and stroke specifically and their 
potentially different relationship with parity. It is therefore necessary to evaluate the risk of parity 
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for CHD and stroke morbidity and mortality to reflect the true incidence of these diseases. 
Knowledge of any association would allow clinicians and women to evaluate their risk of CVD and 
act on this accordingly through lifestyle changes or medical intervention. This would in turn lower 
the incidence rate of these conditions.  
 
1.2 Aims and Objectives 
The aim of this thesis was to explore the relationship between parity and future CVD and the 
specific research question addressed was: is parity a risk factor for CVD? To work towards this 
overall aim, several research objectives, set out at the beginning of the research, were achieved. 
These objectives were as follows: 
1) Evaluate, through a systematic review, the current evidence on the relationship between 
parity and future morbidity and mortality from CHD and stroke. 
2) Assess how this relationship varies between CHD and stroke. 
3) Explore the relationship between parity and cardiovascular disease in the local population 
of North Staffordshire using routinely recorded primary care data and assess the 
feasibility of using such data to investigate this relationship.  
As is explained in the background chapter (see chapter 2), CHD and stroke are responsible for the 
largest burden on society out of all the CVDs. Therefore, objectives 1 and 2, which related to the 
systematic review, focussed on the risk of CHD and stroke with parity, rather than the broader term 
of CVD. As the cohort study, set within a local primary care database, was likely to have a small 
number of outcomes, objective 3 addressed a primary outcome of composite CVD risk as well as 
secondary outcomes of: myocardial infarction (MI), CHD, stroke and type 2 diabetes mellitus 
(T2DM). 
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1.3  Summary of Thesis 
This thesis consists of seven chapters, the first of which is this introductory chapter.  
Chapter 2 gives an in-depth background into both parity as an exposure and CVD and its known risk 
factors. The chapter also summarises the current research which has attempted to ascertain the 
links between parity and CVD.  The previous systematic reviews (Rich-Edwards et al., 2014, Lv et al., 
2015) assessing the relationship between parity and CVD risk are critically appraised.  Chapter 3 
explains the benefits of systematic reviews within research and describes the methods used to 
conduct the systematic review and meta-analysis of the current literature investigating the 
relationship between parity and CVD risk.  Chapter 4 presents the results of the systematic review 
and discusses the notable findings. Chapter 5 explains the advantages of using primary care data 
for research and describes the methods used to conduct the cohort study outlined in objective 3.  
Chapter 6 displays the results of the cohort study and discusses the notable findings. Chapter 7 
combines the results of the three objectives and compares them to the current published literature 
and guidelines for the prevention of CVD.  The potential mechanisms for the link between parity 
and CVD risk are explored and a conclusion is drawn as to whether parity is a risk factor for CVD. 
Finally, the implications of this research on future research and clinical practice are considered. 
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2 Background 
This chapter will expand upon the brief synopsis of the association of parity with cardiovascular 
disease (CVD) given in the introduction chapter. First the prevalence of the exposure of parity will 
be described as well as the outcome of CVD. The potential biological mechanisms behind the 
relationship will be described alongside justification for conducting research on this relationship.  
The previous research on this topic will be explored and the resultant overall question of this 
research explained.  
2.1 Trends in Fertility 
Since the introduction of the contraceptive pill in 1961 in the United Kingdom (UK), under the 
National Health Service (NHS), women have benefited from increasing control over their 
reproductive habits (NHS Choices, 2018). Women are now able to approximately plan when they 
become pregnant and how many children they have in total. This has led to changing fertility trends 
and societal ideals throughout the past half century, with women often postponing their 
childbearing in favour of further education and career progression. This is visible in the birth 
statistics for the UK, with the total fertility rate, in 2016 decreasing to 1.81 children per woman, 
compared to 2.93 in 1964 (Office for National Statistics, 2017a). The total fertility rate is defined as 
the average number of live births every woman in the population would have if she was exposed 
to the same age specific fertility rate, of the year in question, in this example 2016, for all of her 
childbearing years (Office for National Statistics, 2017a). Also, since 2005, most babies are born 
each year to women aged 30-34 years, whereas previously the most common age for giving birth 
was 25-29 years (Office for National Statistics, 2017a). Furthermore, even with advances in fertility 
treatment under the NHS, the number of women who do not reproduce is increasing, meaning 
more women are choosing to not have children. In 2016, the 1971 birth cohort turned 45 years old 
and have mostly completed their reproductive years. Of these women, 18% were childless, 
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compared to only 11% of their mothers in the previous generation (Office for National Statistics, 
2017b). 
Advances in both contraception and gender equality within British culture, have resulted in the 
growing attitude that pregnancy is not inevitable during a woman’s lifetime. This development of 
choice for woman is facilitated by research into the effects of pregnancy long term. This research 
can be explained to women during family planning, to inform them of the potential effects 
childbearing may have on their future health. Furthermore, this knowledge can also be used to 
monitor a woman’s health for primary prevention of diseases following pregnancy, throughout life.  
2.2 Parity Definition  
When a woman is pregnant it is necessary to know how many times she has been pregnant 
previously and what happened in these prior pregnancies, as the management of subsequent 
pregnancies may vary based on this information. For example, it is expected that a woman’s first 
labour will be slower than the subsequent pregnancies. Therefore, if the first stage of labour is 
delayed in a subsequent pregnancy, a full assessment must be made by an obstetrician, as this can 
indicate an obstructed labour (National Institute for Health and Care Excellence, 2014). It is 
important to be able to convey this knowledge consistently and clearly to other healthcare 
professionals. Therefore, specific terms for example; parity, nulliparity and multiparity are used to 
explain a woman’s obstetric history.  
Parity describes the number of times a woman has delivered a live birth or stillbirth, after 24 weeks 
gestation (Creinin and Simhan, 2009; Symonds and Arulkumaran, 2013; Impey and Child, 2017). For 
example, a woman who has been pregnant once and delivered one live baby will have a parity of 
one. A woman who has been pregnant once and delivered twins would have a parity of two, while 
a woman who has been pregnant twice and delivered one live birth after each pregnancy would 
also have a parity of two. The description of parity level is often shortened into ‘para’ followed by 
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the number of potential live births, which in this case is para 2 (Creinin and Simhan, 2009; Symonds 
and Arulkumaran, 2013; Impey and Child, 2017). 
The term nulliparity or nulliparous is used to describe a woman who has never delivered a live birth 
or stillbirth (Impey and Child, 2017). This includes women who have had a miscarriage before 24 
weeks gestation and no live birth or stillbirth from another pregnancy. In this case a woman’s parity 
would be zero or para 0. Conversely, multiparity or multiparous describes a woman who has 
delivered two or more live births or stillbirths, after 24 weeks gestation (Impey and Child, 2017). 
This is represented by para 2 or more. Finally, grand multiparity or grand multiparous describes a 
woman who has delivered five or more times, recorded as para 5+. These definitions were all 
discussed with and approved by a consultant obstetrician, Dr Pensée Wu (PW).  
2.3 Parity as a Risk Factor 
It is necessary to research the consequences of normal pregnancy on a woman’s physiology and 
long-term health, as the majority of women in the UK, 82%, deliver at least one child in their lifetime 
(Office for National Statistics, 2017b), therefore a large number of women are exposed to the 
potential risks or benefits of pregnancy. Pregnancy can be considered as a stress test on a woman’s 
body and any complications which occur can be indicators of future ill health. For example, the 
occurrence of several obstetric conditions including, preterm birth, low birthweight, gestational 
diabetes mellitus (GDM) and pre-eclampsia have been shown to increase the risk of type 2 diabetes 
mellitus (T2DM) and CVD in the future (Hauspurg et al., 2018). For example, a systematic review 
found that a history of pre-eclampsia, doubled the risk of coronary heart disease (CHD) and stroke 
(Wu et al., 2017). Both GDM, which is glucose intolerance due to insulin resistance beginning in 
pregnancy, and pre-eclampsia which is high blood pressure alongside multiorgan dysfunction 
during pregnancy, share risk profiles similar to that of CVD (Blackburn, 2017; Hauspurg et al., 2018). 
However, these conditions do not affect all pregnancies, with the prevalence for each being up to 
8% of pregnancies (Hauspurg et al., 2018). The association of parity with future diseases has 
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therefore been investigated, as this exposure reflects all pregnancies and not just those with 
adverse outcomes. 
The effect of parity on all-cause mortality has been researched with inconsistent results. A 
reoccurring trend in results is however seen across multiple systematic reviews and individual 
studies (Barclay et al., 2016; Zeng et al., 2016). This trend is a ‘J’ shaped or ‘U’ shaped non-linear 
association between parity and mortality, suggesting that nulliparous women are at a higher risk of 
early mortality from varying causes compared to women of lower parities, for example para 1 and 
2. This association then reverses with increasing parity as women with higher parities of para 5+ 
have greater risk of early mortality than the women of lower parities. These results are seen for all 
cause and cause specific mortality including circulatory diseases (Barclay et al., 2016). A systematic 
review of parity and future T2DM also demonstrated an increased risk of diabetes with increasing 
parity level (Li et al., 2016)  
Parity as well as other reproductive factors is associated with female cancers, with nulliparity 
increasing the risk of breast and endometrial cancer, while high parity is protective (Kelsey, 
Gammon and John, 1993; Ali, 2014). As oestrogen and progesterone are linked to the development 
of female cancers, this effect of parity on risk is likely to be due to a woman’s lifetime exposure to 
these hormones. This is dependent on the number of menstrual cycles a woman has and is 
therefore reduced by pregnancy (Kelsey, Gammon and John, 1993; Barclay et al., 2016). On the 
other hand, high parity has been shown to increase the risk of cervical cancer (Grundy and Kravdal, 
2010)  
2.4 Cardiovascular Disease 
CVD is an umbrella term for a plethora of conditions which affect the heart and blood vessels and 
is the largest cause of mortality worldwide (GBD 2016 Mortality Contributors, 2017). Although each 
of the individual diseases have specific development pathways, symptoms and treatment, the 
dominating pathophysiological cause is atherosclerosis.  
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Atherosclerosis is a progressive condition which begins in infancy and develops for decades before 
the onset of associated symptoms, which will be discussed later in this section (Mallika, Goswami 
and Rajappa, 2007). The process is initiated by damage to the inside of blood vessels, the 
endothelium, which could be from high pressure flow of blood, known as hypertension, or chemical 
irritants or toxins, for example; tobacco smoke (Mallika, Goswami and Rajappa, 2007). In response 
to the damage, there is an influx of inflammatory cells through the endothelium, into the intima 
and media layers of the blood vessel wall. This results in the deposition of collagen and lipids, 
predominantly cholesterol, into these layers which over time develops into a fatty plaque with a 
fibrous cap (Grech, 2003; Mallika, Goswami and Rajappa, 2007).  
Atherosclerotic plaques cause CVD by reducing blood flow to the downstream tissues, which 
become deprived of oxygen and undergo ischaemia. Ischaemia is the process of cells converting to 
anaerobic metabolism due to the lack of oxygen, which results in the accumulation of metabolic 
waste products (Rhee, Sabatine and Lilly, 2011). If the oxygen supply is not reinstated, an area of 
irreversible cell death, called infarction, will develop. This will inhibit the optimal function of the 
organ long term  (Rhee, Sabatine and Lilly, 2011). 
Strom and Libby (2011) present five mechanisms of atherosclerosis consequences which can lead 
to CVD. Firstly, the plaques narrow the inside of the blood vessel where the blood flows, called the 
lumen, and subsequently impede blood flow. As well as this fixed vessel narrowing, the damaged 
endothelium surrounding the plaque is unable to maintain normal physiological control. This 
endothelial dysfunction results in vasoconstriction or spasm of the arteries, which further reduces 
blood flow to the tissues. Secondly, the plaques may rupture leading to blood clot formation 
(thrombosis) which significantly reduces the vessel lumen, if not occluding it entirely. Thirdly, the 
microvessels inside the plaque can burst causing intraplaque haemorrhage which rapidly expands 
the size of the plaque and therefore impedes adjacent blood flow. Fourthly, small fragments of the 
plaque (emboli) can break off into the circulation and become lodged in smaller blood vessels 
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downstream, therefore occluding the vessel and preventing blood flow. Finally, the inflammatory 
process of atherosclerosis weakens the blood vessel walls which leads to aneurysm development, 
where the vessel walls balloon out into pockets, which are susceptible to rupture and clot 
formation. Figure 2.1 displays the five consequences of atherosclerosis described by Strom and 
Libby (2011). 
 
 
These mechanisms occur at different sites of the cardiovascular system, meaning the diseases 
contained within the umbrella term CVD have diverse disease processes (Strom and Libby, 2011) 
These atherosclerotic CVDs are; Coronary Heart Disease (CHD), Cerebrovascular Disease (CeVD) and 
Peripheral Vascular Disease (PVD) (Strom and Libby, 2011). 
CHD, also known as ischaemic heart disease, is a condition characterised by atherosclerosis in the 
coronary arteries, which are the blood vessels surrounding the heart (Grech, 2003; Libby and 
Theroux, 2005). The plaques can impede the blood flow to the heart muscle (myocardium). The 
subsequent ischaemia or infarction of the myocardium causes severe pain in the chest and results 
in an impaired cardiac output (Libby and Theroux, 2005). CHD has two distinct manifestations; 
angina, which is the repeated onset of reversible pain from myocardial ischaemia during physical 
Figure 2.1 Consequences of atherosclerosis within an artery.  
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exertion, and myocardial infarction (MI) which is an acute life-threatening event characterised by 
irreversible pain due to the occlusion of a coronary artery by a thrombus (Grech, 2003; Libby and 
Theroux, 2005). As illustrated in figure 2.1, the atherosclerosis consequence 1 (narrowed lumen) 
correlates to symptoms of angina and consequences 2 and 3 (plaque rupture and intraplaque 
haemorrhage) are causes of MI.  
CeVD encompasses all conditions relating to the vasculature of the brain, the most prominent being 
stroke. Stroke is defined by the World Health Organisation (WHO) as an acute onset focal (or global) 
neurological deficit of vascular origin, lasting more than 24 hours (Hatano, 1976). 85% of strokes 
are ischaemic, meaning a reduction in the blood supply to an area of the brain, due to the occlusion 
of a cerebral vessel. This occurs from either an embolus from a distant atherosclerotic plaque, or a 
thrombus forming over a ruptured plaque in situ (Deb, Sharma and Hassan, 2010). The remaining 
15% of strokes are haemorrhagic in nature, and the majority of which, 60%, are accredited to 
hypertension which causes an inflammatory process similar to atherosclerosis, termed hyperplastic 
arteriolosclerosis (Testai and Aiyagari, 2008). The hypertension induced damage instigates smooth 
muscle proliferation, which is replaced by collagen deposition, leading to weak vessel walls which 
are susceptible to rupture (Testai and Aiyagari, 2008).  A transient ischaemic attack (TIA) is a 
condition causing the same symptoms as a stroke, however these only persist for up to 24 hours 
(Coupland et al., 2017).  
PVD is a broad term including many different pathologies which affect the arteries and veins 
throughout the body excluding the coronary and cerebral vessels (Ouriel, 2001; Liang and Creager, 
2011). Venous disease, for example varicose veins, is not due to atherosclerosis, instead being 
caused by structural damage to the venous system, leading to venous hypertension (Eberhardt and 
Raffetto, 2014). The main atherosclerotic diseases affecting the peripheral vasculature are 
aneurysms, which were discussed earlier in section 2.4, and peripheral arterial disease. Peripheral 
arterial disease is characterised by plaques narrowing the lumen of any artery supplying the limbs 
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(Liang and Creager, 2011). The subsequent impaired blood flow to the limb leads to ischaemia of 
the downstream tissues upon physical exertion, causing pain in the limb which resolves with rest 
(Ouriel, 2001). This clinical picture is termed limb claudication and is similar in pathology to angina, 
which is also caused by consequence 1 (narrowed lumen) of atherosclerosis (Liang and Creager, 
2011). The chronic vascular insufficiency also manifests in the skin, causing ulcer formation and 
death of skin tissue. Acute limb ischaemia occurs when an artery is completely occluded either by 
an embolus from a proximal plaque or due to thrombus formation over a ruptured plaque in situ. 
This presents with sudden onset severe pain in the limb which cannot be resolved without medical 
intervention (Ouriel, 2001; Liang and Creager, 2011). 
Table 2.1 summarises the pathophysiology of the different types of CHD, Stroke and PVD using the 
five consequences of atherosclerosis described by Strom and Libby (2011). 
Table 2.1 Pathophysiology of coronary heart disease (CHD), stroke and peripheral vascular disease (PVD) 
according to the consequences of atherosclerosis proposed by Strom and Libby (2011). 
 
 
2.4.1 Cardiovascular Disease Burden 
Data from the Global Burden of Disease (GBD) study, which collects health data worldwide, 
demonstrate that CVD mortality rates have been decreasing since 1990 (Newton et al., 2015; 
Bhatnagar et al., 2016). However, CVD still poses a large burden on both individuals and society 
worldwide. CVD as a whole is the leading cause of mortality worldwide, with CHD and stroke 
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accounting for 85% of these CVD deaths (GBD 2016 Mortality Contributors, 2017). Therefore, 
atherosclerosis poses a significant threat to health. CVD causes 45% of all European deaths, with 
just under half of these due to CHD (Wilkins et al., 2017). In the UK, CVD accounts for 26% of female 
deaths, of these 10% are due to CHD, 8% are from stroke and the remaining 8% are caused by all 
other CVD (Townsend et al., 2015). CHD alone is the biggest individual cause of years of life lost in 
the UK (Townsend et al., 2014; Newton et al., 2015). 
When examining CVD morbidity in the UK by gender, using the British Heart Foundation (BHF) CVD 
Statistics from 2013/14 (Townsend et al., 2015), the incidence is greater in men compared to 
women, with CVD accounting for 10% of hospital admissions in men and 6.2% in women. The 
prevalence of stroke and CHD in women in the UK is 2.1% and 3.5%, respectively. CeVD and CHD 
were also in the top 3 causes of disability adjusted life years (DALYs) in the UK in 2013 (Newton et 
al., 2015). A DALY is defined as a year of healthy life lost and is the sum of the number of years of 
life lost due to premature death from a condition and years lived with a disability due to a condition 
(Newton et al., 2015). Therefore, of all CVD, CHD and stroke present the greatest burden on health.   
As well as CVD affecting the lives of individuals, there is a large economic cost imposed on society, 
both from working days lost due to CVD morbidity and the cost of caring for patients with CVD. In 
the UK, the NHS spent £8.8 billion on treating CVD in 2015, with the majority of expenditure in 
secondary care. This represented 5% of the total healthcare expenditure for that year (Wilkins et 
al., 2017). Alongside this, a further £3.2 billion was spent on informal care for people with CHD and 
stroke in the UK in 2015. The UK also suffered production losses amounting to £6 billion in 2015, 
due to death and illness from CHD and stroke in those of working age (Wilkins et al., 2017).  
2.4.2 Cardiovascular Risk Factors 
Several risk factors have been identified for CVD (Newton et al., 2015) which relate to the 
development of atherosclerosis and are therefore consistent for both CHD and stroke (Hankey, 
2006). The WHO defines a risk factor as “any factor which increases the probability of an adverse 
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health outcome” (World Health Organisation, 2009). The GBD study 2015 (GBD 2015 Risk Factors 
Collaborators, 2016) categorises these characteristics into metabolic, behavioural and 
environmental factors. Metabolic factors are those which are physiological, for example 
hypertension and high cholesterol.  Behavioural factors are those relating to lifestyle, including 
tobacco smoking and dietary intake. The environmental factors also incorporate occupational risks 
and include air pollution and unsafe drinking water (GBD 2015 Risk Factors Collaborators, 2016). In 
high income countries, where poor sanitation is uncommon, environmental risk factors attribute 
only a small proportion of DALYs (Newton et al., 2015).  The GBD 2015 report does not include the 
risks of increasing age, and family history of CVD which are key risk factors but cannot be modified. 
These non-modifiable risks must be considered when evaluating an individual’s risk of CVD. 
However, as they cannot be incorporated into public health promotion they are not further 
discussed in detail.  
The outcomes of the GBD Study 2015 (GBD 2015 Risk Factors Collaborators, 2016) demonstrate 
that the total number of DALYs from all-cause morbidity and mortality in the UK are attributable to 
the following top five risk factors: smoking, hypertension, high body mass index (BMI), total 
cholesterol and fasting plasma glucose. As hypertension, BMI, cholesterol and fasting plasma 
glucose level are partly determined by diet, dietary risks are the biggest cause of DALYs in the UK. 
Furthermore, most DALYS are attributable to behavioural risk factors. (GBD 2015 Risk Factors 
Collaborators, 2016). Looking specifically at modifiable CVD risk factors in women in the UK, the 
biggest attributable causes of CVD are dietary risks, hypertension, high BMI, high cholesterol and 
smoking (Newton et al., 2015). However, there are multiple interactions between these risk factors 
with some proven to be within the causal pathway of atherosclerosis, such as smoking, while others 
are indicators of increased risk ((Yusuf et al., 2001; GBD 2015 Risk Factors Collaborators, 2016)). For 
example, poor diet, meaning a diet high in fat and salt and low in fruits and vegetables, is a 
predisposing factor to high cholesterol and hypertension (Wilkins et al., 2017; Townsend et al., 
2014; GBD 2015 Risk Factors Collaborators, 2016). Poor diet is estimated to account for half of all 
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hypertension cases and is therefore a predisposing factor to CVD by inducing hypertension 
(Townsend et al., 2014; Yusuf et al., 2001).  
Another predisposing risk factor for CVD is socioeconomic status (Mackenbach et al., 2000; Yusuf 
et al., 2001; Cubbin et al., 2006). There are clear trends in health inequality based on socioeconomic 
status which are presented by Public Health England in the 2017 report into inequality in health 
(Public Health England, 2017a). This research revealed that women in the most deprived areas in 
England endure a life expectancy 9 years shorter than in the least deprived areas, with 24% of this 
gap attributable to CVD (Public Health England, 2017a). The prevalences of behavioural risk factors, 
such as smoking and dietary risks, also increase proportionally to the amount of deprivation. Low 
socioeconomic status is therefore a risk factor for CVD due to its presence indicating an increased 
likelihood of behavioural risk factors. Furthermore, the rate of premature mortality from CVD is 3.5 
times higher in the most deprived compared to the least deprived (Public Health England, 2017a).  
Table 2.2 lists the traditional modifiable risk factors for CVD categorised into behavioural and 
metabolic factors. 
Table 2.2 List of modifiable risk factors for cardiovascular disease grouped into behavioural and metabolic 
factors.                                                         
Behavioural Risk Factors Metabolic Risk Factors 
Tobacco Smoking 
Low Physical Activity 
High Body Mass Index 
Diet 
 
Total Cholesterol 
High Low Density Lipoproteins 
Low High Density Lipoproteins 
Hypertension 
Elevated Fasting Plasma Glucose 
Carotid Stenosis 
 
As well as these traditional risk factors, there are other proposed factors. These are termed novel 
risk markers and are based on an extensive list of genetic, inflammatory, and haematological 
markers, among others (Hankey, 2006; Strom and Libby, 2011). Research is being conducted to 
determine if these biomarkers are risk factors for CVD or if they present new methods of measuring 
atherosclerosis progression and targets for future risk reducing therapies (Strom and Libby, 2011). 
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However, there is limited evidence to confirm that these biomarkers are risk factors for CVD 
(Hankey, 2006; Strom and Libby, 2011) and will therefore not be discussed in this thesis.  
There is a dynamic interplay between all of the risk factors mentioned above (GBD 2015 Risk Factors 
Collaborators, 2016) and it is beyond the scope of this thesis to determine the exact causal pathway 
between each risk factor and CVD. The following paragraphs give a brief synopsis of the modifiable 
risk factors most pertinent to the research within this thesis.  
2.4.2.1 Dietary Risks 
A systematic review by Mente et al. (2009) evaluated the evidence of certain dietary components 
increasing the risk of CVD. Strong evidence was found indicating that high dietary intake of fat 
increases the risk of atherosclerosis, while high salt intake increases the risk of hypertension. 
Conversely, high intake of vegetables and a ‘Mediterranean’ style diet are protective against CVD 
(Mente et al., 2009). The Mediterranean diet consists of olive oil, high levels of plant based foods 
including nuts and vegetables, with low to moderate levels of animal products including dairy and 
meat (Salas-Salvadó et al., 2018). A narrative synthesis of several meta-analyses identified a 
reduced risk of both CHD and stroke in those who adhered to the Mediterranean diet (Salas-Salvado 
et al., 2018). This may be due to the reduction in low density lipoproteins (LDLs) and body weight 
which was associated with adherence to this diet (Salas-Salvado et al., 2018). A recent review of 
the evidence relating to dietary management of high blood pressure, found that a reduction in salt 
intake and adherence to a Mediterranean style diet reduced blood pressure in a dose response 
progression (Ozemek et al., 2018). Elements of the Mediterranean diet have therefore been 
incorporated into national guidelines, including those for the UK (Khanji et al., 2018). Multiple 
guidelines recommend that a healthy diet includes five portions of fruit or vegetables a day and less 
than 6g of salt. However, according to data collated by the BHF 2014 report, less than a third of 
adults in the UK meet the advised quota of five fruit and vegetable portions a day and 70% of the 
population exceeded the recommended level of salt intake. Therefore, dietary risks are still highly 
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prevalent in the population and contribute the most to CVD DALYs (GBD 2015 Risk Factors 
Collaborators, 2016). 
2.4.2.2 Hypertension 
Hypertension is defined by the National Institute for Health and Care Excellence (NICE) Guidelines 
as a blood pressure over 140/90mmHg (NICE, 2016). It is a common condition affecting 14.5% of 
women in the UK (Townsend et al., 2014) with estimates of lifetime prevalence reaching 90% for 
people over 55 years (Lee, Williams and Lilly, 2011). The cause of hypertension is unknown in 
approximately 90% of cases, however targeting obesity and poor diet, as discussed above, has been 
shown to reduce blood pressure (Geleijnse, Grobbee and Kok, 2005). These risk factors must 
therefore contribute to the development of hypertension. Hypertension has many detrimental 
effects on the cardiovascular system among other organs, for example, kidneys, by weakening 
blood vessel walls and accelerating atherosclerosis progression (Lee, Williams and Lilly, 2011). This 
damage leads to CVD as previously explained in section 2.4 and contributes to hypertension being 
a major risk factor for both CHD and stroke (Wilkins et al., 2017).  
2.4.2.3 High Body Mass Index 
BMI is a measure of adiposity and is calculated by dividing a person’s weight in kilograms (kg) by 
their height squared in meters (m2) (World Health Organisation, 2018) The scores of BMI are 
categorised into: underweight <18.5 kg/m2, ideal 18.5-24.9 kg/m2, overweight 25-29.9 kg/m2 and 
obese >30 kg/m2 (WHO, 2018). A high BMI describes those falling within the overweight and obese 
categories. Overweight and obesity are caused by an energy intake which exceeds the energy 
expenditure, causing energy to be stored as fat (Wilkins et al., 2017). A high BMI is therefore 
associated with poor diet, high cholesterol and low physical activity, which are also risk factors for 
CVD (Wilkins et al., 2017). Research beginning with the Framingham Heart Study (Hubert et al., 
1983) has proven that obesity is an independent risk factor for CVD, irrespective of the associated 
risk factors. While the prevalence of most CVD risk factors is declining worldwide due to health 
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promotion and preventative healthcare, there is a pandemic of obesity across western countries 
(Wilkins et al., 2017). The prevalence of overweight and obesity in the UK has steadily increased, 
with the national average BMI of 23.4 kg/m2 in 1975 increasing to 27 kg/m2 in 2016, with 28% of 
females being obese in 2016 (WHO, 2017).  
2.4.2.4 High Cholesterol 
Cholesterol is a molecule produced by the liver from dietary fat, which is transported in the blood 
by lipoproteins. The two types of lipoproteins commonly recorded in medical practice are: low 
density lipoproteins (LDLs), which can build up in the intima of blood vessels, perpetuating 
atherosclerosis development and high density lipoproteins (HDLs) which transport cholesterol away 
from the peripheries back to the liver for disposal (Strom and Libby, 2011). Due to these distinct 
differences in function, LDLs are termed ‘bad cholesterol’ and the levels of this should be low, while 
HDLs are termed ‘good cholesterol’ and should be at higher levels (Strom and Libby, 2011; Wilkins 
et al., 2017). Due to the increasing prevalence of obesity alongside a diet with increasing fat content 
and low physical activity levels, 57% of women in the UK in 2011 had elevated total cholesterol 
levels (Townsend et al., 2014).  
2.4.2.5 Tobacco Smoking 
Cigarette smoking is a major cause of mortality worldwide, with 14% of CVD deaths attributable to 
smoking in the UK in 2013 (Townsend et al., 2014). Smoking accelerates atherosclerosis at all stages, 
by causing inflammation in the intima of blood vessels, increasing the oxidation of LDLs and 
promoting a prothrombotic state in the blood (Ambrose and Barua, 2004; Strom and Libby, 2011). 
Many studies including the large Framingham Heart Study (Mamun et al., 2004) and the 
INTERHEART Study (Teo et al., 2006) have reported statistically significantly increased risks of CHD 
and stroke in smokers compared to non-smokers. The INTERHEART Study found that the increased 
risk in smokers reduced from an odds ratio (OR) of 2.95 (95% Confidence Interval (CI) 2.77-3.14) to 
1.87 (95% CI 1.55-2.24) after three years of smoking cessation. Following this, public health 
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campaigns have succeeded in reducing the prevalence of smoking by half, with 18% of women in 
the UK smoking regularly in 2011 compared to 41% in 1974 (Townsend et al., 2014).  
2.4.2.6 Elevated Fasting Plasma Glucose 
T2DM is a condition characterised by high plasma glucose due to insufficient insulin production 
from β islet cells in the pancreas, which causes the uptake of glucose into cells (Kahn, Cooper and 
Del Prato, 2014). Insulin resistance in these tissues also occurs and is caused in part by hormones 
released from adipocytes, which store fat (Kahn, Cooper and Del Prato, 2014). Therefore, there has 
been an increase in T2DM incidence alongside the increasing prevalence of obesity (Wilkins et al., 
2017). As well as being associated with obesity, T2DM is an independent risk factor for CVD. This is 
because raised plasma glucose levels irritate the endothelium of blood vessels, thereby catalysing 
atherosclerosis (Strom and Libby, 2011). It is estimated that elevated plasma glucose causes 15% 
of CVD deaths in Europe (Wilkins et al., 2017). In 2014, the UK female age standardised prevalence 
of T2DM was 4.9% of the population (Wilkins et al., 2017).  
2.4.2.7 Carotid Stenosis 
Carotid stenosis occurs due to the development of atherosclerotic plaques in the carotid artery 
which is the main artery supplying the head and neck. A common cause of ischaemic stroke is from 
embolization of small plaque fragments within the carotid artery which occlude cerebral vessels 
downstream (Deb, Sharma and Hassan, 2010). The risk of both CHD and stroke increases 
proportionally to the thickness of the intima media layers in the carotid artery, known as the carotid 
intima-media thickness (CIMT) (O’Leary et al., 1999). After adjustment for other CVD risk factors 
the increased risk of a high CIMT remained, meaning that carotid stenosis is an independent risk 
factor for CVD (O’Leary et al., 1999). 
2.4.2.8 Oestrogen Exposure 
The female sex hormone oestrogen has been shown to elevate HDL and lower LDL levels, improve 
endothelial function and reduce insulin resistance (Gerval and Stevenson, 2017). Therefore, the 
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incidence of CVD is much lower in premenopausal women compared to men of the same age, 
however after menopause the incidence is similar for both sexes (Strom and Libby, 2011; Gerval 
and Stevenson, 2017). This suggests that the oestrogen deficiency which occurs after the 
menopause is a risk factor for CVD. Giving low dose oestrogen replacement to postmenopausal 
women has been shown to be beneficial in reducing the risk of CVD in these women (Gerval and 
Stevenson, 2017).  
2.4.2.9 Attributable Risk 
Despite in-depth research into the traditional risk factors and novel biomarkers for CVD, the GBD 
2013 Study found that the attributable burden of these known risk factors only accounted for 83.9% 
of CVD DALYs (Newton et al., 2015). Therefore, there is a requirement for ongoing research into 
exposures such as parity, to identify any further risk factors for CVD, the knowledge of which can 
inform public health initiatives to reduce the risk of CVD at both global and individual levels.   
The increased risk of CVD associated with obstetric complications, such as pre-eclampsia is not 
accounted for in the GBD studies, and therefore will represent some of these unexplained CVD 
DALYs. It is also therefore difficult to compare the attributable risk of the obstetric complications 
and the traditional risk factors. However, growing evidence demonstrates that these obstetric 
complications increase the risk of CVD, and should therefore be considered as major risk factors, 
particularly GDM and pre-eclampsia which lead to hypertension and a high fasting plasma glucose 
(Wu et al., 2017; Hauspurg et al., 2018). Although, this research aims to determine if parity is a risk 
factor for CVD, the associated I ncreased risk, if any, is likely to be small compared to that of the 
known traditional risk factors and obstetric complications.  
2.5 How pregnancy might lead to CVD 
There are several biological mechanisms which underpin the theory of parity being a risk factor for 
CVD. These focus on the drastic changes to the anatomy and physiology of the cardiovascular and 
metabolic systems during pregnancy. These adaptations are necessary to accommodate the 
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developing foetus and prepare the mother and baby for labour. However, some studies have shown 
that these adaptations during pregnancy progress into CVD risk factors later in life. These risk 
factors are: increased blood pressure, reduced insulin sensitivity, and increased lipid levels during 
pregnancy. All of which are mediated by the sex hormones oestrogen and progesterone.  
2.5.1 Cardiovascular System 
The major maternal adaptation in the cardiovascular system is the steady increase in cardiac output 
throughout pregnancy which reaches a peak increase of 40-50% in the third trimester. This is to 
ensure the placenta receives enough blood to nourish the fetus. Cardiac output is determined by 
the stroke volume, which is the volume of blood forced out of the left ventricle per cardiac cycle, 
and the heart rate, which is the number of heart beats per minute (Thornburg et al., 2000; Tan and 
Tan, 2013; Sanghavi and Rutherford, 2014). 
The equation is as follows: Cardiac output = stroke volume x heart rate 
In order for the cardiac output to increase so drastically, there are vast changes throughout the 
cardiovascular system as pregnancy progresses.  
Firstly, the pregnancy hormones oestrogen and progesterone cause the release of renin from the 
kidneys which activates the Renin-Angiotensin-Aldosterone System. This pathway ultimately leads 
to the retention of salt and water in the kidneys, which increases the amount of fluid in the blood 
(Heidemann and McClure, 2003; Sanghavi and Rutherford, 2014). The fluid component of blood is 
called plasma, and therefore this physiological process results in an approximate 45% increase in 
plasma volume. With the increased plasma volume there is more blood reaching the heart from the 
systemic circulation. To accommodate this, the maternal heart undergoes remodelling during 
pregnancy. The heart is lifted up and rotated forwards, the chambers are dilated, and the muscular 
walls double in thickness (Tan and Tan, 2013; Sanghavi and Rutherford, 2014). These anatomical 
changes allow the heart to hold a greater volume of blood at the end of the filling phase of the 
cardiac cycle, a term called end-diastolic volume. As well as the increased end-diastolic volume the 
22 
 
heart increases its muscle mass to force the blood into the circulation (Tan and Tan, 2013). These 
two adaptations lead to an increase in stroke volume.   
Also, oestrogen and progesterone relax and dilate the systemic blood vessels, causing a decrease 
in peripheral vascular resistance. The resistance decreases by approximately 40% of the baseline, 
with the majority of the change occurring in the first trimester (Sanghavi and Rutherford 2014; Tan 
and Tan, 2013). Due to the reduced resistance the heart is able to pump more blood out into the 
aorta, therefore increasing the stroke volume further.  Overall, the stroke volume increases by 30% 
during the first and second trimester of pregnancy and is the main factor which contributes to the 
increased cardiac output (Heidemann and McClure, 2003). 
The systemic vascular dilatation leads to a drop in blood pressure of up to 10 mmHg which reaches 
its lowest point in the second trimester. The reduced blood pressure causes a reflex tachycardia, 
which means an increased heart rate, which contributes to the increasing cardiac output. Oestrogen 
itself also acts directly on the heart to increase the heart rate.  The heart rate increases by 25% of 
the baseline rate which equates to an extra 10-20 beats per minute. The heart rate progressively 
increases throughout pregnancy reaching its maximum in the third trimester (Heidemann and 
McClure, 2003; Sanghavi and Rutherford, 2014). 
These cardiovascular adaptations are exaggerated in women with a multiple pregnancy, meaning a 
pregnancy with more than one fetus, for example twins (Tan and Tan, 2013). The cardiac output of 
women with twins is 15-20% higher than women with a singleton pregnancy due to a higher stroke 
volume and heart rate. The cardiac remodelling is also more pronounced (Tan and Tan, 2013; 
Sanghavi and Rutherford, 2014).  
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The cardiovascular changes which occur are summarised in figure 2.2 below: 
 
                          
          
       
                  
 
 
 
 
 
 
The evidence suggests that these adaptations have long lasting effects on the cardiovascular system 
and that these effects become more prominent with increasing parity. Firstly, Clapp and Capeless 
(1997) found that the increase in stroke volume and end diastolic volume during pregnancy is 
greater in a woman’s second pregnancy compared to her first. Demonstrating that a woman’s 
cardiovascular system will undergo more strain with each subsequent pregnancy. Most recently, 
Harris et al. (2018) measured a number of anatomical and physiological parameters within the 
hearts of 3,019 women and found significant associations between parity and longer cardiac cycles, 
increased left ventricular end volumes and left ventricular mass. These findings demonstrate that 
the heart is affected in numerous ways by repeated pregnancies. More specifically Keskin et al. 
(2017) and Aggarwal et al. (2017) assessed left ventricular diastolic dysfunction in women using 
echocardiography. It is hypothesised that cardiofibrosis occurs in the cardiac remodelling process 
of pregnancy, which can cause ventricular dysfunction in the future. Both studies discovered that 
grand multiparous women had significantly higher rates of ventricular dysfunction than nulliparous 
women, with 81% of grand multiparous women showing ventricular dysfunction compared to 46% 
of nulliparous women (p <0.01) (Aggarwal et al., 2017). Although, slightly higher rates of ventricular 
dysfunction were found in women from lower parity levels, these were not statistically significant, 
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Figure 2.2 Cardiovascular adaptations during pregnancy which achieve an increased cardiac output. 
Key: CO; Cardiac Output, SV; Stroke Volume, HR; Heart Rate, PV; Plasma Volume, PVR; Peripheral Vascular 
Resistance, BP; Blood Pressure, RAAS; Renin-Angiotensin-Aldosterone System, O&P; Oestrogen & 
Progesterone.  
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suggesting that with each repeated pregnancy the long-term effects on the cardiovascular system 
are increased. However, both studies were small, with less than 2000 participants combined and 
both study samples were not generalisable. The study by Keskin et al. (2017) only included women 
with a clinical indication for echocardiogram, and therefore the study sample does not represent 
the normal, healthy population. Whereas Aggarwal et al. only included Hispanic and Latino women. 
Although Keskin et al. explain that women with certain previous medical conditions, including pre-
eclampsia were excluded, as well as those with structural heart changes, a clear description of the 
exclusion criteria was not presented. Aggarwal et al. did not exclude women with pre-eclampsia or 
other previous medical conditions but did adjust for the main CVD risk factors: age, BMI, 
hypertension, diabetes mellitus and pre-diabetes, smoking status, cholesterol level, education and 
income. Keskin et al. also adjusted for age, BMI, diabetes mellitus, smoking, hypertension and 
hyperlipidaemia. However, neither of the studies adjusted for breastfeeding, which is known to be 
protective against CVD, or the duration of inter-pregnancy intervals or age at first-birth, which are 
both associated with an increased CVD risk. Considering these limitations, there is more research 
needed to examine the cardiac function in women of all parity levels to determine if multiparty 
increases the risk of CVD. Preferably future studies will take repeated measurements from the same 
women, after recurrent pregnancies, to give a clearer picture of the reversibility of the cardiac 
adaptations during pregnancy as well as in the effect on the cardiovascular system long term. 
As well as the studies assessing pregnancy cardiovascular changes, studies have shown that an 
increased heart rate in the general population is associated with higher blood pressure and 
therefore a greater risk of CVD (Palatini and Julius, 1997). 
As well as the heart being affected by the maternal adaptations of pregnancy, it is thought that the 
blood vessels are damaged due to oxidative stress, caused by increased LDLs and increased 
oestrogen levels (Dhawan, Brookes and Kaufman, 2004). A study by Dhawan, Brookes and Kaufman, 
(2004) using rats found that due to this damage, repeatedly bred rats had a reduced arterial 
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compliance when compared to virgin rats (p <0.05). This study suggests that the arteries of 
multiparous rats were stiffer and therefore more likely to lead to high blood pressure in the future, 
and in turn CVD. However, due to the invasive nature of the experiment these results have not been 
replicated in humans.  
 
2.5.2  Metabolic System 
The metabolic system undergoes physiological changes during pregnancy to balance the energy 
demand of both the mother and fetus.  Pregnancy is characterised by two distinct metabolic phases: 
the anabolic phase which occurs in the first two trimesters and the catabolic phase which occurs in 
the third trimester (Zeng, Liu and Li, 2017). The aim of the anabolic phase is to increase maternal 
lipogenesis, meaning that energy is stored as fat until it is needed later in pregnancy. This is 
achieved by an increase in hepatic glucose production through glycogenolysis which is mirrored by 
an increase in insulin secretion from the pancreatic beta islet cells (Blackburn, 2017). It is thought 
that the increase in maternal insulin levels is the cause of the increased fat storage (Zeng, Liu and 
Li, 2017). The maternal adipocytes, fat cells, are more sensitive to insulin than other tissues, 
allowing a shift of circulating glucose into adipose tissue. This means that although there is an 
increase in maternal glucose supply during pregnancy the serum glucose levels are lower than pre-
pregnancy values (Blackburn, 2017).  
As pregnancy progresses the increase in placental hormones; specifically, oestrogen, progesterone, 
and human chorionic somatomammotrophin cause maternal tissues to become less sensitive to 
insulin (Zeng, Liu and Li, 2017). The maternal sensitivity to insulin decreases by 50-70% in 
pregnancy, causing a relative insulin resistance and diabetic state (Blackburn, 2017). This leads to a 
net flux of glucose from the mother to the fetus, to fulfil the high metabolic demands throughout 
the third trimester. It is the insulin resistance which is thought to be the cause of the switch to a 
maternal catabolic state.  
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The catabolic state is dominated by breakdown of lipids which were stored in adipose tissue during 
the anabolic stage. This lipolysis results in high levels of serum triglycerides, which are broken down 
into fatty acids and glycerol, as well as LDLs (Zeng, Liu and Li, 2017). These lipoproteins increase 
throughout gestation and the overall cholesterol levels increase by 50% by late pregnancy. As the 
maternal tissues are unable to uptake adequate glucose, the energy is created by fatty acid 
oxidation, which highlights the need for the lipid production and storage during the anabolic phase 
(Blackburn, 2017).  
Overall pregnancy leads to weight gain due to fat storage and a diabetogenic state with 
hyperinsulinaemia. To counteract this lack of available glucose for the maternal tissues, lipid 
breakdown occurs leading to hyperlipidaemia and hypercholesterolaemia, with triglycerides 
increasing by 250% at term (Blackburn, 2017). As diabetes, hypercholesterolaemia and obesity are 
risk factors for CVD, there has been extensive research to determine if these maternal adaptations 
resolve completely after pregnancy or if they have long term effects on the mother’s physiology.  
According to Trikudanathan et al. (2013) there is no statistically significant association between 
parity and adiposity measures when adjusted for age and lifestyle behaviours, such as smoking and 
exercise status. The study involved 868 women who participated in the Framingham Heart Study 
and underwent computerised tomography to measure body composition. However, the Stockholm 
Pregnancy and Women’s Nutrition Study (Linné et al., 2003) found that increased weight gain 
during pregnancy, and failure to lose that weight after 1 year post-partum was an indicator of being 
overweight 15 years after pregnancy. Gunderson et al. (2004) also found that weight gain relating 
to pregnancy is greatest in women who were overweight before pregnancy. Therefore, even though 
there is no clear association of parity with adiposity, the physiological changes which occur during 
pregnancy appear to affect women’s weight gain throughout life on an individual basis.  
Studies have also shown statistically significant results in the relationship between parity and the 
development of atherosclerosis (Skilton et al., 2010; Eren et al., 2013). The CIMT of women, which 
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is the layer of the blood vessel where lipids are deposited, increases with each parity, irrespective 
of age. In contrast to this, the CIMT of men was inversely proportional to increasing number of 
children, suggesting that the biological mechanisms of pregnancy for women is directly linked to 
the atherosclerosis development (Skilton et al., 2010). The cumulative effect of lipoprotein 
alterations, insulin resistance and oxidative stress which occurs during pregnancy, causes 
progressive insults on the blood vessels with each successive pregnancy, contributing to 
atherosclerosis development (Eren et al., 2013).  
The relationship between parity, in the absence of GDM, and type 2 diabetes mellitus (T2DM) has 
also been investigated. A large Australian study (Liu, Jorm and Banks, 2010) of 52,731 women 
reported that compared to nulliparous women, parous women who did not breastfeed are at an 
increased risk of T2DM in the future (Odds Ratio OR 1.48, 95% CI 1.26–1.73, p<0.001), however this 
risk is reduced by breastfeeding. Further to this, another large study by Carr et al. (2008) found that 
among women who did not reach the criteria for a GDM diagnosis, increasing glucose intolerance 
led to an increased risk of developing T2DM in the future. This suggests that even the normal 
physiological changes in insulin sensitivity during pregnancy, which do not reach pathological limits, 
can increase the risk of future T2DM compared to nulliparity. It could be postulated that with 
subsequent insults on the metabolic system from increasing parity, this risk would be increased in 
multiparous women when compared to nulliparous women.  
2.6 Parity and Cardiovascular Disease Literature 
Through a search of the database MEDLINE, two published systematic reviews synthesising the 
literature on the association of parity with CVD were identified (Rich-Edwards et al., 2014; Lv et al., 
2015). The author Ashleigh Woodland (AW) evaluated these reviews using the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist (Moher et al., 2009) and an 
assessment of their quality was made using the AMSTAR 2 tool (Shea et al., 2017). The PRISMA 
checklist (Moher et al., 2009) was developed to guide professionals in appraising systematic reviews 
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but also to devise a standardised approach for researchers to report a systematic review and meta-
analysis. The checklist consists of 27 items related to the methods, results and discussion of a 
systematic review which should be reported in a publication. This enables readers to draw 
appropriate conclusions from the research, having learned the specific characteristics of the review, 
for example the study population or the risk of bias from the included studies.  
The AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews 2) (Shea et al., 2017) is used to 
critically assess the quality of systematic reviews of both randomised and non-randomised studies. 
It has recently been updated from the original AMSTAR tool (Shea et al., 2007), which has been 
validated for use in critically appraising systematic reviews (Shea et al., 2009). The suggestions for 
improvement received for the original tool have been implemented in the AMSTAR 2 update. For 
example, more domains have been introduced related to the risk of bias from included studies and 
the heterogeneity of individual study results. The authors of AMSTAR 2 (Shea et al., 2017) explain 
that the tool does not produce an overall score of quality, as this can overlook critical weaknesses 
in specific areas of the study methods. Instead the AMSTAR 2 generates an overall rating of 
confidence, which is dependent on the review’s performance in seven critical domains. These 
domains are related to: the risk of bias from the included studies, publication bias, the 
comprehensiveness of the literature search and screening process, the appropriateness of the 
statistical analysis and whether the protocol was registered before the review began. The authors 
have identified these domains as those most likely to affect the validity of a review. The rating of 
confidence generated by the tool is on a scale from high to critically low confidence (Shea et al., 
2017).  
The first review by Rich-Edwards et al. (2014) collated studies assessing the association between a 
number of pregnancy complications as well as parity with CVD mortality and morbidity. Because 
multiple exposures were assessed in this review, there was not an in-depth review of the literature 
focussing on parity and CVD, as more emphasis was given to pregnancy complications. Only four 
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studies were identified which addressed the exposure of parity and a meta-analysis was not 
performed.  The short narrative synthesis focussed mainly on a study by Parikh et al. (2010). The 
Parikh study is the largest to date and followed up 1,332,062 Swedish women for 9.5 years starting 
from their 50th birthday. The large sample size allowed an in-depth analysis of CVD risk per parity 
level, which found a statistically significant ‘J shaped’ association between parity and CVD. The risk 
of cardiovascular mortality decreased initially inversely to parity level, with the lowest risk at two 
pregnancies, after which the risk increased with each subsequent pregnancy. The review (Rich-
Edwards et al., 2014) was not fully reported (Moher et al., 2009) with only 7/27 items from the 
PRISMA checklist completed. There was no explanation of the selection of included studies and 
there was no quality appraisal. Also, three out of the four parity studies cited within the review 
were published before the year 2000, meaning many newer studies had not been included, which 
had been identified in the second systematic review published a year later (Lv et al., 2015). This 
may be because only one database was searched for relevant studies.  According to the quality 
assessment using the AMSTAR 2 (Shea et al., 2017), the review was of critically low quality, with 
flaws appearing in all of the critical domains. For example, an adequate literature search was not 
completed, there was no assessment of the risk of bias from studies and no justification for 
including or excluding studies. Due to these limitations, an accurate conclusion on the relationship 
between parity and CVD cannot be drawn from this systematic review (Rich-Edwards et al., 2014). 
The second review by Lv et al. (2015) was more comprehensive than the Rich-Edwards et al. (2014) 
paper and completed 22/27 items on the PRISMA checklist (Moher et al., 2009). The quality was 
also better, and was graded as a high quality review using the AMSTAR 2 tool (Shea et al., 2017) 
with all seven critical domains satisfied. This was mainly due to the incorporation of a risk of bias 
assessment in the study methods, the results of which were considered when drawing conclusions 
from the meta-analysis output. The review included ten cohort studies evaluating the risk of 
cardiovascular mortality by parity level. A meta-analysis including six of these studies reporting ever 
parity results found a reduced risk, albeit non-statistically significant, of mortality from CVD in ever 
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parous women when compared to nulliparous women (Risk Ratio 0.79, 95% CI: 0.59-1.06). 
However, there was significant heterogeneity of results (I2 = 90.9%; p <0.001) which the authors 
suggest could be due to the inconsistent adjustment for smoking among the studies. Following from 
this, a dose-response meta-analysis revealed a non-linear ‘J shaped’ association between parity and 
CVD mortality with the minimum risk at four pregnancies, with the risk increasing thereafter until 
para 10. This conflicts with the large Swedish study (Parikh et al., 2010) which found the lowest risk 
was at two pregnancies. This may be due to the homogenous sample population in the Swedish 
study compared to the varied study populations used across the studies identified by Lv et al. 
(2015). Also, the cardiovascular outcomes used by Parikh et al. (2010) included hospitalisation as 
well as death from CHD and stroke whereas Lv et al. (2015) only evaluated studies reporting 
mortality as outcomes.  Hence the study by Parikh et al. (2010) was not included in the review by 
Lv et al. (2015).  
Although this systematic review was of high quality, there are several limitations to the research 
due to the methods and criteria utilised in the review process. Firstly, whilst cardiovascular 
mortality is an important outcome, as 49% of all deaths in females in Europe are due to CVD (Wilkins 
et al., 2017), cardiovascular morbidity should not be ignored as a long term outcome of pregnancy. 
The GBD Study for 2013 (Newton et al., 2015) rates CHD and cerebrovascular disease in the top 
three diseases causing most disability adjusted life years (DALYs). It is therefore also important to 
assess parity as a risk factor for cardiovascular morbidity as well as mortality. 
Another limitation of the systematic review by Lv et al. (2015) is that the authors only conducted a 
composite meta-analysis of the included studies, without stratifying by type of CVD. As the two 
CVDs used as outcomes for the review; CHD and stroke, have different pathogeneses, parity may 
influence the risk of developing each disease differently. Performing meta-analyses for CHD and 
stroke separately may therefore clarify the relationship between parity and these two diseases.  
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Finally, the reviews by Lv et al. (2015) and Rich-Edwards et al. (2014) did not include case-control 
studies which also provide observational evidence and can be used to evaluate the association 
between parity and CVD. By only including cohort studies the authors may have excluded papers 
which would have contributed information to the review, given the low number of cohort studies 
identified.  
 
The aforementioned limitations of both systematic reviews (Rich-Edwards et al., 2014, Lv et al., 
2015) highlight the need to produce an updated systematic review. This review would include both 
cohort and case-control studies which reported outcomes of morbidity and mortality from CHD and 
stroke. The data from these studies could be used to conduct separate meta-analyses for the two 
CVDs.  
2.7 Conclusion 
In conclusion, there are several theories linking parity with an increased risk of future CVD. The 
potential biological mechanisms behind this association focus on the maternal adaptations of 
pregnancy and the long term effect on a woman’s physiology. There has been no comprehensive 
synthesis of the published research evidence on the link between parity and CVD morbidity and 
mortality, focussing specifically on CHD and stroke, which cause the most DALYs of all CVD. As the 
majority of women are parous by the end of their reproductive years, it is important to establish 
the effect of parity on the risk of these two diseases. Research has shown that the current known 
risk factors for CVD are not responsible for all of the CVD DALYs. This gap in attributable risk of CVD 
may be in part due to parity. To address this, the aim of this research is to determine if parity is a 
risk factor for CVD, specifically CHD and stroke.  Chapter 3 will explain the methods used to conduct 
the systematic review of the association between parity and CHD and stroke for this MPhil research.  
32 
 
33 
 
3 Systematic Review on the association of parity with CVD: Methods 
The previous chapter discussed the importance of conducting research on parity and cardiovascular 
disease (CVD) and summarised the biological mechanisms of pregnancy which are theorised to 
increase the risk of future CVD.  The current literature was also briefly evaluated, which focussed 
on the two published systematic reviews addressing this relationship (Lv et al., 2015 and Rich-
Edwards et al., 2014). Due to the limitations of these reviews that were highlighted in Chapter 2, it 
was necessary to complete another systematic review with separate meta-analyses for coronary 
heart disease (CHD) and stroke. By synthesising the relevant published research, this review will 
aim to determine if parity is a risk factor for CHD and stroke.  
 
This chapter will begin by outlining the principles of a systematic review and explain the value of 
systematic reviews to health research.  Following this, the methods used to conduct this systematic 
review and meta-analysis are reported and the justifications for using certain resources or methods 
discussed. The results of the review are reported in Chapter 4. 
3.1 What is a systematic review? 
Throughout the 1990’s there was a shift in medical training to encourage the integration of health 
research into everyday clinical practice, rather than the previous reliance on the experiences of 
senior professionals (Rosenburg and Donald, 1995). This style of medical practice, termed ‘evidence 
based medicine’, has progressed throughout the past three decades to underpin the extensive 
clinical guidelines which direct modern day medicine. To enable this, the quantity of influential 
research being published has risen dramatically during this time. Records from the United States 
(US) National Library of Medicine (US National Library of Medicine, 2016) indicate that compared 
to the 392,354 citations added to MEDLINE in 1995, there were 869,666 new citations incorporated 
into the database in 2016 alone. It is therefore difficult for healthcare professionals to keep up to 
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date with the relevant literature.  This overload of available research has fuelled the increasing 
requirement for systematic reviews, which summarise and appraise several studies into one article.    
The Cochrane Collaboration, which was established in 1992, conducts systematic reviews of 
randomised controlled trials and other clinical research within health care. These Cochrane Reviews 
compile high quality research to guide evidence-based medical practice, thus improving the 
treatment and management of medical conditions (The Cochrane Collaboration, no date).  
Systematic reviews are also widely used within epidemiological and public health research, 
synthesising observational studies as well as randomised controlled trials.  
The overall aim of a systematic review is to collate and summarise the available literature on a 
certain topic and to draw conclusions from the combined studies to answer a specific research 
question (Boland, Cherry and Dickson, 2014). A systematic review differs from a literature review 
because of the requirement to follow a predetermined method of identifying and critically 
appraising studies addressing a specific question. This planned method is explained in-depth within 
a protocol which is developed before the systematic review begins. The protocol is then adhered 
to by all researchers involved, throughout the progression of the review. This ensures the best 
quality evidence is included and reduces the risk of introducing reviewer bias during the research 
process.  
Bias is introduced into a review when the selection criteria are ambiguous, meaning different 
reviewers could include or exclude studies based on their own opinions or knowledge (McDonagh 
et al., 2013). This may inherently alter the results and conclusions of a review. For example, if a 
review protocol assessing the effectiveness of treatment for pneumonia, defined the population of 
interest as patients with pneumonia, a reviewer could include studies of patients which required 
hospital treatment or those who were treated in the community. As the severity of pneumonia 
would be greater in hospitalised patients, the outcomes of the review may suggest that the 
treatment was ineffective. However, if the study population was community-based patients, the 
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results may demonstrate an effective treatment. This process of introducing bias can occur at any 
stage of a review, therefore explicit directions should be written in a protocol and discussed with 
the entire review team to ensure everyone involved understands the planned aims and methods of 
the research.  A systematic review is therefore considered the gold standard approach to 
synthesising research, especially within health research where the conclusions from such reviews 
may be used to update clinical guidelines.  
A systematic review has a clear structure which must be observed, irrelevant of the type of study 
design included. The Centre for Reviews and Dissemination (2009) has published a comprehensive 
guideline for completing a systematic review in healthcare research, which explains the necessary 
stages of a review and gives advice on the different techniques available. First, the reviewers must 
use the research question to develop the inclusion and exclusion criteria which potential studies 
must fulfil to be incorporated into the review. Furthermore, a strategy is created for searching the 
literature to identify all relevant research. This includes the databases to be searched and key words 
used and may include methods for searching for grey literature and abstract submissions for 
conferences.  Studies identified by the search are then screened using the predefined criteria and 
all studies satisfying these criteria are included within the review. The quality of the included studies 
is then assessed using a standardised tool catered to the specific research design of the studies. For 
example, The Cochrane Collaboration have designed a ‘Risk of Bias’ tool for randomised controlled 
trials within a Cochrane Review (Higgins and Green, 2011). Preferably, the studies are 
independently screened, and quality assessed by at least two reviewers, as this ensures the studies 
are correctly evaluated and classified by reducing the chance of human error. Also, by 
independently assessing studies and then discussing differences in opinion, the risk of introducing 
reviewer bias is reduced. The outcomes of the quality assessment influence which papers are given 
greater weight when drawing conclusions from the collective results. The required data are 
extracted from the studies and combined either by narrative synthesis or quantitatively using meta-
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analysis.  The results of the review are then presented by the reviewers and used to answer the 
research question.  
Ideally, the methodological theories behind the chosen method for each stage of the review should 
be explained in the published review (Boland, Cherry and Dickson, 2014). This demonstrates that 
the researchers have been systematic in the approach to the review and have conducted the 
research in such a way to produce high quality evidence with limited bias from the ambiguity of the 
review methods.  
3.2 Methods of this systematic review 
3.2.1 Objective 
The objectives of this systematic review were to determine if parity is a risk factor for i) CHD and               
ii) stroke and to assess whether the risk of these diseases changes with each parity level.  
3.2.2 Protocol 
Once the final research question had been formed, as explained in chapter 2, the international 
register of prospective systematic reviews, PROSPERO (Booth et al., 2012) was checked for any 
systematic reviews on the relationship of parity with future onset of CVD, and there were no 
ongoing or completed reviews registered. This meant that there were no systematic reviews being 
conducted on the same research question, so the development of the review protocol could begin.  
A protocol was created using the template developed within the Research Institute for Primary Care 
and Health Sciences (iPCHS), which follows the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) Checklist (Moher et al., 2009). As well as the PRISMA checklist, the 
Meta-analysis of Observational Studies in Epidemiology (MOOSE) Guidelines were followed 
throughout the course of this systematic review (Stroup et al., 2000). As the specific question for 
the review was finalised during the early stages of the research, the protocol was adapted to ensure 
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the correct studies to answer the review question would be detected and included. A final version 
of the protocol is shown in Appendix A.  
As well as using the protocol template created by the iPCHS systematic review team, the team were 
consulted during the protocol design for guidance on appropriate databases to search and eligibility 
criteria to set. The team also taught the author, Ashleigh Woodland (AW) how to produce a search 
strategy with appropriate wildcards, which will be discussed later in this chapter.  
3.2.3 Inclusion criteria 
In order for this systematic review to assemble publications which would answer the review 
question, potential studies had to satisfy several criteria which were outlined in the protocol. These 
inclusion criteria followed the PICOSS Framework (Schardt et al., 2007) which facilitates the 
deconstruction of a research question into separate concepts. Table 3.1 demonstrates the PICOSS 
concepts and the correlating inclusion criteria used in this review.  
Table 3.1 Inclusion criteria for this systematic review with the equivalent PICOSS concept. 
Inclusion Criteria for Studies in this Systematic Review: 
PICOSS Concept: Inclusion Criteria: 
P is for the Population or 
Participants of interest 
The participants in the studies must be adult women aged 
16 years and over 
I is for the Intervention or 
Exposure of interest 
The exposure being analysed in the studies must be parity  
C is for the Comparison 
group required 
The studies must include a comparison group of 
nulliparous women 
O is for the Outcomes of 
interest 
The outcomes of studies must include morbidity or 
mortality from either CHD or stroke 
S is for the Setting if a 
specific type is required 
There was no restriction on the setting of research studies 
S is for the Study design 
required 
The studies must be observational, of either a cohort or 
case-control design 
 
The biological theory behind this research is that the maternal adaptations during pregnancy have 
long term effects on the cardiovascular system, which increases the risk of developing CVD in the 
future. Thus, the population of included studies needed to be adult women as the exposure being 
assessed in this review was parity. It was therefore necessary for the included studies to use a 
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control group of nulliparous women in order to compare the difference in risk of CVD between 
women who had and had not undergone maternal adaptations during pregnancy.  
The overall question of this research was to determine if parity was a risk factor for CHD and stroke, 
therefore the outcomes required from included studies were morbidity and/or mortality from any 
form of these diseases. This was building on the previous review (Lv et al., 2015) which only used 
mortality from CVD as their outcome. As both of these diseases are managed in primary and 
secondary care, there was no restriction on the setting of studies for this review.  
The inclusion criteria for the outcome of CHD in this review, included angina and myocardial 
infarction as well as unclassified CHD. The outcome of stroke included haemorrhagic and ischaemic 
stroke as well as transient ischaemic attack (TIA). This did not include subarachnoid haemorrhage 
as this has a distinct underlying pathophysiology (Nikolić, Banjanin and Stanojević, 2004). Studies 
which only examined the outcome of composite CVD were not included in this systematic review.  
In order to determine if parity was a risk factor for CVD, the included studies needed to demonstrate 
temporality. Therefore, the only observational studies with an appropriate study design for this 
review were case-control and cohort studies.  
As well as these specific points relating to the research question, the inclusion criteria also allowed 
for studies in any language, with no date restriction. This was to ensure all relevant studies were 
incorporated into the review.  
3.2.4 Exclusion criteria 
The inclusion criteria explained above were used to identify papers that would answer the research 
question, whereas the set of exclusion criteria were used to refine the list of included studies with 
concepts that were not part of the PICOSS Framework. The exclusion criteria also focussed on 
ensuring the studies had conducted appropriate analysis and reported the results in enough detail 
to be included in this review and meta-analysis.  
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The exclusion criteria were as follows: 
Studies which included study participants with CVD before or during pregnancy and the puerperium 
e.g. pre-existing hypertension or pregnancy-induced hypertension, were excluded.  This review was 
assessing if parity was a risk factor for CVD, therefore including women with pre-existing CVD or 
other significant risk factors e.g pre-eclampsia would not allow assessment of parity as a risk factor 
for CVD.  
 
Studies that gave composite outcomes for men and women together were excluded. Some studies 
evaluate the association between child-rearing and CVD, and therefore can include men and 
women who have children. This review however, was focussed on the biological effect of being 
pregnant and therefore only results specific for child-bearing (parity) could be included. 
 
Studies that did not analyse the exposure of parity separately from other exposures were excluded. 
Some studies looked at the effect of multiple reproductive factors on CVD, for example; age at 
menarche and menopause as well as parity. Also, some studies assessed gravidity, which is the total 
number of pregnancies a woman has had, including those ending before 24 weeks. As this review 
was dedicated to the exposure of parity, it was necessary to ensure all included studies had a 
separate analysis and estimates of risk for parity with sufficient data presented. 
 
Studies were excluded if the outcome reported was not either in the form of adjusted risk estimates 
or raw numbers which could be used to calculate a risk estimate. This was necessary to ensure the 
results of included papers could be used in a meta-analysis.  
 
The inclusion and exclusion criteria were used to construct the search strategy for this review and 
were used simultaneously during the screening process to identify all studies capable of answering 
the review question.  
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3.2.5 Search strategy 
The search strategy for this review was to search three core medical databases: MEDLINE, EMBASE 
and CINAHL from the inception of the database to the most recent upload. MEDLINE is the US 
National Library of Medicine bibliographic database, which has a focus on biomedicine and health 
journals (US National Library of Medicine, 2017). MEDLINE was searched via the platform Ovid ‘Ovid 
MEDLINE ® Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE ® Daily 
and Ovid MEDLINE ® 1946 to Present’.  EMBASE is a bibliographic database published by Elsevier 
which contains journals for biomedicine and pharmacology (Elsevier, 2018). This database was also 
accessed through the platform Ovid. CINAHL is the Cumulative Index to Nursing and Allied Health 
Literature, which contains research studies relevant to nurses and allied health professionals. 
CINAHL Plus with Full Text was searched, which is an expanded form of the database, via the 
platform EBSCO Host (EBSCO, 2018)  
Other databases such as AMED and Web of Science were also considered, however due to the time 
restraints of this research it was decided to restrict the search to three databases. The previous 
systematic reviews by Lv et al. (2015) and Rich-Edwards et al. (2014) both used MEDLINE, while Lv 
et al. (2015) also searched EMBASE and Web of Science. As MEDLINE and EMBASE were the largest 
medical databases available, they were incorporated into the search strategy. After researching the 
remaining databases, CINAHL was chosen for this systematic review as it incorporates research 
relevant to allied health professions, including midwifery. As the research was linked to cardiology, 
obstetrics and midwifery it was valuable to search this database as well as the medical databases. 
As this review was expanding on the previous publications, it was necessary to ensure the previous 
studies would also be detected using the search strategy.  Therefore, once the search was complete, 
the previous reviews (Rich-Edwards et al., 2014; Lv et al., 2015) were checked to ensure all the 
studies included in these reviews had been found using the search strategy.  
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To construct the search strategy for each database, the key words from publications researching 
parity and CVD, identified in the scoping searches, were recorded, including the search terms used 
in the previous systematic reviews. Additional terms were sought by exploring alternative words or 
lay person terms for medical phrases. In addition, the American English spellings for several words 
were included as well as acronyms. It was necessary to include all these free text words to ensure 
the search would identify all relevant studies to the review question. As well as free text words, the 
subject headings for each database were examined to find headings which would be valuable to 
the search strategy.   
Each search term was trialled in MEDLINE to assess how relevant the resulting articles were to the 
research question and was then adjusted or included accordingly. Wildcards, which are symbols 
programmed to modify a search term, were utilised to allow for the searching of part of a word 
with multiple suffixes (Boland, Cherry and Dickson, 2014). The use of these wildcards increased the 
effectiveness of the search strategy at finding all appropriate publications, without needing to add 
more search terms.   To reduce the number of irrelevant search results the free text words were 
only searched in the title and abstract of articles. As this systematic review only included 
observational studies, several search terms were incorporated into the strategy to highlight articles 
which were of an observational study design or were aiming to assess risk factors for disease. This 
reduced the number of papers on randomised controlled trials in the search results, therefore 
improving the search strategy. Boolean operators ‘OR’ and ‘AND’ were used to refine the search to 
publications which contained at least one search term for parity, CVD and study design (Boland, 
Cherry and Dickson, 2014). Throughout the development of the search strategy the systematic 
review team at the iPCHS offered advice to ensure the wildcards and search terms would be 
effective enough to conduct a robust search. Once the search strategy had been finalised the 
systematic review was registered on the PROSPERO website (Booth et al., 2012). 
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The original search strategy was created using MEDLINE, which had to be adapted to suit EMBASE 
and CINAHL. This is because each database uses different symbols for wildcards and has a unique 
set of subject headings. The final version of the search strategy for MEDLINE is shown in Appendix 
B and the free text search terms used are shown in table 3.2. The final searches for each database 
took place on 6th December 2017 for MEDLINE, 8th December 2017 for EMBASE and 2nd January 
2018 for CINAHL. The search results from each database were exported into Legacy RefWorks, 
which is an online reference management software, and the duplicates were deleted.  
Table 3.2 Free text terms used in the search strategy for this systematic review. Note: a forward slash (/) 
depicts where a wildcard would have been used to truncate a search term. 
Exposure Terms: Outcome Terms: Study Design Terms: 
Pregnant/Pregnancy/cies Angina Epidemiology 
Multiparous/Multiparity Myocardial infarct/Infarction Etiology 
Parity MI Risk/s 
Parous Myocardial ischaemia Cohort/s 
Gravidity Ischaemic myocardium Predict/s/Prediction 
Live Birth/s Ischaemic heart disease  
 CHD  
 Heart attack/s  
 Coronary artery disease  
 Coronary heart disease  
 Acute coronary syndrome/s  
 ACS  
 Stroke/s  
 Cerebral infarct/s/infarction  
 Cerebrovascular disease  
 Cerebrovascular accident/s  
 Cerebrovascular event/s  
 CVA  
 Cardiovascular disease/s  
 CVD  
 Cardiovascular outcome/s  
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3.2.6 Screening Process 
The selection process of studies for this systematic review was defined within the protocol in order 
to reduce bias and conflict between reviewers during screening, as studies can only be included if 
they fulfil the predefined criteria at each stage of screening. The titles of the imported studies were 
screened against the inclusion criteria, by a single reviewer, AW, within Legacy RefWorks. The 
studies which were deemed potentially eligible were imported into Covidence (Veritas Health 
Innovation Ltd, 2018), an online systematic review software which facilitates screening by multiple 
reviewers. Two reviewers; AW and Dr Pensée Wu (PW), independently screened all the abstracts 
of the studies against the inclusion and exclusion criteria. After this stage of screening, the full texts 
of the remaining studies were independently screened by the same two reviewers. Any conflicts 
which arose were dealt with by further scrutiny of the study in question as well as discussion 
between the two reviewers until a consensus was reached. The studies which satisfied the inclusion 
and exclusion criteria were included within the systematic review. The references of these included 
studies were searched for any eligible papers which had not been identified by the search strategy 
or the screening process.  
3.2.7 Data extraction 
To compare the characteristics and outcomes of the studies through a narrative synthesis and 
meta-analyses, a large amount of information was required from each paper. To ensure all the 
necessary information was extracted from the included studies a form was developed using 
Microsoft Excel 2013. It was important for the form to be clear and easily readable but also 
comprehensive. Therefore, the form was trialled before data extraction began to highlight any 
relevant data which may be missed or any elements of the form which were ambiguous in the 
potential information needed. The two reviewers AW and PW discussed the form to ensure both 
understood what was required in response to each item. A single reviewer, AW, extracted the data 
from all of the included studies whilst the second reviewer, PW, extracted data from 30% (six) of 
the included papers. The data were compared for the six papers which both reviewers had 
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extracted, to check for any mistakes in recording the information and any disagreements were 
resolved by discussion.  The author of one paper (Peters et al., 2016) was contacted for additional 
raw data which had not been published, and this was provided.  The headings included in the data 
extraction form can be seen in Appendix C.   
3.2.8 Quality Assessment 
When conducting a systematic review, it is vital that the quality of included studies is assessed and 
taken into account when forming conclusions from the results. A standardised approach to assess 
quality must be used to reduce reviewer bias and to allow a clear comparison of studies within the 
review. The quality of a study is largely dependent on the internal validity, i.e. the risk of bias and 
confounding introduced through the research process, and the external validity, i.e. how 
generalisable the study results are to the whole population (Szklo and Nieto, 2014). The criteria used 
to judge the quality of a research paper differ depending on the study design. The quality 
assessment tool used in this review was the Newcastle-Ottawa Quality Assessment Scale (Wells et 
al., 2014), and is presented in Appendix D. This tool was chosen because it was designed specifically 
to assess both case-control and cohort studies, which were included within this review. The 
Newcastle-Ottawa Scale (NOS) has been validated in terms of the content and inter-rater reliability 
(Wells et al., 2014). Also, a Health Technology Assessment report (Deeks et al., 2003) assessed 
several quality assessment tools and concluded that the NOS was one of the best tools and was 
suitable for use in a systematic review.  
The NOS is comprised of eight questions within the three domains of selection, comparability and 
outcome for cohort studies and the domains of selection, comparability and exposure for case-
control studies. All of the research methods that could have been used for each question are ranked 
and stars are awarded for the research method/s which are deemed of the highest quality. For 
example, the potential methods for the ascertainment of exposure in a study are: searching secure 
records such as medical notes, conducting a structured interview and participant self-report 
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through a questionnaire. As there is a greater potential for recall bias with an interview or 
questionnaire, in this question of the NOS, the star was awarded for the use of secure records, with 
the second best method being an interview and the self-report ranked lowest.  This allocation of 
stars and ranking methods allows a reviewer to rate the overall quality of a study, by how many 
stars it has been awarded, but also assess in which areas the study has performed well or poorly.  
The comparability domain within the NOS focussed on whether the exposed and unexposed 
participants within a cohort are sufficiently comparable, based on the management of risk factors 
in either the design or analysis of a study. Studies which adjusted for age, which was considered 
the most important confounding factor in these studies by the reviewers (AW and PW), were 
awarded a star. Studies which additionally adjusted for the physiological risk factors of CVD, 
smoking, hypercholesterolaemia, hypertension, obesity and diabetes mellitus, were awarded a 
second star. As well as this, adjustment for socioeconomic status indicators e.g. income and 
education level was credited with a second star.  
One of the questions within the outcome domain of the NOS, asked whether the follow up of 
participants was long enough for the outcome to occur. For this review, the adequacy of follow up 
was dependent on the age of the participants at the start of follow up, as there is a considerable 
time difference between exposure and outcome. This lag effect (Yusuf et al., 2001) is due to slow 
development of atherosclerosis over decades (Grech, 2003; Libby and Theroux, 2005) which in turn 
causes CHD and stroke (Strom and Libby, 2011). There is no defined age at which atherosclerosis 
will manifest in diagnosed CVD, meaning there is no clear definition of adequate follow up time for 
this review. However, according to data collated by the British Heart Foundation (BHF) (Townsend 
et al., 2014) in 2013, the prevalence of angina and stroke did not surpass 1% of the female 
population until the age category of 55-64 years. Therefore, the definition of an adequate follow 
up in this systematic review was if the follow up was long enough for all of the participants to reach 
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at least 55 years of age. This represented the minimum length of follow up which would be 
adequate for a cohort study assessing the relationship between parity and CVD.  
In this review, the questions within the NOS were incorporated into the data extraction sheet to 
simplify the extraction process. The data relevant to the quality assessment were then copied into 
a separate table which explicitly gave the results for each question of the NOS. The same method 
as for the data extraction was used for quality assessment, with AW assessing all of the studies and 
PW assessing six of the included papers. Both reviewers then compared results to discern any 
difference in opinions of the level of bias for each study and resolved conflicts in opinion through 
discussion. The blank quality assessment table can be seen in Appendix E.  
3.2.9 Analysis (narrative / meta-analysis) 
In order to easily compare the studies, a brief narrative synthesis was completed before the meta-
analyses were performed.  This involved tabulating the key characteristics and results of each study 
and summarising the similarities and differences between the studies. This element of the analysis 
focussed on the design, methods and key findings of each study as well as the quality assessment.  
The main analysis in this systematic review was conducted quantitatively by performing meta-
analyses, complemented by subgroup and sensitivity analyses. The studies included within the 
review were evaluated to decide whether the results were sufficiently homogenous to combine in 
a meta-analysis. Although the studies varied in follow up time and overall risk estimates, all the 
studies recruited adult women and examined the exposure of parity on either CHD or stroke 
incidence. It was therefore decided that the studies were sufficiently homogenous to conduct a 
meta-analysis. As there were small differences in the study designs, subgroup analyses were also 
completed by stratifying the studies by adequacy of follow up length and continent of origin.  
In order to combine the results of several studies, the reference group for the risk estimates for 
each study had to be the same, which for this review was nulliparous women. As the included 
studies used different reference groups in the analysis, for example some studies used para 1 
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women, the risk estimates from each study were converted to all use nulliparous women as the 
reference group. This was achieved by the method derived by Hamling et al. (2008) using the 
conversion spreadsheet downloaded from www.pnlee.co.uk/software.htm. This method was also 
used to calculate ever parous vs nulliparous risk estimates from studies which only reported results per 
parity level. The risk estimates which were adjusted for the most confounders were extracted from 
the papers and used for these conversions. The risk estimates reported by the studies were either 
relative risk or hazard ratios, which were treated as equivalent in the analysis.  
Once the data were in an appropriate, consistent form, Review Manager Version 5.3 (RevMan5), a 
software developed by The Cochrane Collaboration (2014) was used to conduct the meta-analyses.  
RevMan5 allows the input of adjusted risk estimates or raw numbers from which unadjusted risk 
estimates are calculated. The included studies were all slightly different from each other in terms 
of the exact population chosen or the recorded outcome. Therefore, random effects analyses were 
completed, as this method assumes each study has a different true effect size being examined 
(Boland, Cherry and Dickson, 2014). As the data available from the studies were dichotomous, 
either participants had a CVD event, or they did not, the raw data were analysed using the inverse 
variance method to create unadjusted risk ratios. The adjusted risk estimates, either hazard ratios 
or relative risk, were inputted using the generic inverse variance setting of the RevMan5 software.  
This utilised the DerSimonian and Laird method for conducting meta-analyses where the true effect 
size is different but related across studies (DerSimonian and Laird, 1986; Higgins and Green, 2011). 
To test the statistical heterogeneity between the studies and between the outcomes, an I2 statistic 
was calculated. This statistic describes the percentage of difference between the study estimates 
which are due to heterogeneity rather than chance (Higgins and Green, 2011). A high I2 statistic 
indicates large heterogeneity between the studies or stratified outcomes.  
This analysis was completed for the cohort studies, stratified by the outcomes of CHD and stroke. 
The case-control studies were analysed separately to the cohort studies and all investigated the 
outcome of CHD, meaning there was no stratification by outcome for case-control studies. There 
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was not enough raw data from the case-control studies to conduct an unadjusted analysis, 
therefore only an adjusted random effects analysis was performed. Of the five case-control studies, 
three presented a relative risk estimate and two reported odds ratios. As there was a small number 
of outcomes in these studies, the odds ratios and relative risks were treated as equivalent. The final 
meta-analysis of the case-control studies was reported as an odds ratio.  
These methods were used to assess ever parous versus nulliparous risk ratios and each parity level 
of 1 to 5+ versus nulliparous. One of the cohort studies (Magnus et al., 2017) categorised women 
into para 4+ and so could not be compared with the 5+ parity levels used in other studies. For this 
study, only the parity levels 1, 2 and 3 were used in the analysis. Two of the cohort studies reported 
parity levels of 5 and 6+ and so could also not be directly compared to the remaining studies. The 
para 5 and 6+ levels from one of the studies (Steenland, Lally and Thun, 1996) was combined using 
the technique proposed by Hamling et al. (2008), to form a para 5+ risk estimate, which was used 
in the meta-analysis. However, the other study (Simons et al., 2012) did not present enough raw 
data to transform the categories, meaning only the parity levels 1, 2, 3 and 4 were used in the 
analysis. Once the parity level analyses were performed, the pooled result for each parity level was 
transferred to a graph, to display the change in risk of CVD as parity increases.  
3.2.10 Changes to the Protocol 
As the systematic review progressed, it became necessary to update the protocol as certain issues 
arose which had not been considered at the time of protocol design. This was done so both 
reviewers were aware of the revised eligibility criteria during the screening process and to ensure 
both were clear on their role within the review.  
Firstly, during the full text screening stage, it was recognised that some studies used gravidity as 
the exposure criteria rather than parity. Gravidity is the number of pregnancies a woman has had, 
including those ending before 24 weeks, which would therefore include parous women. However, 
as this review was based upon the biological mechanisms which occur throughout the three 
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trimesters of pregnancy, it was necessary to only include women who would have been exposed to 
the adaptations of carrying a pregnancy to term. The protocol was altered to reflect this by explicitly 
stating in the exclusion criteria that studies which only recorded exposure as gravidity or ‘number 
of pregnancies’ should be excluded.  
Also, due to the time restraints of this review, it was decided that the second reviewer, PW, would 
not extract data from all the included studies, as was originally intended. Instead the first reviewer 
AW extracted data from all the studies and PW extracted from 30% of the studies to quality assess 
AW’s extraction. The protocol was updated accordingly.  
3.3 Conclusion 
This systematic review screened the databases; CINAHL, MEDLINE and EMBASE for observational 
studies researching the association between parity and CVD, specifically CHD and stroke. The search 
results were screened against pre-specified criteria and all eligible papers were included within the 
review. These studies were then quality assessed using the NOS and the relevant data extracted. 
The individual risk estimates, for both ever parous and per parity level versus nulliparous, were then 
combined using random effects meta-analyses for CHD and stroke separately. The results are 
reported in the next chapter. 
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4 Systematic Review of association of parity with CVD: Results 
The previous chapter discussed the development of systematic reviews as a distinct research 
category and the benefits systematic reviews provide for evidence based medicine. The main 
principles which underpin a systematic review were outlined as well as the generic process which 
is followed when conducting a review. The previous chapter also detailed the methods used to 
complete this systematic review of the association between parity and cardiovascular disease (CVD) 
and explained the reasons for selecting the methods employed.  
This chapter will present the results of the systematic review, including a brief narrative synthesis 
of the included studies and a quantitative synthesis comprised of several meta-analyses. The 
chapter will detail the outputs from each section of the review process, starting with the selection 
and description of the included studies, the quality assessment and the individual results reported 
from each study. The meta-analyses will then be presented along with subgroup analyses.  
4.1 Selection of Included Studies: 
As explained in the previous methods chapter; three databases: MEDLINE, EMBASE and CINAHL 
were searched for any relevant publications. The published conference abstracts available from 
these databases were also searched but this did not reveal any studies related to parity and CVD. 
Figure 4.1 follows the PRISMA reporting guidelines (Moher et al., 2009) and displays the number of 
studies reviewed at each stage of the selection process with the reasons for exclusion of studies. 
Even though the Web of Science database, used in the previous systematic review by Lv et al. 
(2015), was not included in the search strategy for this review, all the studies that were included in 
the Lv et al. review were also identified in the current search. Also, all of the studies included in the 
Rich-Edwards et al. (2014) review were identified by the search strategy for this review.  
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Figure 4.1 The screening process of studies identified by the search strategy for inclusion in this 
systematic review. Flow diagram adapted from the PRISMA guidelines (Moher et al., 2009). 
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4.2 Included Studies 
The final number of studies included within the systematic review was eighteen, comprising 
thirteen cohort studies and five case-control studies. These studies provided information from 
2,869,391 women, with the most participants originating from the cohort study by Parikh et al. 
(2010), which contributed 1,332,062 women. The smallest cohort study was Cooper et al. (1999) 
which included 867 women. Out of the participants from the cohort studies, 322,440 were 
nulliparous. This equates to approximately eight parous women: one nulliparous woman.  In 
comparison to the cohort studies, the case-control studies included less women, with the smallest 
being (Beard, Fuster and Annegers, 1984) with 507 women and the largest being Rosenberg et al. 
(1999) with 2,112 women. Overall the case-control studies contributed 6,626 women to the total 
number of women included in this review.  
The publication dates of the studies ranged from 1984 to 2017, although most of the papers (n=11) 
were published after 2000. Due to the varying length of follow up and time to publication, the 
studies may have started many years before publication. For example, (Jacobsen et al., 2011) used 
data recorded from 1976-1988.  
Of the eighteen studies in this review, nine focussed on the outcome of coronary heart disease 
(CHD), two studies assessed the risk of stroke, while seven of the studies assessed both CHD and 
stroke. All five of the case-control studies identified CHD cases only. Therefore, sufficient data were 
available to conduct meta-analyses for CHD and stroke separately. As explained in chapter 2, this 
systematic review included studies reporting on both morbidity and mortality from CVD with the 
outcome of CVD being specific to either CHD, stroke or both. Of the included studies, five used non-
fatal CVD events as the outcome, four used fatal CVD events and nine reported outcomes of both 
fatal and non-fatal CVD events.  
The included studies were carried out in several different countries; eight papers were carried out 
in the United States (US), seven papers were from European countries, two were from China and 
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one study was from Australia. Many of the papers from the US and Europe included predominately 
white participants, with Magnus et al. (2017), Cooper et al. (1999) and Colditz et al. (1987) reporting 
a study population with ≥95% white women. Vladutiu et al. (2017) oversampled black women in 
the US to create a cohort with approximately equal numbers of black and white women and 
reported separate results for each group. Also, Rosenberg et al. (1999) used data from the Black 
Women’s Health Study in the US.  
The study design and methods varied between studies, with some researchers using national 
databases and others using questionnaires or medical examinations to collect data. Some studies 
were carried out using data from previous trials which used cohorts whereas others recruited 
participants to form a new cohort. Of the cohort studies the median length of follow up ranged 
from six years (Magnus et al. 2017, Colditz et al., 1987) to fifty-one years (Cooper et al., 1999). As 
stated in chapter 3, an adequate length of follow up was defined as, a follow up long enough for all 
participants to reach at least 55 years of age. Which was achieved by seven of the cohort studies 
included in this review.  
The main characteristics and findings of the cohort and the case-control studies are summarised in 
tables 4.1 and 4.2. The study ID is used to identify studies and is derived from the lead authors 
surname and the year of publication from each study.
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Table 4.1 Main characteristics and results of cohort studies included in this systematic review. 
Study ID Country 
Number of 
Participants 
Age at 
start of 
follow up 
(years) 
Outcome 
Number of 
Outcome 
Events 
Follow 
up 
Period 
Length of 
Follow Up 
(years) 
Adjusted 
HR/RR (95% CI) 
Parous vs Nulliparous 
Adjusted Factors 
Cohort Studies  
Colditz,  
1987 
United 
States 
118,376 
Range 
30-55 
Non-fatal MI and 
death due to CHD 
299 
1976-
1982 
Total 6 CHD: 0.83 (0.56-1.25) Age 
Cooper,  
1999 
United 
States 
867 
Range 
63-81 
Fatal and non-
fatal CHD events 
45 
1935-
1990 
Range 
51-56 
CHD: 0.78 (0.40-1.51) Age 
Gallagher, 
2011 
China 256,023 Mean 52.4 
Fatal CHD and 
stroke events 
1054 
1989-
2000 
Range 
9-11 
CHD: 0.87 (0.50-1.52) 
Stroke: 0.80 (0.51-1.26) 
Age and smoking 
Jacobsen, 
2011 
United 
States 
9,863 Mean 64 
Mortality from 
CHD and stroke 
800 
1976-
1988 
Mean 
10.7 
CHD: 0.93 (0.75-1.14) 
Stroke: 1.21 (0.85-1.71) 
Marital status and level 
of education 
Klingberg, 
2017 
Sweden 16,515 Mean 57.7 
Fatal or non-fatal 
MI or stroke 
1540 
1991-
2010 
Median 
15.8 
CHD: 1.08 (0.86-1.36)  
Stroke: 1.05 (0.83-1.33) 
Age, diet quality, 
smoking, exercise, 
education, HRT, country 
of birth, hx of 
miscarriage, BMI and 
weight change 
Magnus, 
2017 
United 
Kingdom 
180,626 Mean 55 
Mortality and 
morbidity from 
CHD and stroke 
 
1187 
2006-
2015 
Median 
6 
CHD: 1.21 (0.99-1.48) 
Stroke: 0.85 (0.65-1.10) 
Age, ethnicity, 
qualifications, income, 
Townsend deprivation 
index, fhx of CVD, 
smoking, alcohol, 
exercise, BMI, DM and 
high BP 
Parikh,  
2010 
Sweden 1,322,032 All 50 
Hospitalisation 
for CHD or stroke 
59,143 
1982-
2005 
Median 
9.5 
CHD: 1.06 (1.02-1.11) 
Stroke: 1.0 (0.97-1.03) 
Age, birth year, income, 
education level and 
country of birth 
Peters, 
 2016 
10 
European 
Countries 
12,161 Mean 52.7 
Fatal and non-
fatal CHD events 
4612 
1991-
2010 
Median 
11.1 
CHD: 1.19 (1.01-1.41) 
Age, education level, 
smoking, high BP, 
cholesterol, hx DM and 
BMI 
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Peters, 
 2017 
China 289,573 Mean 50.5 
Fatal and non-
fatal CHD and 
stroke events 
34,365 2004- 
Median 
7.1 
CHD: 0.88 (0.77-1.0) 
Stroke: 0.97 (0.86-1.09) 
Age, education level, 
income, exercise, 
smoking, alcohol, high 
BP, cholesterol, hx DM 
and BMI 
Simons,  
2012 
Australia 1571 Mean 72.3 
Mortality from 
CHD and 
ischaemic stroke 
N/A 
1988-
2004 
Total 
16 
N/A 
Age, alcohol, smoking, 
peak flow, disability, 
health, AF, high BP, DM 
and BMI 
Steenland, 
1996 
United 
States 
585,445 Median 56 
Mortality from 
CHD 
4787 
1981-
1989 
Total 
7 
CHD: 0.94 (0.85-1.04) 
Age, race, smoking, 
baseline health, blue 
collar status, education, 
exercise, high BP, BMI, 
oestrogen use, and 
vegetable consumption 
Vladutiu, 
2017 
United 
States 
13,954 
Mode  
50-59 
Fatal or non-fatal 
stroke 
447 
2003-
2014 
Mean 
7.5 
Stroke: 
 White Women  
0.9 (0.61-1.32) 
Black Women: 
1.09 (0.71-1.69) 
Age, race, education, 
marital status, income, 
location, smoking, 
alcohol, menopausal 
status, OC use and HRT 
Yang,  
2009 
Sweden 45,729 
Range 
30-49 
Fatal or non-fatal 
stroke 
193 
1991-
2004 
Mean  
12.9 
Stroke: 0.90 (0.5-1.4) 
Age, BMI, education, 
alcohol, smoking, 
exercise, high BP and 
DM 
 Key: AF; Atrial Fibrillation, BMI; Body Mass Index, BP; Blood Pressure, CHD; Coronary Heart Disease, CI; Confidence Interval, CVD; Cardiovascular Disease, DM; Diabetes 
Mellitus, fhx; Family History, HR; Hazard Ratio, HRT; Hormone Replacement Therapy, hx; History, OC; Oral Contraceptive, RR; Rate Ratio. 
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Table 4.2 Main characteristics and results of case-control studies included in this systematic review. 
Key: BMI; Body Mass Index, BP; Blood Pressure, CHD; Coronary Heart Disease, CI; Confidence Interval, DM; Diabetes Mellitus, fhx; Family History, HRT; Hormone 
Replacement Therapy, hx; History, OR; Odds Ratio, RR; Rate Ratio. 
 
Study ID Country 
Number of 
Participants 
Age (years) Outcome 
Number of 
Outcome 
events 
Follow up 
Period 
Adjusted  
OR/RR (95% CI) 
Parous vs Nulliparous 
Adjusted Factors 
Case-control Studies  
Beard, 
 1984 
United 
States 
507 Less than 60 
CHD mortality 
and morbidity 
/ 1960-1974 1.4 (0.9-2.1) Unadjusted Ratio 
Bertuccio, 
2007 
Italy 1715 
Median 53 
and 56 
Non-fatal MI 1368 1983-2003 1.45 (1.07-1.97) 
Age, education, BMI, smoking, 
coffee, alcohol, cholesterol, 
DM, obesity, high BP, HRT and 
fhx MI 
La Vecchia, 
1987 
Italy 576 
Median 45 
and 47 
Non-fatal MI 418 1983-1986 1.45 (0.92-2.27) Age 
Palmer,  
1992 
United 
Status 
1716 Median 60 Non-fatal MI 1505 1986-1990 1.8 (1.0-3.30) 
Age, smoking, high BP, 
cholesterol, DM, fhx MI, 
exercise, BMI, alcohol, 
education, oestrogen use, 
occupation, age at menarche, 
age at first birth, menopausal 
status, marital status, hx of 
hysterectomy and 
oopherectomy 
Rosenberg, 
1999 
United 
States 
2112 Median 38 CHD morbidity 1794 1995 1.67 (0.87-3.22) 
Age, education, smoking, high 
BP,DM, cholesterol, fhx MI and 
height 
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4.3 Quality Assessment 
The Newcastle-Ottawa Scale (NOS) (Wells et al., 2014) was used to assess the quality of each study 
in the systematic review. The NOS assesses internal validity by evaluating the risk of selection bias, 
meaning the likelihood that the participants selected for the study will shape the results towards a 
certain outcome (Pannucci and Wilkins, 2010).  For example, the study by Colditz et al. (1987) only 
recruited nurses to the study, who would have a greater knowledge of healthy lifestyle behaviours 
than the general population. The NOS also evaluates the risk of information bias, which occurs when 
the recording of outcomes is not consistent or reliable (Pannucci and Wilkins, 2010). A specific 
example of this can be seen in Cooper et al. (1999) as the participants were required to self-report 
the incidence of CHD after 51 years of follow up, which is reliant on the individual’s ability to 
accurately recall this information, introducing recall bias or response bias (Sedgwick, 2014). 
However, as this condition causes chest pain and can require hospital admission, it is likely that a 
participant would remember this life event.  
As explained in chapter 2, the NOS has distinct domains and questions to suit the differences in 
design of cohort and case-control studies. The results therefore are presented separately in table 
4.3 for cohort and table 4.4 for case-control studies.  
There was large variability in the results of the quality assessment, not only between studies but 
also between different domains of the same study.  For example, Rosenberg et al. (1999) achieved 
2/2 stars for the adjustment of confounding factors within the comparability domain but scored 
poorly, 1/3 stars, in the exposure domain. Similar trends are seen in many of the studies (Steenland, 
Lally and Thun, 1996; Bertuccio et al., 2007; Simons et al., 2012; Vladutiu et al., 2017) which 
adjusted for multiple important confounders within the analysis of results, but potentially 
introduced bias through participant selection, or outcome assessment. A difference across domains 
can also be seen from (Peters et al., 2017) which achieved all available stars in the selection and 
comparability domains but did not have a long enough follow up for the outcome of interest 
59 
 
(defined as all participants reaching at least 55 years of age) and therefore scored 2/3 in the 
outcome domain.  
Due to the diversity of the study designs, there are differences in the quality assessment across 
studies. On the other hand, some consistencies exist between the studies. Firstly, for the ‘selection 
of the non-exposed’ element of the selection domain for cohort studies, all of the studies sampled 
nulliparous women from the same population as the parous women. All of the studies 
accomplished this by recruiting participants and then identifying the exposure status of the women. 
As explained previously in this chapter, this selection method is reflected in the low number of 
nulliparous women compared with parous women within the studies.  
Another similarity between the studies is that the majority of studies (n=12), adjusted for multiple 
confounding factors and therefore attained the two available stars in the comparability domain. 
There was variation in the number of adjusted confounders, however, all studies, except Jacobsen 
et al. (2011), adjusted for age.  
Within the case-control study quality assessment, all of the studies recruited controls which had no 
history of CVD and therefore gained a star in the ‘definition of controls’ section of the selection 
domain. Also, all the studies used the same method of ascertaining the exposure status for both 
cases and controls and therefore achieved a star in the ‘same method of ascertainment for cases 
and controls’ question of the exposure domain.  
The study which, according to the NOS, had the highest quality was Parikh et al. (2010), as it met 
the criteria for all of the available stars in each domain. This is reassuring as this study was also the 
largest, contributing almost half of all the participants included in this review and therefore was 
given the greatest weight in the meta-analyses. Consequently, the meta-analyses were influenced 
most by a study with limited potential for bias in the design and analysis.  
The studies which appeared to be of the lowest quality were Cooper et al. (1999), Gallagher et al. 
(2011) and Jacobsen et al. (2011), which all scored only one star in the selection domain. These 
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studies did not use women who were representative of the general female population or reliably 
ascertain exposure information or display temporality in the design methods. Jacobsen et al. (2011) 
was also not awarded any stars in the outcome domain, due to not reliably assessing the presence 
of the outcome and not having an adequate length of follow up for the outcome of interest to 
occur, therefore introducing information bias.  
There was an additional feature of quality specific to the cohort studies included in this review, 
which was not assessed by the NOS. This was whether the assumption of proportional hazards had 
been met when conducting the Cox proportional hazards regression. All of the cohort studies used 
Cox proportional hazards regression, except Cooper et al. (1999), Colditz et al., (1987) and Jacobsen 
et al., (2011) which used logistic regression. These three studies reported risk estimates as risk 
ratios (RR), while the studies which used Cox regression reported hazard ratios (HR). Only six of the 
ten studies which used Cox regression reported that the assumption had been tested during 
statistical analysis and only two of these (Simons et al., 2012; Peters et al., 2017) declared that the 
assumption was met. The other four studies did not give an explanation as to whether the 
assumption had been tested.  
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Table 4.3 Results of the quality assessment of the cohort studies in this systematic review using the Newcastle-Ottawa Scale. 
Study ID Selection Comparability Outcome 
Surname, 
Year 
Representativen-
ess of the 
exposed cohort 
Selection of 
non-exposed 
Ascertainment 
of exposure 
Tempora-
lity in 
results 
Total 
number 
of stars 
(max. 4) 
Confounders 
adjusted for 
in analysis 
Total 
number 
of stars 
(max. 2) 
Assessment 
of outcome 
Was 
follow up 
long 
enough? 
Particip-
ants lost 
to follow 
up 
Total 
number 
of stars 
(max. 3) 
Colditz, 
1987 
Selected group of 
nurses 
Drawn from 
same 
community as 
exposed 
Self-report yes 2 Age 1 
Record 
linkage 
no 
 
4.6% lost 
 
2 
Cooper, 
1999 
Somewhat 
representative. 
All college 
educated 
Drawn from 
same 
community as 
exposed 
Self-report no 1 Age 1 Self-report yes 
8.06% 
lost 
2 
Gallagher, 
2011 
Selected group of 
factory workers 
Drawn from 
same 
community as 
exposed 
Self-report no 1 Age 1 
 
Record 
linkage 
 
no 0% lost 2 
Jacobsen, 
2011 
Selected group of 
Seventh Day 
Adventists 
Drawn from 
same 
community as 
exposed 
Self-report no 1 Education 1 Self-report no 
Not 
explained 
0 
Klingberg, 
2017 
Truly 
representative 
Drawn from 
same 
community as 
exposed 
Self-report yes 3 
Age, 
smoking, 
education* 
2 
Record 
linkage 
yes 
Not 
explained 
2 
Magnus, 
2017 
Truly 
representative 
Drawn from 
same 
community as 
exposed 
Structured 
interview 
yes 4 
Age, 
smoking, 
education* 
2 
Record 
linkage 
yes 
Not 
explained 
2 
Parikh, 
2010 
Truly 
representative 
Drawn from 
same 
Swedish Multi yes 4 
Age, 
education* 
2 
Record 
linkage 
yes 
 
0% lost 
3 
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community as 
exposed 
Generation 
Register 
Peters, 
2016 
Truly 
representative 
Drawn from 
same 
community as 
exposed 
Self-report yes 3 
Age, 
smoking 
education* 
2 
Record 
linkage and 
self-report 
yes 
Not 
explained 
2 
Peters, 
2017 
Truly 
representative 
Drawn from 
same 
community as 
exposed 
Structured 
interview 
yes 4 
Age, 
smoking 
education* 
2 
Record 
linkage 
no 
 
0% lost 
2 
Simons, 
2012 
Truly 
representative 
Drawn from 
same 
community as 
exposed 
Self-report no 2 
Age, 
smoking* 
2 Self-report yes 
Virtually 
complete 
2 
Steenland, 
1996 
Somewhat 
representative. 
American Cancer 
Society 
volunteers and 
friends 
Drawn from 
same 
community as 
exposed 
Self-report yes 2 
Age, 
smoking, 
education* 
2 
Record 
linkage 
no 0.2% lost 2 
Vladutiu, 
2017 
Somewhat 
representative. 
Drawn from high 
risk stroke areas 
Drawn from 
same 
community as 
exposed 
Self-report yes 2 
Age, 
smoking, 
education* 
2 
Record 
linkage 
yes 
Not 
explained 
2 
Yang, 
2009 
Truly 
representative 
Drawn from 
same 
community as 
exposed 
Self-report yes 3 
Age, 
smoking, 
education* 
2 
Record 
linkage 
no 
Virtually 
complete 
2 
 *Other confounders were adjusted for, however the maximum available stars for this question was 2, awarded for adjustment for age, or physiological factors, for example 
smoking or socioeconomic status, for example education. The confounders have therefore been summarised into age, smoking and education. 
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Table 4.4 The results of the quality assessment of the case-control studies in this systematic review using the Newcastle-Ottawa Scale. 
 *Other confounders were adjusted for, however the maximum available stars for this question was 2, awarded for adjustment for age, or physiological factors, for example 
smoking or socioeconomic status, for example education. The confounders have therefore been summarised into age, smoking and education. 
 
 
Study ID Selection Comparability Exposure 
Surname, 
Year 
Is the case 
definition 
adequate? 
Representa-
tiveness of 
the cases 
Selection 
of controls 
Definition 
of 
controls 
Total 
number 
of Stars 
(max. 4) 
Confounders 
adjusted for in 
the design or 
analysis* 
Total 
number 
of stars 
(max. 2) 
Ascertainment 
of exposure 
Same method 
of 
ascertainment 
for cases and 
controls? 
Non-
response 
rate 
Total 
number 
of stars 
(max. 3) 
Beard,  
1984 
Not 
described 
Representa-
tive cases. 
Taken from 
community 
Selected 
from 
community 
No 
history of 
disease 
2 Age  1 
Medical 
record 
Yes  
Non-
respond-
ers 
described  
1 
Bertuccio, 
2007 
Not 
described 
Representa-
tive cases. 
Taken from 
hospitals 
Selected 
from 
hospital 
No 
history of 
disease 
2 
Age, smoking, 
education* 
2 Interview Yes 
Same 
rate for 
cases and 
controls 
2 
La Vecchia, 
1987 
Validated 
medical 
records 
Representa-
tive cases. 
Taken from 
hospitals 
Selected 
from 
hospital 
No 
history of 
disease 
2 Age  1 Interview Yes 
Same 
rate for 
cases and 
controls 
2 
Palmer, 
1992 
Validated 
medical 
records 
Representa-
tive cases. 
Taken from 
hospitals 
Selected 
from 
community 
No 
history of 
disease 
4 
Age, smoking, 
education* 
2 Interview Yes 
Same 
rate for 
cases and 
controls 
2 
Rosenberg, 
1999 
Self report 
with 10% 
linked to 
medical 
records 
Selected 
cases with a 
subscription 
to Essence 
magazine 
Selected 
from 
community 
No 
history of 
disease 
2 
Age, smoking, 
education* 
2 Self report Yes 
Not 
described 
1 
64 
 
4.4 Meta-Analyses 
There were sufficient studies in the review to allow separate meta-analyses for CHD and stroke. A 
generic inverse variance, random effects model was used to complete the meta-analyses for risk 
estimates of ever parity and per parity level versus nulliparity. Both unadjusted and adjusted results 
are presented in this section. Three of the included cohort studies could not be used in both the 
ever parous and per parity level analyses due to insufficient data. Therefore, Cooper et al. (1999) 
and Yang et al. (2009) were only incorporated in the ever parous meta-analyses for CHD and stroke, 
respectively. Simons et al. (2012) could only be included in the per parity level analyses for both 
outcomes. The study completed by Vladutiu et al. (2017) reported separate results for black and 
white women and treated these samples as separate cohorts and were therefore included as 
separate cohorts in the meta-analyses. The results, in the form of RR, from these analyses will be 
reported throughout as follows; RR estimate (95% Confidence Interval). RR denotes an unadjusted 
estimate and aRR represents an adjusted risk estimate.  
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4.4.1 Ever parous versus Nulliparous Results 
Figure 4.2 displays the forest plot for the unadjusted meta-analysis of ever parous vs nulliparous 
risk of CHD and stroke from the cohort studies, which was calculated using the raw data from the 
studies. 
 
Twelve studies were included in this analysis, and as can be seen from the figure 4.2, six of these 
studies reported risk estimates for both CHD and stroke. This resulted in the use of ten studies in 
the CHD outcome and eight studies for stroke. For the outcome of CHD there were large variations 
in estimated risk, from Gallagher et al. (2011) reporting RR 0.14 (0.09-0.22) to Magnus et al. (2017) 
presenting RR 1.55 (1.27-1.89). Three studies reported statistically significant estimates implying an 
increased risk of CHD in ever parous women (Parikh et al., 2010; Peters et al., 2016; Magnus et al., 
2017) five reported statistically significant estimates indicating a reduced risk in ever parous women 
Figure 4.2 Forest plot demonstrating unadjusted ever parous versus nulliparous risk of CHD and stroke from 
cohort studies in this systematic review. 
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(Steenland, Lally and Thun, 1996; Cooper et al., 1999; Gallagher et al., 2011; Jacobsen et al., 2011; 
Peters et al., 2017) and two studies had non-significant results. The pooled estimate for the CHD 
meta-analysis was therefore a borderline statistically significant reduced risk of CHD for ever parous 
women, RR 0.79 (0.62-1.00).  
For the outcome of stroke the studies also varied in estimated risk, but with a smaller difference 
than seen for CHD. Again, Gallagher et al. (2011) reported an outlying low RR 0.12 (0.08-0.16). The 
Vladutiu et al. (2017) result for white women represented the largest risk increase for ever parous 
women compared to nulliparous with RR 1.36 (0.87-2.11). In contrast to the CHD outcome, all of 
the studies except Gallagher et al. (2011) were non-statistically significant. The pooled estimate for 
the stroke outcome was very similar to that of CHD, RR 0.82 (0.61-1.11), representing a reduced 
risk of stroke for ever parous women, however this was not statistically significant.  
As can be seen from the I2 statistics, there was large heterogeneity between the studies for the CHD 
and stroke outcomes (I2 = 98% and 96% respectively). The heterogeneity between the CHD studies 
was only slightly altered (97%) when the outlying results from Gallagher et al. (2011) were excluded. 
However, when the results from Gallagher et al. were excluded from the stroke outcome, the 
pooled estimate increased to RR 1.05 (0.94-1.18) albeit non-statistically significant, with a reduced 
heterogeneity of I2 = 64%.  
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A meta-analysis using adjusted data was performed and the resulting forest plot can be seen in 
figure 4.3. It must be noted that each study adjusted for different confounders, so even though the 
most adjusted data were taken from the primary papers, the results are not all adjusted for the 
same factors. The list of the confounders used in each study can be found in the previous section 
on quality assessment in table 4.3. 
 
The range of risk estimates across the studies reduced after adjustment, with the lowest aRR 
estimate for CHD coming from Gallagher et al. (2011) with aRR 0.83 (0.56-1.23) and the highest at 
aRR 1.21 (0.99-1.48) from Magnus et al. (2017). Similar results were found in the stroke outcome 
with the risk estimates ranging from aRR 0.80 (0.51-1.25) in Gallagher et al. (2011) to aRR 1.21 
(0.85-1.72) in Jacobsen et al. (2011). The adjustment lowered the heterogeneity in both outcomes, 
with I2 = 53% for CHD and I2 = 0% for stroke. The negligible heterogeneity between the stroke studies 
is likely due to the substantial weighting given to Parikh et al. (2010).  
Figure 4.3 Forest plot demonstrating adjusted ever parous versus nulliparous risk of CHD and stroke from 
cohort studies in systematic review. 
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The pooled adjusted estimates for the ever parous versus nulliparous risk of both CHD and stroke 
were both close to the null, aRR 1.01 (0.94-1.09) and 1.00 (0.97-1.03) respectively. In the CHD 
outcome, most of the studies reported adjusted risk ratios of <1. However, the largest studies gave 
higher ratios and gained the majority of weighting in the analysis. Parikh et al. (2010) presented 
aRR 1.06 (1.02-1.10) as well as Magnus et al. (2017) with aRR 1.21 (0.99-1.48) and Peters et al. 
(2016) aRR 1.19 (1.01-1.40). Following adjustment only two of the risk estimates remained 
statistically significant, which were from Parikh et al. and Peters et al. due to the large sample sizes. 
This equated to a null pooled result when combined with the smaller studies reporting reduced risk 
ratios.  
Within the stroke outcome, the majority of weight (89.4%) was given to Parikh et al. (2010) due to 
the very small standard error, resulting from the large sample size. The stroke events reported by 
Parikh et al. equated to 59% of all the stroke events (n=55,153), from the eight cohort studies 
recording this outcome. However, the reported aRR was not statistically significant, as were none 
of the other studies in the stroke outcome. The high RR favouring nulliparity for white women, from 
Vladutiu et al. (2017), in the unadjusted results became aRR 0.90 (0.61-1.33) after adjusment.  
 
4.4.2 Per Parity Level versus Nulliparous Results 
As well as analysing the risk of CHD and stroke in nulliparous compared to parous women, this 
systematic review aimed to determine whether the effect varied by number of pregnancies. 
Therefore, meta-analyses were conducted using data from each parity level (number of children), 
compared to nulliparous results.  
4.4.2.1 CHD 
The forest plot created from the meta-analysis for the unadjusted per parity level versus nulliparous 
risk of CHD is shown in figure 4.4. This analysis used the raw data from the studies to calculate the 
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pooled risk estimate. The parity levels used in this analysis were para 1, 2, 3, 4 and 5+ as the majority 
of the included studies reported the results in these categories. Eight papers were eligible for 
inclusion, however as Magnus et al. (2017) categorised participants into parity levels 1, 2, 3 and 4+, 
the risk estimates from this paper are only included in the first three levels; para 1, 2 and 3.   
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Figure 4.4 Forest plot demonstrating unadjusted per parity level versus nulliparous risk of CHD from cohort 
studies in this systematic review. 
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The unadjusted pooled estimates depict a clear trend of increasing risk ratios with ascending parity 
levels. Starting from para 1, the risk of CHD reduced, RR 0.71 (0.51-0.98), which increased to RR 
0.76 (0.61-0.96) with two children, but still demonstrated a decreased risk compared to nulliparous 
women. The pooled result for para 3 indicated a higher risk of CHD compared to para 1 and 2, 
however this risk was still less than the nulliparous risk, RR 0.82 (0.62-1.18). At para 4 the risk of 
CHD was no different to that of nulliparity RR 1.00 (0.67-1.49), whereas the risk of CHD after having 
five of more children was much higher compared to being nulliparous, RR 1.39 (0.90-2.14). 
However, only the pooled risk estimates for the para 1 and 2 outcomes were statistically significant, 
and they were unadjusted for confounding factors such as age and other CVD risk factors.  
Although there was a clear overall trend of increasing risk with each parity level from the pooled 
risk estimates, the pattern for individual studies was varied. The lowest estimated risk within parous 
women was found to be for para 1 in three of the studies (Gallagher et al., 2011, Magnus et al., 
2017, Peters et al., 2017), para 2 in three studies (Parikh et al., 2010; Peters et al., 2016; Klingberg 
et al., 2017) and para 3 in two studies (Steenland, Lally and Thun, 1996; Jacobsen et al., 2011). The 
highest risk was found to be in para 5+ for all of the studies except for Steenland, Lally and Thun 
(1996), which reported the highest risk of CHD in para 1. The heterogeneity for each parity level 
was therefore high, being at least 12 = 97%.  
A meta-analysis was performed using adjusted data from the studies and figure 4.5 displays the 
resulting forest plot. Two additional papers (Simons et al., 2012; Colditz et al., 1987) were included 
in this analysis, as they did not present enough raw data to be used in the unadjusted pooling, but 
gave adjusted risk estimates to use directly in the adjusted analysis. This increased the number of 
studies to ten. Similar to the previous analysis, Magnus et al., (2017) was used only in the first three 
parity levels and Simons et al. (2012) in the first four levels.  
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After adjustment for confounders, the pooled estimates for each parity level were largely altered 
from the unadjusted results. The estimates for para 1,2 and 3 were all close to the null, indicating 
no difference in risk between parous and nulliparous women. The risk of CHD increased in para 4 
compared to nulliparity, aRR 1.10 (0.93-1.31) with the highest risk being at para 5+, aRR 1.21 (0.93-
1.56). However, none of the pooled risk estimates were statistically significant.  
The individual study estimates were more consistent after adjustment, with a noticeable difference 
in Gallagher et al. (2011), which was a low outlier in the unadjusted analysis, which then reported 
higher adjusted risk ratios, in keeping with the rest of the studies (para 1 RR 0.85 (0.48-1.51)). Also, 
there was a change in estimate from Steenland, Lally and Thun (1996) which reported para 1 as the 
highest risk in the unadjusted results, but para 5+ as the highest risk in the adjusted results. The 
introduction of Simons et al. (2012) into the analysis affected the pooled results, even though it 
was a small study with limited weighting, as the risk ratios from this paper were outliers, showing 
an increased risk of CHD in parous women, compared to nulliparous, at each level (para 2 RR 2.11 
(1.11-4.01)). Colditz et al. (1987) reported conflicting results to Simons et al. as their risk estimates 
suggest a reduced risk of CHD for parous women at all parity levels. Despite the addition of more 
papers, the heterogeneity of each parity group was lower than in the unadjusted analysis, with the 
lowest being para 2 at I2 = 61%.  
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Figure 4.5 Forest plot demonstrating the adjusted per parity level versus nulliparous risk of CHD from 
cohort studies in this systematic review. 
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Figure 4.6 shows the change in risk of CHD with increasing parity using the pooled risk estimates 
from each parity level in the parous versus nulliparous adjusted meta-analysis. This demonstrates 
the equivalent risk of CHD for parous and nulliparous women in parity levels 1, 2 and 3 and the 
increased risk in parous women at para 4 and 5+. However as can be seen from the overlapping 
error bars on the graph, representing the confidence intervals, the results were not statistically 
significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.2.2 Stroke 
The forest plot resulting from the meta-analysis of unadjusted stroke risk per parity level is shown 
in figure 4.7. Ten studies were included in this analysis, however Magnus et al. (2017) was only 
included in the estimates for para 1, 2 and 3. The trend is similar to that of CHD risk, with the risk 
of developing stroke increasing from para 1 onwards, however this was not statistically significant 
at any parity level.  
There was once again a large variation between the studies within each parity group, with Gallagher 
et al. (2011) providing the lowest risk estimate for every parity level. However, the number of 
Figure 4.6 Per parity level versus nulliparous risk of CHD from cohort studies 
in this systematic review. 
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statistically significant risk estimates from the individual studies increased per parity level, with only 
one study (Parikh et al., 2010) for para 1, reaching five studies for para 5+ (Parikh et al., 2010; 
Klingberg et al., 2017; Peters et al., 2017; Vladutiu et al., 2017). The heterogeneity scores reflect 
these large differences between studies with all parity levels reaching at least I2 = 98%.  
When Gallagher et al. (2011) was excluded from the analysis the heterogeneity greatly reduced to 
as low as I2 = 44% (para 5+) whilst still retaining the same pattern of increasing risk after para 1. The 
pooled risk estimates for Para 3, 4 and 5+, compared to nulliparity gained statistical significance 
(para 3 RR 1.20 (1.08-1.33), para 4 RR 1.52 (1.33-1.73), para 5 RR 1.96 (1.75-2.20)).  
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Figure 4.7 Forest plot demonstrating unadjusted per parity level versus nulliparous risk of stroke from 
cohort studies in this systematic review. 
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The adjusted study results were also pooled to estimate the risk of stroke per parity level, and the 
corresponding forest plot can be seen in figure 4.8. Simons et al. (2012) was included in the adjusted 
analysis, although it was given little weight due to the large standard errors associated with the 
estimates. After adjustment for age, the risk estimates from Gallagher et al. (2011) were more 
comparable with the other studies (Para 1 aRR 0.87 (0.55-1.38)). The changes in risk ratios from this 
study and others contributed to the large reduction in heterogeneity for the adjusted estimates 
compared to the unadjusted across all parity levels, with the lowest being at para 1 and 2 at I2 = 0% 
and the highest in para 5+ with I2 = 50%.  
Within each parity level, Parikh et al. (2010) was allocated the largest weight, with Peters et al. 
(2017) receiving the second largest percentage. Therefore, the overall trend of risk with parity levels 
closely follows the results from Parikh et al. Figure 4.9 shows the pooled risk estimates of stroke for 
each parity level which follow a ‘J’ shaped curve. The para 1 risk was equivalent to nulliparity, with 
the nadir of risk being at para 2 (aRR 0.94 (0.91-0.97)), the risk of stroke increased with each parity 
level thereafter, reaching a maximum at para 5+ (aRR 1.21 (1.06-1.39)). Only the risk estimates for 
para 2 and para 5+ were statistically significant. 
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Figure 4.8 Forest plot demonstrating adjusted per parity level versus nulliparous risk of stroke from cohort 
studies in this systematic review. 
79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.3 Subgroup Analysis 
In order to determine whether differences in study characteristics affected the overall pooled 
results for the risk of CHD or stroke, subgroup analyses were performed. The studies were 
subgrouped based on study characteristics which were: the location in which the study took place, 
and whether the follow up time was adequate or not, based on the study sample and outcomes of 
interest. Subgroup analyses were performed for both CHD and stroke outcomes, using adjusted risk 
estimates. There were not enough studies to assess the risk of CHD and stroke per parity level within 
the subgroups.  Therefore, only the ever parous versus nulliparous risk was assessed in the 
subgroup analyses. As a result, Simons et al. (2012) was excluded from the analyses as this study 
did not report enough data to produce an ever parous risk ratio. 
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Figure 4.9 Per parity level versus nulliparous risk of stroke from cohort 
studies in this systematic review. 
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Risk of CHD  
The subgroup analyses for the risk of CHD in ever parous women comprised 10 studies. Figure 4.10 
shows the results of the analysis based on location. The studies were categorised into three groups: 
US (four studies), Europe (four studies) and China (two studies). The pooled risk estimates were 
conflicting, with the studies from the US and China demonstrating a lower risk of CHD in ever parous 
women (aRR 0.93 (0.85-1.01) and aRR 0.88 (0.77-1.00) respectively) with the European studies 
indicating an increased risk (aRR 1.08 (1.03-1.14)). The largest study in the review, Parikh et al. 
(2010) was included in the European subgroup which may have contributed to this being the only 
subgroup with a statistically significant result. Having said this, the Chinese subgroup reached 
borderline statistical significance. The studies within each subgroup were very similar, indicated by 
a negligible I2 statistic in the US and Chinese subgroups and only an I2 of 9% in the European group. 
There was however, clear discrepancy between the subgroups highlighted by the I2 = 85.9% result.  
 
Figure 4.10 Forest plot demonstrating ever parous versus nulliparous risk of CHD in subgroup analysis 
based on location of study, of cohort studies included in this systematic review. 
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A subgroup analysis based on the adequacy of follow up was also conducted. These results can be 
seen in figure 4.11, where the ‘Yes’ group is those with an adequate follow up and the ‘No’ group 
is those studies which did not. The ‘Yes’ group showed a higher risk of CHD for parous women (aRR 
1.08 (1.03-1.13)) and the ‘No’ group showed a reduced risk (aRR 0.92 (0.85-0.98)), with both 
estimates reaching statistical significance. This is reflected by the very slight heterogeneity within 
each subgroup and the high heterogeneity between the subgroups (I2 = 92.6%).  
 
4.4.3.1 Risk of stroke 
The same subgroup analyses, as explained above, were also performed on eight studies assessing 
stroke risk. The first analysis based on location, produced varying results across the subgroups, as 
the US group of studies found a higher risk of stroke in parous women (aRR 1.13 (0.96-1.33)) while 
the Chinese group determined a slightly lower risk (aRR 0.96 (0.85-1.08)) and the European group 
found no difference (aRR 1.00 (0.97-1.03)). There was also an apparent null effect of parity on 
stroke risk when the studies were categorised into those with and without an adequate follow up 
time. For the subgroup analysis on adequacy of follow up, the risk estimate for the ‘Yes’ group was 
Figure 4.11 Forest plot demonstrating ever parous versus nulliparous risk of CHD in subgroup analysis 
based on the adequacy of follow up of cohort studies included in this systematic review. 
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aRR 1.00 (0.97-1.03) and for the ‘No’ group the risk was aRR 1.02 (0.87-1.19). None of the pooled 
results from either of the stroke subgroup analyses were statistically significant. Notably, due to 
the large number of participants in the Parikh et al. (2010) study and therefore small standard error, 
the study took the largest weight, at least 90%, in every subgroup to which it was assigned. 
Therefore, the pooled risk estimates of the subgroup analyses for Europe and adequate follow up 
period directly correspond to the risk estimate from the Parikh et al. study.  
4.4.3.2 Summary of Subgroup Analyses 
The results of the subgroup analyses for both CHD and stroke outcomes are summarised below in 
table 4.5.  
Table 4.5 Results of the subgroup analysis for both CHD and stroke risk in ever parous versus nulliparous 
women, from the cohort studies included in this systematic review. 
 Coronary Heart Disease Results: Stroke Results: 
Subgroup: 
Number 
of 
Studies: 
Pooled Risk 
Ratio: 
I2value: 
(%)** 
Number 
of 
Studies: 
Pooled Risk 
Ratio: 
I2 value: 
(%)≠ 
Location: 
United States 
Europe 
China 
 
4 
4 
2 
 
0.93 (0.85-1.01) 
1.08 (1.03-1.14) 
0.88 (0.77-1.00) 
85.9  
2* 
4 
2 
 
1.13 (0.96-1.33) 
1.00 (0.97-1.03) 
0.96 (0.85-1.08) 
24.7 
Follow up 
Adequate: 
Yes 
No 
 
 
5 
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4.4.4 Meta-analysis of Case-control Studies 
The adjusted odds ratios (aOR) from the five case-control studies were combined in a meta-analysis 
comparing risk of CHD in ever parous versus nulliparous women. There were insufficient data for 
an unadjusted analysis. Beard et al. (1984) categorised parous women into those with less than four 
live births or four and more live births. As the majority of women in England and Wales have less 
than four children (Office for National Statistics, 2017b), the results reported for the more than four 
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births category of parous women were used within the analysis. The forest plot corresponding to 
the adjusted meta-analysis is displayed in figure 4.12.  
In the analysis Bertuccio et al. (2007) was allocated the largest weight, which also had a statistically 
significant individual aOR. The pooled aOR for CHD was significant and suggested almost a 50% 
increase in odds of CHD in parous women, aOR 1.49 (1.23-1.82), with low heterogeneity (I2 = 0%).  
4.4.5 Publication Bias 
A funnel plot was created using the cohort studies from the adjusted ever parous versus nulliparous 
risk of CHD and stroke analysis seen in figure 4.3.  The funnel plot in figure 4.13 displays the number 
of studies assessing stroke and CHD, therefore some studies are included twice. The graph 
highlights the lack of small studies included in this systematic review which present an increased 
risk of CVD in parous versus nulliparous women.  Most of the studies favour parity rather than 
nulliparity.  
Figure 4.12 Forest plot demonstrating adjusted ever parous versus nulliparous risk of CHD from case-
control studies in systematic review. 
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4.5 Discussion 
The aim of this systematic review was to determine if parity was a risk factor for CVD, specifically 
for CHD and stroke. This discussion summarises the findings of the review, discusses the notable 
results in comparison to previous research and presents the strengths and limitations of the review.  
4.5.1 Summary of findings 
This systematic review included eighteen studies which assessed the association between parity 
and CVD, with the specific outcomes of either CHD and/or stroke. Of these publications, thirteen 
were cohort studies and five were case-control studies.  
The quality of the studies was assessed using the NOS (Wells et al., 2014). The results were varied 
across the studies with one (Parikh et al., 2010) achieving all nine stars available for the research 
methods and some scoring poorly with only 2-4 stars (Beard et al., 1984; Cooper et al., 1999; 
Gallagher et al., 2011; Jacobsen et al., 2011).  
Figure 4.13 Funnel plot displaying the spread of risk estimates from the cohort studies included in this 
systematic review. 
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The unadjusted and adjusted results of the cohort studies were combined independently by 
random effects meta-analysis to evaluate the difference in risk of CVD in parous versus nulliparous 
women. The unadjusted analyses presented substantial diversity within the study risk estimates, 
which may be explained by the different ages and risk factor profiles of the individual sample 
populations. The adjusted ever parous versus nulliparous analysis for cohort studies reported no 
difference in risk for both CHD and stroke. Further analysis of risk per parity level suggested that 
the risk of these diseases changes with increasing parity. The CHD results suggest that the risk is 
equivalent for parous and nulliparous women until para 3, after which the risk increases, reaching 
a maximum at para 5+ (RR 1.21 (0.93-1.56)). For stroke risk the results follow a ‘J’ shaped curve, 
with a slightly reduced risk appearing at para 2 (RR 0.94 (0.91-0.97)) compared to para 0, and an 
increase in risk thereafter. Out of these analyses, only the pooled estimates for the parities with 
the lowest and highest risk of stroke were significant.  
The subgroup analyses highlighted a difference in risk of CHD based on location, with the US and 
China reporting a reduced risk in ever parous women and the European studies stating an increased 
risk. These results were not consistent with the stroke analysis, which found an increased risk from 
the US subgroup and reduced risk from the Chinese studies, with no apparent effect of parity on 
stroke risk according to the European subgroup. Notably, the risk of CHD was significantly increased 
(RR 1.08 (1.03-1.13)) in the studies which did have an adequate follow up time compared to a 
reduced risk (RR 0.92 (0.85-0.98)) in those which did not.  
The pooled result from the case-control studies represented a large increase in risk of CHD 
morbidity for ever parous women (aOR 1.49 (1.23-1.82)) compared to nulliparous women.  
4.5.2 Notable Findings 
The ratio of parous to nulliparous women within the 2,869,391 included in this review was 8:1. This 
high ratio is due to the majority of women worldwide having at least one child, for example in 
England and Wales in 2016, only 18% of menopausal women were nulliparous (Office for National 
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Statistics, 2017b). Therefore, when randomly sampling participants for a cohort study, the 
proportion of nulliparous women is comparatively low. It is necessary to note that many of these 
studies looked at different exposures or populations as well as those meeting the criteria for this 
review. Therefore, the total number of participants quoted in the original publications of these 
studies will be different to what is recorded in this chapter. 
The death and disability adjusted life year (DALY) rates of CVD have been steadily declining since 
1980, possibly due to improving disease prevention and healthcare provision (Bhatnagar et al., 
2016). Therefore, the CVD incidence from the most recent cohort studies is not directly comparable 
to the earliest studies. However, as the nulliparous and parous women in each study would have 
been treated by the same healthcare standards available for that time, the risk estimates produced 
for parous versus nulliparous women by each study are comparable.  
The quality assessment of the studies included in this systematic review highlighted the poor 
research methods used in several of the studies, especially the six cohort studies which had an 
inadequate follow up time for the outcomes of interest to develop. This must be taken into account 
when drawing conclusions from the combined results of these studies, as an inadequate follow up 
time could bias the results towards the null. However, the studies which achieved the most stars 
were given the most weight in the meta-analyses due to their large sample sizes and consequent 
small standard error. This means the pooled risk estimates of this review are drawn mainly from 
results with limited potential for bias. Having said that, the study which achieved all available stars 
on the NOS (Parikh et al., 2010), did not adjust for all traditional CVD risk factors e.g. smoking. 
Therefore, even the studies scoring highly in the quality assessment still present some potential for 
bias.  
The pooled adjusted risk estimate of CHD in ever parous versus nulliparous women from the case-
control analysis was much larger (aOR 1.49 (1.23-1.82) than that for the cohort studies (aRR (1.01 
(0.94-1.09)). This may be because all of the case-control studies, except for a small proportion of 
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cases in the Beard et al. (1984) study, recorded outcomes only of CHD morbidity, whereas the 
cohort studies assessed both morbidity and mortality. Also, one of the studies (Beard et al., 1984) 
only presented an unadjusted risk estimate which was included in the analysis, and one study (La 
Vecchia et al., 1987) only adjusted for age. This means the 38.3% of the weighting in the case-
control analysis given to these studies, represented data highly susceptible to confounding. 
Despite the potential confounding effect on the case-control pooled risk estimate, a study 
method used by the cohort studies may explain this discordance in results. All but three (Cooper 
et al., 1999; Gallagher et al., 2011; Jacobsen et al., 2011) of the cohort studies excluded women 
with CHD at the start of follow up, to ensure temporality in the results. However, it was not 
possible to determine whether the CHD occurred before or after the exposure of pregnancy, as 
some of these cohorts began after women’s reproductive years. Therefore, there may have been 
exclusion of women who were free from CVD before pregnancy and developed CVD afterwards. 
This exclusion may have introduced survival bias (Saracci, 2007) into the results of the cohort 
studies and diluted the association between parity and CHD.  
From the cohort study meta-analyses, the adjusted risks of CHD and stroke were equal between 
ever parous and nulliparous women. This is potentially due to the change in risk per parity level, 
demonstrated in figures 4.5 and 4.8.  As the variation in risk per parity level is relatively small, the 
parities with the lowest risk can attenuate the increased risk of the 4 or 5+ parities. Therefore, when 
these parities are combined to form an ever parous risk, there appears to be no effect. This 
contrasts with the previous systematic review by Lv et al. (2015) which suggested a protective effect 
of parity on CVD mortality (Hazard Ratio HR 0.79 (0.59-1.06)). However, that review only included 
studies of CVD mortality, therefore the outcome incidence from the studies would have been lower 
than this review, which also included morbidity cases. Also, the previous review included a study 
by Jaffe, Eisenbach and Manor (2011) which recorded mortality from all types of CVD, not only CHD 
and stroke. When this study was removed from the Lv et al., meta-analysis the hazard ratio altered 
to only 0.91 (0.85-0.95), therefore still showing a protective effect but to a lesser extent.  
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Several of the studies which recorded outcomes of both CHD and stroke reported opposite risk 
estimates across the two diseases in the ever parous analysis. The risk ratio for CHD from Jacobsen 
et al. (2011) was aRR 0.93 (0.75-1.15) whereas the equivalent for stroke was aRR 1.21 (0.85-1.72), 
suggesting that the risk of stroke is greater with ever parity compared to a reduced risk of CHD. In 
contrast to this, Magnus et al. (2017) found parity to be protective against stroke, RR 0.85 (0.65-
1.11), but increased the risk of CHD, RR 1.21 (0.99-1.48). These results suggest that there is an 
underlying difference in the effect of parity on the risk of these two diseases. However, neither of 
these papers’ results were statistically significant and when the results of the individual studies are 
combined in both the ever parous and per parity level analyses the risk estimates for CHD and 
stroke are very similar.  
The analysis of stroke risk per parity level demonstrated a ‘J’ shaped curve which was also reported 
by Parikh et al. (2010) and Lv et al. (2015). The results for both stroke, and to a certain extent CHD, 
compliment those from Parikh et al. which observed the lowest risk of these diseases to be at para 
2 and the risk increasing with each parity level thereafter. This is due to the large weight which was 
given to this study in the meta-analyses. In contrast, the dose response analysis performed by Lv et 
al. found that women with four or five live births had the lowest risk of CVD mortality. This 
difference may again be due to the inclusion of both CVD morbidity and mortality in this review and 
the large weighting of the Parikh et al. study, whereas the Lv et al. review assessed the risk of CVD 
mortality alone.  
The CHD subgroup analysis also demonstrated a statistically significant difference in results based 
on the location of the study. The studies from the US and China yielded a reduced risk of CHD in 
parous women, compared to a higher risk in Europe. However, this may be due to the inadequate 
follow up of the studies from China and the US compared to the studies from Europe which did 
have an adequate follow up length. Furthermore, all the studies from the US included women who 
had been college educated. Within the study by Colditz et al., (1987) the study population consisted 
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only of nurses who have more knowledge of healthy lifestyle behaviours than the general 
population. As these characteristics would lower the prevalence of CVD risk factors in the study 
populations, the incident cases would have been proportionally lower than the studies from Europe 
which all recruited from the general population.  
The two Chinese studies (Gallagher et al., 2011, Peters et al., 2017) show a clear trend of increased 
age of women at the higher parity levels within the cohorts. This is most likely due to the 
introduction of the one child policy in 1979 (Jiang, Feldman and Li, 2014) which greatly increased 
the number of women with only one child compared to the previous generations. Thus, the women 
of higher parity levels are much older than those in the para 1 group. This explains why the outlying 
unadjusted risk estimates from Gallagher et al. (2011) diminished after age adjustment. Both 
papers conclude that these intergenerational variations in parity have not affected the risk of CVD 
as the risk estimate favours parous women. However, the number of cases of stillbirth or 
spontaneous abortion were much greater in the nulliparous group in the Peters et al. (2017) study. 
Also, the nulliparous women were more likely to have never been married, which in Chinese culture 
is rare and shamed upon (Jiang, Feldman and Li, 2014). Both of these characteristics of nulliparous 
women suggest that underlying health problems or low socioeconomic status may account for their 
increased risk of CVD rather than the lack of physiological adaptations during pregnancy.  
The stratified results reported by Vladutiu et al. (2017) reflect a small increase in stroke risk for ever 
parous black women compared to nulliparous black women, whereas the estimate for ever parous 
white women suggests a slightly reduced risk, RR 1.09 (0.71-1.67) and RR 0.90 (0.61-1.33) 
respectively. These results are congruous with those from the case-control study by Rosenberg et 
al. (1999) of black US women, which found a 67% increased risk of MI in parous women, RR 1.67 
(0.87-3.22). The baseline characteristics of the Vladutiu et al. (2017) participants present skewed 
trends in parity, with the para 5+ women being more likely to be black, have limited education and 
low income and the para 1 women more likely to be white, college educated with a higher income. 
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Similar trends were found by Spence and Eberstein (2009) who compared all-cause mortality in 
black and white women, based on parity. These clear divides may infer that the difference in stroke 
risk between parous and nulliparous black and white women is not biological but due to a variety 
of biopsychosocial factors. Therefore, the conflicting risks of CVD reported by the Chinese and 
European studies in this review, may be due to contrasting cultures and psychosocial determinants 
and not solely due to differences in study design.  
The CHD subgroup analysis revealed a significant difference between the studies which had an 
adequate follow up time, where there was a small increased risk with parity, compared to those 
which did not (a small decreased risk). An adequate follow up time in this review was defined as 
long enough for all of the participants to reach at least 55 years of age. This was a subjective cut-
off for the dichotomisation of follow up length, as there is no defined time for the development of 
CVD. The results of this subgroup analysis may therefore change if a different cut-off was used. The 
difference in risk seen between the subgroups suggests that the proportional hazards assumption 
was not met in the studies which used Cox proportional hazards regression and did not declare the 
conclusion of testing the assumption.  A similar result to this was found by Jacobs et al. (2012) which 
reported the association between number of pregnancies and CVD mortality were stronger after 
ten years of follow up.  This highlights the effect poor quality studies have on the results of a review 
and the importance of designing studies with robust methodology which includes the consideration 
of the pathophysiological course of the outcome of interest. Additional studies with a long follow 
up are required to determine if this difference in risk of CHD is due to parity.  
4.5.3 Strengths and Limitations 
This systematic review is the largest to date, including 2,869,391 women from eighteen studies 
across four continents. The clear protocol which was determined before the research began 
ensured both reviewers were aware of their roles and of the strict criteria which were used to 
screen studies for inclusion. The search strategy covered two core medical databases, MEDLINE and 
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EMBASE and a further database, CINAHL Plus, which focussed on allied health professional’s 
research, including midwifery. The search was therefore aimed at the relevant platforms to the 
research question and was successful in identifying all of the studies used in the previous two 
systematic reviews (Rich-Edwards et al., 2014; Lv et al., 2015) on parity and CVD. To prevent the 
introduction of publication bias, there was no restriction placed on the language of the studies 
included in this review and the abstracts from conference proceedings were searched. The search 
results were also screened independently by two reviewers and any conflicts in opinions discussed 
in relation to the pre-defined eligibility criteria. This prevented the introduction of reviewer bias 
during screening and the misclassification of studies (McDonagh et al., 2013). Due to the revision 
of the exclusion criteria during the screening process, to discount studies which only assessed 
gravidity with CVD, we can be confident that the included studies address the research question by 
specifically investigating parity as the exposure. The quality assessment was completed using the 
NOS, which allowed an evaluation of the quality of a study overall, but the domain format also 
displayed which areas the included studies had design flaws or high standard research methods, in 
terms of reducing bias.  
This systematic review was able to separately evaluate the risk of developing CHD and stroke, which 
had not been determined by the previous reviews (Rich-Edwards et al., 2014; Lv et al., 2015). These 
diseases have separate pathophysiological processes and implications on quality of life, therefore 
it was necessary to draw conclusions on the individual risk of these conditions rather than the 
umbrella term of CVD. This review included studies assessing both the morbidity and mortality from 
CHD and stroke, meaning the results from this review are closely reflective of the global burden of 
these diseases. The previous review (Lv et al., 2015) only included mortality from CVD and therefore 
underestimated the incidence and risk of these conditions.  
The inclusion of studies from a number of countries and races has allowed for a discussion on the 
effect of cultural or biological factors on parity and the risk of CHD and stroke. The results from this 
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study are also generalisable to a wider population as most of the studies, especially the largest by 
Parikh et al. (2010) recruited women from the general population.  
Although this review presented novel data on the risk of two distinct CVDs, there are several 
limitations to the research. Firstly, focussing on the methods of this review, due to time restrictions, 
only one reviewer, Ashleigh Woodland (AW) conducted the data extraction and quality assessment 
of the studies. The second reviewer (Dr Pensée Wu, PW) completed this process for 30% of the 
studies in order to assess the quality of the first reviewer’s technique. This may have introduced 
slight inaccuracies during quality assessment as this is a subjective process and is best assessed 
independently by at least two researchers. However, there were only small changes made after PW 
checked the data extraction and quality assessment completed by AW.  
As explained in the methods chapter (see chapter 3), the data reported from the included studies 
was often not in the same format due to parities other than nulliparity being used as the reference 
group in reported analyses. Therefore, a technique proposed by Hamling et al. (2008) was utilised 
to convert some of the adjusted risk estimates from the studies into the ever parous and per parity 
level risk ratios used in the meta-analyses, with nulliparity made the reference category. The risk 
ratios used are therefore only estimates of the risk ratios which would have been derived based on 
the original data. Despite this, the risk ratios are still adjusted for the confounders included in each 
individual paper, and the method facilitated a more in-depth analysis of the studies than would 
have been possible using only the reported risk estimates.  
As the studies did not present unadjusted risk ratios, the unadjusted meta-analyses in this review 
were calculated using only the raw data from the studies. This would not have taken into account 
the censoring of participants, which is a feature of the Cox regression analysis. However, the 
adjusted risk estimates were also presented, and these estimates were used to draw conclusions 
from the studies in the review.  
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Despite the conversion of data, there was still insufficient results to complete subgroup analyses 
for the risk of CVD per parity level. This would have been beneficial as the ever parous results do 
not represent a clear risk estimate for parity, as the risk changes with every pregnancy.  
Due to the short time available for conducting this review, a formal dose response analysis was not 
performed, which would have further assessed the risk of CHD and stroke with increasing parity. 
However, the pooled adjusted risk estimates for each parity level were calculated and presented 
on graphs for easier interpretation.  
Although attempts were made to find all relevant studies to the review, the grey literature was not 
searched extensively. Therefore, there may be studies which met the eligibility criteria for the 
review which were not identified. In addition, one study (Jacobs et al., 2012) which was screened 
following the database search, reported a non-statistically significant weak inverse association of 
parity with CVD but did not present the results. Therefore, this study could not be included within 
the meta-analysis. This suggests there may be other studies which did not produce significant 
results and have therefore not been published, thus introducing reporting bias through selective 
outcome reporting (Sterne et al., 2011). This may explain the apparent lack of small studies 
favouring nulliparity, especially for the outcome of CHD, in the funnel plot in figure 4.13. However, 
the graph is roughly symmetrical with a range of study sizes.   
Throughout the review process limitations in the form of potential biases also arose from the 
studies themselves. The studies ranged in quality, with some studies scoring poorly for the possible 
introduction of selection bias. For example, the study by Colditz et al. (1987) only recruited nurses 
to the study. Also, due to the unreliable recording of outcomes, for example self-report, some 
studies may have introduced information bias or recall bias. Therefore, the results of the meta-
analyses should be interpreted with this in mind. The largest studies within the analysis were 
however of good quality, meaning the largest weighting in the results comes from largely unbiased 
evidence.  
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Although the inclusion of participants with prior pregnancy complications, such as pre-eclampsia, 
was one of the exclusion criteria, seventeen of the included studies did not include this history in 
the baseline questionnaires. The only study which did ascertain a history of obstetric conditions 
from the participants was Parikh et al. (2010), which included exposed individuals but adjusted for 
this in the analysis.  Therefore, the majority of studies will have involved patients with these risk 
factors but did not report it and therefore have been included in this systematic review. As 
discussed in chapter 2, pre-eclampsia carries a substantial increased risk of CVD for exposed women 
in the future (Wu et al., 2017).  The effect of this residual confounding may have altered the risk 
estimates of studies, potentially showing a false increased risk of CVD with parity. This will therefore 
have over-estimated the risk of CVD associated with parity.  
However, a large Swedish study by Hernández-Díaz, Toh and Cnattingius (2009) found that the risk 
of pre-eclampsia is lower in parous women than nulliparous women. This suggests that the 
inclusion of women with previous pre-eclampsia is unlikely to have greatly affected the statistically 
significant result, for the increased risk of stroke at para 5+, found in this review. Also, several of 
the studies adjusted for diabetes and high blood pressure, although not specifically for obstetric 
conditions. The largest study by Parikh et al. (2010) included women with these obstetric 
conditions, but adjusted for them in the analysis and is therefore more accurate in assessing the 
independent risk associated with parity than the studies which did not ask about a history of these 
conditions.  
4.5.4 Conclusion 
The results of this systematic review suggest that ever parity is not a risk factor for CVD, however 
further research with longer follow up is needed to confirm this. The risk of CHD is equivalent for 
parous versus nulliparous women until para 3, after which the risk increases with each parity level. 
The risk of stroke in parous versus nulliparous women follows a ‘J’ shaped curve, as the lowest risk 
is at para 2, with the risk increasing thereafter. A statistically significant increase in stroke risk is 
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seen in women with five or more live births, compared to nulliparous women. As 10% of parous 
women have four or more children (Office for National Statistics, 2017b), this increased risk is 
potent within the parous population and should be acknowledged when assessing the likelihood of 
stroke or CHD, among other risk factors, in grand multiparous women.  
The use of electronic health data recorded in primary care is increasingly being used to complete 
observational research and may be a potential resource for assessing the relationship between 
parity and CVD risk with a long follow up time. The next chapter describes the methods used to 
complete a feasibility cohort study, to assess this relationship, set within a local primary care 
database. 
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5 Cohort study set within primary care of association of parity with 
CVD: Methods 
The previous two chapters explained the methods and results of the systematic review on the 
association between parity and cardiovascular disease (CVD). As this review collated data from 
participants across several continents, which all have a varied prevalence of disease and lifestyle 
behaviours, it is not possible to draw direct conclusions for specific populations. For example, the 
studies from China reported a higher risk of CVD in nulliparous women compared to parous women, 
which was the opposite of the European study results. This may have been due to the cultural 
differences, with nulliparous women in China being more likely to have an underlying health 
condition or be of low socioeconomic status. 
Several of the studies included in the systematic review were of poor methodological quality as 
assessed by the Newcastle-Ottawa Scale (NOS) (Wells et al., 2014). For example, one study only 
included nurses (Colditz et al., 1987) while another only included college educated women (Cooper 
et al., 1999). These studies would not have produced a cohort representative of the general female 
population. Four of the studies recorded outcome events based on self-reporting from participants 
(Cooper et al., 1999; Jacobsen et al., 2011; Simons et al., 2012; Peters et al., 2016)). This method of 
outcome ascertainment is susceptible to recall bias and would be improved by using medical 
records to identify CVD outcomes. The length of follow-up was also too short in many of the cohort 
studies included in the review. To overcome these limitations, it would be beneficial to conduct a 
cohort study which could assess the relationship of parity and CVD using longitudinal electronic 
health records (EHR) from general practice. EHR are becoming increasingly available for research 
and follow patients over a long period of time. Primary care is the gateway to the health service in 
the UK and over 95% of the population are registered with a general practice.  Therefore, the cohort 
would be representative of the population registered to those practices, with no criteria based on 
educational level or occupation. Also, the ascertainment of exposure and outcomes would not be 
98 
 
subject to recall bias and should be more reliable as health data is recorded by healthcare 
professionals at the time of consultation.  
A cohort study using the EHR of the local population of North Staffordshire was designed to 
investigate the strengths and limitations of using HER to assess the relationship between parity and 
CVD. The study therefore acted as a feasibility study, the methods of which could be developed 
further based on the findings of this feasibility study and applied to a larger, national general 
practice (GP) database, with longer follow-up time, to further explore the relationship in a wider 
population.  
Stoke-on-Trent, the main city in North Staffordshire, is one of the most deprived local authorities 
in England, ranked 13th out of 326 districts (Department for Communities and Local Government, 
2015), with 50% of its neighbourhoods falling within the most deprived national quintile (Public 
Health England, 2017b). The area fares worse than the national average for most health indicators 
(Public Health England, 2017b), including smoking and obesity prevalence, which are known risk 
factors for CVD. This study will therefore also give an indication of the potential relationship 
between parity and CVD in an area with high deprivation and CVD prevalence.  
This chapter details the methods used to conduct the cohort study, including justification for the 
sample population, eligibility criteria and outcomes used, as well as details of the data analysis. The 
results of the cohort study are presented in chapter 6.  
5.1 Aim of Study 
The aim of the study was to explore the relationship between parity and CVD in the local population 
of North Staffordshire, in order to address the overall question of this research; Is parity a risk factor 
for CVD? This aim was achieved using routinely recorded electronic health data from the primary 
care setting.  
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5.2 Study Population 
The participants for the cohort study were taken from the population of patients included within 
the Consultations in Primary Care Archive (CiPCA). CiPCA contains electronic primary care records 
of patients registered to currently nine GPs across North Staffordshire, with an annual registered 
population of just under 100,000. CiPCA is managed by the Research Institute for Primary Care and 
Health Sciences, Keele University. The practices which contribute to the database have undertaken 
training and quality assessments in recording health data electronically (Porcheret et al., 2004). This 
patient data is recorded in the form of Read codes, which are a widely used set of hierarchical codes 
used for recording conditions, symptoms, procedures and test results in the United Kingdom (UK) 
primary care (Read, 1990; O’Neil, Payne and Read, 1995). Prescribed medications are also recorded. 
The data is pseudo-anonymised, meaning the names, addresses and free text of consultations of 
patients are not included within the data available to researchers, whilst year of birth is recorded 
rather than date of birth. Patients who have asked for their records not to be used in research have 
their records tagged at the practice, so they are not included in the extraction of data. 
With sufficient completeness of recording, the Read codes can be used to estimate the prevalence 
or incidence of disease within this specific population and to track a patient’s health over time. The 
completeness of coding from general practitioner consultations (i.e. percentage of consultations 
allocated a Read code) is over 90% in the CiPCA practices, which provide high quality patient records 
from 2000 to 2015 (Porcheret et al., 2004). In a review comparing GP databases in 2001, the 
population contained within the CiPCA database was similar to the general population of England 
and Wales, in terms of the age and sex distribution (Jordan et al., 2007).  
5.3 Inclusion Criteria 
As this cohort study aimed to assess the link between pregnancy and CVD in North Staffordshire, 
the study sample was women of childbearing age within the CiPCA database. This contrasts to some 
of the studies included in the systematic review which only included women who were 
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postmenopausal and therefore could not become pregnant during the follow up. However, as the 
CiPCA database only provided patient data from 2000 to 2015, the study required women to have 
a pregnancy code recorded during this time, and therefore would have been pre-menopausal at 
some point during the study period. 
 In order to evaluate the relationship between the exposure of parity and CVD, a comparison group 
of nulliparous women was required, which was also required of the cohort studies included in the 
systematic review. For this study, two unexposed (nulliparous) women were matched by age, within 
five years, to each exposed woman. 
The accuracy of coding pregnancy outcomes, either livebirth, stillbirth or abortion, within the 
database was not deemed high quality enough to only include parous women, being women who 
delivered after 24 weeks gestation. To prevent the misclassification and subsequent incorrect 
inclusion or exclusion of participants, the exposure of interest in this study was broadened to 
encompass all pregnancies, including those of any gestational length. As the cardiovascular 
adaptations commence early in pregnancy, with blood pressure lowering within six weeks of 
conception (Sanghavi and Rutherford, 2014), a woman is still exposed to cardiovascular strain, even 
if the pregnancy terminates before 24 weeks. The results of this study can therefore still be used 
alongside previous studies which assessed the total number of pregnancies, for example (Ness et 
al., 1993) in order to answer the research question of whether parity is a risk factor for CVD.  
The inclusion criteria for participants in the study was therefore set as follows: 
 Women between 15 and 45 years of age at any point between 1st January 2000 and 31st 
December 2015 and who were registered with a GP which contributed to the CiPCA. 
 For the exposed group, women must have been recorded as pregnant at least once 
between 1st January 2000 and 31st December 2015. 
 For the unexposed, comparison group, women must have no record of pregnancy between 
2000 and 2015.  
101 
 
5.4 Exclusion Criteria 
In order to gauge the relationship between pregnancy and CVD incidence, it was necessary for 
eligible participants to be free from cardio-metabolic disease at the beginning of the study follow 
up. This included the pregnancy complications of gestational diabetes and pre-eclampsia as these 
have been identified as independent risk factors for CVD (see chapter 2). Also, the participants must 
have not received a diagnosis or test result indicating the presence of the metabolic CVD risk 
factors, for example hypertension, which were being used as secondary outcomes in this study, 
prior to the record of pregnancy. Women with specific non-modifiable diseases (prior to pregnancy) 
which could increase the risk of CVD but had pathophysiological causes unrelated to the CVD 
outcomes, were also excluded. These included type 1 diabetes mellitus and secondary 
hypertension. To ensure these criteria were met, women were only included in the study if there 
were available data in CiPCA for one year preceding the first recorded pregnancy code, or for the 
comparison group, data for one year before follow up started. This was decided on the assumption 
that patients with a CVD or defined risk factor would present to the GP regarding these conditions 
at least once during a year and therefore would have this coded for on their record. These codes 
could then be identified, and the appropriate women excluded from the study.  
The exclusion criteria for participants in this study were defined as: 
 Women with a record of type 1 or type 2 diabetes mellitus before their first pregnancy 
 Women with a record of CVD before their first pregnancy  
 Women with a record of the metabolic CVD risk factors of hypertension and 
hyperlipidaemia prior to their first pregnancy 
 Women with a record ever of gestational diabetes mellitus or pre-eclampsia  
 Women without one year of records before the first recorded pregnancy code (index date) 
For the never pregnant, unexposed group the same exclusions applied, however the index date was 
set as the latest of either the first recorded pregnancy date of the matched exposed woman or one 
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year after the start of the unexposed woman’s records in CiPCA. This maximised the number of 
women able to be in the unexposed group.  
5.5 Variables 
5.5.1 Exposure Identification 
As explained above, the exposure in this study was pregnancy of any outcome, including 
spontaneous or planned abortion, stillbirth or livebirth. To identify women with this exposure 
within the CiPCA database, a list of Read codes relating to pregnancy were compiled. This 
incorporated codes for a diagnosis of pregnancy and pregnancy related diseases, codes for the test 
or examination results within antenatal care as well as the codes for labour and outcomes of 
pregnancy. These codes were taken from previous published work (Tata et al., 2005, 2007), except 
for the codes relating to abortions and miscarriages which were determined through the National 
Health Service (NHS) Clinical Terminology Browser, using the 5-byte Version 2 Read codes. The full 
list of exposure codes can be found in Appendix F.  
5.5.2 Outcome Identification 
The primary outcome in this cohort study was any outcome of CVD which was termed ‘any CVD’. 
This outcome included codes for: CHD including myocardial infarction (MI), angina and heart 
operations used as treatment, heart failure, hypertension, peripheral vascular disease (PVD) and 
stroke including ischaemic and haemorrhagic stroke and transient ischaemic attack (TIA). CHD and 
stroke were chosen due to their combined burden of causing a third of all female deaths in Europe 
(Wilkins et al., 2017). Heart failure was included as an outcome as it is the final outcome of cardiac 
disease of all forms, including CHD and hypertension, and therefore demonstrates severe disease 
(Chattterjee and Fifer, 2011). PVD has a similar pathogenesis to CHD including hypertension and 
atherosclerosis, whereby 40% of patients with atherosclerotic PVD also have significant CHD (Liang 
and Creager, 2011). Therefore, women could be acknowledged as at an increased risk of CHD due 
to the presence of PVD. Hypertension was included in this variable as although it is not a CVD, it is 
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a disease of the circulatory system and is commonly treated as a CVD in clinical practice (Lee, 
Williams and Lilly, 2011).  
To identify women with these outcomes a list of Read codes was compiled, including codes for the 
diagnosis, monitoring and treatment of these diseases. This list incorporated codes which had been 
published as part of previous research (Kontopantelis et al., 2014, 2015; Wright et al., 2017; Zhong 
et al., 2018). The list was reviewed by Dr Pensée Wu (PW), a consultant obstetrician, for the 
appropriateness of each code in identifying the outcome of interest. For the ‘any CVD’ outcome 
participants were censored after the first outcome event. 
The outcomes of MI, CHD, stroke and type 2 diabetes mellitus (T2DM) were also investigated in 
isolation as secondary outcomes. Stroke and CHD were chosen as they are responsible for the 
majority of CVD deaths, with most of the CHD deaths attributable to MI (Townsend et al., 2015). As 
the follow up time available through the CiPCA database was short, with a maximum of fifteen 
years, known metabolic risk factors for the development of CVD were included as secondary 
outcomes. These are type 2 diabetes mellitus and hypercholesterolaemia (GBD 2015 Risk Factors 
Collaborators, 2016). Therefore, given the likelihood of a limited number of cases of diagnosed CVD 
e.g. CHD and stroke, the incidence of risk factors could be used to determine how many participants 
were at an increased risk of CVD. Table 5.1 presents the primary and secondary outcomes for this 
cohort study.  
Table 5.1 The primary and secondary outcomes for this cohort study. 
Primary Outcome Secondary Outcomes 
Any CVD 
(including: CHD, stroke, 
PVD, hypertension and 
heart failure) 
Coronary Heart Disease 
Myocardial Infarction 
Stroke 
Type 2 Diabetes Mellitus 
Hypercholesterolaemia  
 
 
These outcomes were again identified through Read codes corresponding to the diagnosis and 
management of these conditions. The codes for diabetes and hypercholesterolaemia were found 
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through the NHS Clinical Terminology Browser, using the 5-byte Version 2 Read codes. The codes 
for hypertension were compiled using the previous research of Zhong et al. (2016) and 
Kontopantelis et al. (2015). The use of prescription codes of cardiovascular medications was 
considered for the identification of outcomes. However, as these medications are not specific to a 
certain condition and some have uses other than treating CVD, it was decided to only utilise the 
specific Read codes for each disease of interest. The full list of outcome codes can be found in 
Appendix G.  
The follow up for participants started from their individual index date. For the exposed group this 
was the date of first pregnancy record and for the unexposed group it was the latest out of either 
the date of first pregnancy record of a matched exposed woman, or one year after the start of 
records for the unexposed participant.  The participants were followed up from their index date 
until the earliest of either leaving the practice or the end of the study on 31st December 2015.  
5.5.3 Covariates 
There are several recognised risk factors for CVD which were explained in detail in the background 
chapter (see chapter 2). The metabolic risk factors which are independent diseases; T2DM, 
hypertension and hypercholesterolaemia were defined as outcomes in this study to indicate an 
increased risk of CVD due to the short follow up time for CVD development. Women with these risk 
factors at baseline were therefore excluded to ensure temporality in the results. The risk factors 
which were statistically adjusted for in this cohort study were: age, practice, obesity or being 
overweight, smoking and neighbourhood deprivation. Obesity and overweight were determined by 
the body mass index (BMI) which allows categorisation of patients into underweight, ideal, 
overweight and obese. This covariate was taken from the closest record of BMI before the 
participant’s index date or the first record after if there was no record before the index date. 
Smoking status was dichotomised into ‘ever smokers’, meaning a record of being a current or ex-
smoker at any point in the study period and ‘non-smokers’ being those recorded as a non-smoker 
at any point in the study period or those with no recorded smoking status. Those with no recorded 
105 
 
smoking status were defined as non-smokers as the Quality and Outcomes Framework (QOF), which 
is a voluntary reward programme for GP’s, recommends that a non-smoker should be asked their 
smoking status until the age of 25, and if they have consistently been a non-smoker, at this point 
they do not need to be asked again (NHS Employers, 2014). Therefore, the absence of a smoking 
status code will most likely represent a non-smoker. The level of deprivation for each participant is 
reported as the index of multiple deprivation (IMD) score for the area which corresponds to the 
patient’s postcode. The IMD is a score based on 37 indicators of deprivation within an area, which 
are categorised into 7 domains, for example ‘employment deprivation’ and ‘barriers to housing and 
services’ (Department for Communities and Local Government, 2015). These domains are then 
combined to give an overall IMD score. In CiPCA the deprivation scores reflect a weighted average 
of the IMD scores for the patient’s wider area of residence, as a full postcode is not available. 
Deprivation was categorised into four groups from most to least deprived, based on the quartiles 
of IMD scores measured from the study participants.  
These risk factors could act as confounders within the cohort study if the distribution of participants 
with these attributes was not equal between the exposed and non-exposed groups. Ensuring 
comparability between the cohort groups can be achieved by matching exposed to unexposed 
participants based on confounders, or by adjusting for these in the analysis (Szklo and Nieto, 2014).  
In this study each exposed participant was matched to up to two unexposed women whose age 
was within five years of the exposed woman’s age. The participants were matched this way to 
increase the power compared to a 1:1 ratio of unexposed to exposed participants. Also, it was 
unlikely that there would have been enough unexposed to match more than two to each exposed 
participant. In order to maximise the number of unexposed participants included in the study, the 
participants were matched on age within five years. As the participants could not be matched on 
exact age, this was adjusted for along with the remaining risk factors in the analysis.  
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It is important to note that the CVD risk factors of family history, low physical activity and poor diet 
were not included in this analysis as these variables would not be extensively coded for in primary 
care records. However, the presence of obesity and hypercholesterolaemia, which were 
incorporated in the study, are indicators of a diet in high saturated fat and low physical activity 
(Strom and Libby, 2011). 
The women in the database with these risk factors were detected by a list of Read codes 
corresponding to the diagnosis, treatment and monitoring of the conditions. The 
hypercholesterolaemia codes were derived from the NHS Clinical Terminology Browser, whereas 
the codes for smoking, and BMI were assembled using published code lists (Reeves et al., 2014; 
Joseph et al., 2017). The full list of Read codes for the confounders identified in this study can be 
found in Appendix H.  
5.5.4 Codes for Excluded Conditions 
To implement the exclusion criteria on the women within the database, a list of codes was compiled 
which matched the diagnoses or management of hereditary conditions or those which begin in 
childhood, for example, type 1 diabetes and pure hypercholesterolaemia. These codes were found 
using the NHS Clinical Terminology Browser.  As well as this list of codes, all of the women with a 
cardiovascular outcome before their index date, were excluded.  
 
5.6 Data Retrieval 
The proposal for this research was reviewed by the CiPCA Academic Custodianship Committee to 
ensure the planned research met the ethical approval assigned to the CiPCA database for secondary 
analysis of the stored data. CiPCA has been approved as a research database by North West – 
Haydock REC ref: 17/NW/0232.  Advice and guidance from the CiPCA Data Manager and the 
committee was incorporated into the research proposal throughout its development. Once the 
project proposal had been accepted, the data manager used the lists of Read codes to identify all 
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exposed women from the database for this cohort study and matched each woman to two 
unexposed women. The dataset was then cleaned by Professor Kelvin Jordan using IBM SPSS 
Statistics Data Editor Version 24. Ashleigh Woodland (AW) used this software to exclude 
participants who met each of the exclusion criteria and recoded variables to account for missing 
data, specifically the smoking, BMI and IMD variables. AW also used SPSS to complete all of the 
statistical analysis outlined below.  
 
5.7 Analysis 
The prevalence of the cardio-metabolic outcomes: ‘any CVD’, angina, MI, CHD, heart failure, stroke, 
hypertension, PVD, hypercholesterolaemia and T2DM was first calculated. This was also completed 
for the behavioural risk factors of ever smoking and obesity. This provided an indication of the 
burden of CVD in North Staffordshire. These prevalences were calculated using the frequency of 
outcome events, at any time between 2000 and 2015 in the original 15-45 year old cohort of 
women, before the exclusion criteria were applied. For the behavioural risk factor prevalences the 
frequency of participants with a relevant code was recorded.  
 
A descriptive analysis of the participants within the final cohort (after exclusion criteria were 
applied) was completed to assess the baseline comparability between the exposed and unexposed 
groups. As all of the variables within the study except the matching variable of age were categorical, 
this was achieved using chi-squared tests. Statistical significance was set at a p-value of <0.05. For 
the continuous age variable, the mean and standard deviation with minimum and maximum ages 
for each group was calculated and an independent sample 2 tailed t-test was performed.  To 
investigate the association between pregnancy and CVD risk, a Cox proportional hazards regression 
was performed. The time scale in the Cox model was follow-up time since cohort entry (index date), 
with censoring at time of first outcome event for the ‘any CVD’ variable, end of registration at 
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practice, or end of collected data (31st December 2015). Three models were created for the analysis, 
model 1 producing the unadjusted hazard ratio for ever pregnant versus never pregnant risk of 
cardio-metabolic disease (‘any CVD’) incidence. Model 2 adjusted this estimate for age at index date 
and model 3 included all the baseline covariates: age at index date, general practice, BMI, smoking 
status and index of multiple deprivation. Differences in the strength of association of the risk factors 
with cardio-metabolic disease were assessed between exposed and unexposed women using 
interaction terms. The analyses were repeated for the secondary outcomes of: MI, CHD, stroke and 
T2DM. There were only two outcome events for hypercholesterolaemia, meaning this outcome was 
not included in the Cox regression.  
The assumption of proportional hazards was first tested for all outcomes in SPSS using the 
complementary log minus log plot, which showed that the data met the assumption. It was 
determined at a late stage of the analysis that the SPSS plots were incorrectly produced, as the 
statistical programme assumed that the data met the proportional hazards assumption when 
generating the complementary log minus log plot.  The assumption was therefore tested again, this 
time by Professor Kelvin Jordan, using the Schoenfeld residuals in Stata and the assumption was 
met for the primary ‘any CVD’ outcome after adjustment for covariates. This method of testing the 
proportional hazards assumption is more accurate than using the log minus log plot as the plot is 
interpreted by visual inspection alone and can therefore be inaccurate in plots with a small hazard 
function. 
 
5.8 Conclusion 
This cohort study was completed using the CiPCA database which retrieves patient data from GPs 
within North Staffordshire. The exposure was pregnancy of any outcome and the comparison group 
was comprised of women with no recorded pregnancies. Women with pre-existing cardio-
metabolic disease were excluded. The outcomes of interest were cardio-metabolic diseases which 
occurred during the follow up period which began on each individual’s index date. Participants were 
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censored after the presence of an ‘any CVD’ outcome, leaving the GP practice or the end of follow 
up on 31st December 2015. A Cox proportional hazards regression model was used to investigate 
the association between pregnancy and cardio-metabolic disease. The next chapter presents the 
results of the cohort study.  
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6 Cohort Study set within primary care of association of parity with 
CVD: Results 
The previous chapter explained the rationale behind conducting a cohort study using the 
Consultations in Primary Care Archive (CiPCA) to investigate the relationship between parity and 
cardiovascular disease (CVD). The methods used to complete the research were also detailed. This 
chapter presents the results of the study which include: the prevalences of cardio-metabolic 
diseases and risk factors within the population, the baseline characteristics of the study participants 
and the association of parity with CVD.  
6.1 Formation of Cohort 
In order to compile a cohort of women eligible for participation in the study, the CiPCA database 
was first searched for women who met the inclusion criteria. Using the exposure Read codes, the 
CiPCA data manager first extracted all women with a recorded pregnancy between 2000 and 2015 
and able to be matched to two women (within five years of age) without a recorded pregnancy in 
this period. This yielded 12,024 exposed women matched to 24,048 unexposed women (36,072 in 
total). Women aged less than 15 or greater than 45 at their index date (as defined in chapter 5) 
were removed. This identified 31,715 women aged 15-45 years old between 2000 and 2015, with 
11,721 of these being exposed women, matched to 19,994 unexposed women. Using the outcome 
and exclusion Read codes, the exclusion criteria were imposed on the participants resulting in a 
final eligible cohort of 20,513 women. To maximise numbers in the analysis, all initially identified 
unexposed and exposed women who fitted the inclusion and exclusion criteria were retained in the 
final analysis regardless of whether their matched unexposed or exposed woman/women was also 
retained. The, mean age of the two groups in the final analysis was very similar and age was 
included as covariate in final models.  The flow chart in figure 6.1 depicts the exclusion process of 
potential participants for this cohort study.  
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6.2 Prevalence of Cardio-metabolic Disease 
To determine the burden of disease within the local population of North Staffordshire the period 
prevalences of the cardio-metabolic outcomes were calculated for the study period 2000-2015. The 
original population of 31,715 women was used for this calculation as this would include all women 
who had an outcome at any time during the study period and gives an estimate for the prevalence 
of cardio-metabolic disease in women aged 15-45 years. Table 6.1 displays the period prevalences 
of the cardio-metabolic outcomes and behavioural risk factors in this study.  
 
 
 
Figure 6.1 Flow diagram demonstrating the exclusion process of potential participants from the 
Consultations in Primary Care Archive, for this cohort study. GDM; Gestational Diabetes Mellitus. 
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Table 6.1 Table depicting the period prevalence between 2000 and 2015* of cardio-metabolic disease for 
31715 women in North Staffordshire aged 15-45 years≠. 
Cardio-metabolic 
Disease: 
Total Period 
Prevalence: (%) 
Unexposed 
Period 
Prevalence: (%) 
Exposed 
Period 
Prevalence: (%) 
Any CVD¥ 3.5 2.9 4.5 
Angina 0.1 0.1 0.1 
Myocardial Infarction 0.1 0.1 0.1 
Coronary Heart Disease∞ 0.3 0.3 0.3 
Heart Failure 0.1 0.1 0.1 
Stroke 0.1 0.1 0.1 
Hypertension 2.3 2.1 2.6 
Peripheral Vascular Disease 1.1 0.7 1.9 
Hypercholesterolaemia 0.02 0.02 0.03 
Type 2 Diabetes Mellitus 1.8 1.6 2.2 
Behavioural Risk Factor:    
Ever Smoker 41.4 29.8 61.2 
Obesity (BMI>30) 22.0 20.9 23.1 
* Not all women were followed up for 15 years. Maximum follow up was 15 years with a median follow up of 3.8 years 
≠ Women were aged 15-45 years at the start of follow up  
¥ Any CVD = Cardiovascular Disease and includes all individual outcomes listed except hypercholesterolaemia and type 2 
diabetes mellitus. For this variable, participants were censored after first CVD outcome. 
∞ Coronary Heart Disease includes records of myocardial infarction, angina, unclassified coronary heart disease, and heart 
operations used as treatment for the disease.  
 
6.3 Baseline Characteristics 
The baseline characteristics of the 20,513 women included in the cohort study are presented in 
table 6.2. The p-values relating to the chi-squared tests for categorical variables and t-test for age, 
show that the differences in baseline characteristics for the exposed and unexposed groups were 
statistically significant. Although, the mean difference in age was small (0.24 years). These baseline 
characteristics were therefore included as covariates and adjusted for in the Cox regression models. 
The key disparities are in smoking status and deprivation. The majority of unexposed women were 
non-smokers (62.2%), whereas the majority of exposed women were ever smokers (62.0%). Most 
of the unexposed (27.8%) women were in the 2nd deprivation quartile while the largest percentage 
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of the exposed women (27.8%) were in the 3rd quartile for deprivation. It is important to note that 
there was missing data for deprivation and body mass index (BMI), with most of this originating 
from the unexposed group. Index of multiple deprivation (IMD) data was missing from 6.5% of the 
unexposed participants with full data for the exposed. A BMI code was not recorded for 29.5% of 
the unexposed and 9.5% of the exposed. 21% and 2% of the unexposed and exposed participants 
respectively did not have a smoking status code, however the participants without a smoking code 
were classified as non-smokers in the analysis.  
Table 6.2 Baseline characteristics of participants within this cohort study, n=20513. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* IMD and BMI contained missing data. 6.5% missing for IMD in unexposed. 29.5% missing for BMI in unexposed and 9.5% 
missing for exposed. 
≠ The p-value significance is for chi-squared test in all variables except age which is for an independent samples 2 tailed 
t-test 
Characteristics: 
Unexposed: 
n= 10886 
% (n) 
Exposed: n= 9627 
% (n) 
p-value: ≠ 
Significance 
at <0.05 
Practice:   <0.001 
1 14.6 (1588) 10.9 (1050) 
2 13.7 (1496) 10.6 (1020) 
3 12.1 (1315) 13.8 (1330) 
4 11.1 (1209) 11.3 (1090) 
5 4.1 (449) 2.9 (282) 
6 6.9 (752) 11.8 (1134) 
7 19.3 (2105) 12.7 (1227) 
8 8.2 (890) 9.9 (953) 
9 9.9 (1082) 16.0 (1541) 
Age: (SD) 
Minimum 
Maximum 
Mean 
 
15 
45 
27.80 (8.6) 
 
15 
45 
28.04 (6.9) 
0.028 
Index of Multiple 
Deprivation (IMD)*:  
  
<0.001 
 
 
 
Most Deprived 22.8 (2321) 25.3 (2438) 
2nd 27.8 (2834) 20.9 (2008) 
3rd 25.3 (2573) 27.8 (2680) 
Least Deprived 24.1 (2450) 26.0 (2501) 
Smoking Status:   <0.001 
Non Smoker 62.2 (6774) 38.0 (3663) 
Ever Smoker 37.8 (4112) 62.0 (5964) 
Body Mass Index 
(BMI)*: 
  
<0.001 
 
 
 
 
Ideal (18.5-24) 48.4 (3717) 46.9 (4087) 
Underweight (<18.5) 6.6 (503) 4.6 (398) 
Overweight (25-29) 23.5 (1801) 27.0 (2356) 
Obese (≥30) 21.5 (1653) 21.5 (1872) 
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6.4 Incidence of Cardio-metabolic Disease 
The participants were followed up for the outcomes explained in chapter 5 until they left the 
practice or the end of follow up on 31st December 2015. As all of the participants entered the study 
at different index dates, the length of follow up varies, from a minimum of one day to a maximum 
of fifteen years. The median length of follow up for the exposed women was 4.4 years compared 
to 3.4 years for the unexposed participants. During this follow up 761 participants had a recorded 
outcome, which corresponded to 3.7% of the cohort. There were 919 recorded outcomes in total, 
as participants could contribute more than one outcome, however only the first outcome was 
counted in the ‘any CVD’ variable.  Of the recorded outcomes, 693 were CVD including 
hypertension, 224 were type 2 diabetes mellitus (T2DM) and 2 were hypercholesterolaemia.  Table 
6.3 depicts the number of events for each outcome in the exposed and unexposed groups.  
Table 6.3 Incidence of primary and secondary outcomes during the follow up period 2000-2015, in this 
cohort study, n=20513. 
Outcome: 
Unexposed: 
n= 10886 
% (n) 
Exposed: n= 9627 
% (n) 
Any CVD* 2.9 (321) 2.9 (281) 
Stroke 0.1 (15) 0.1 (10) 
Coronary Heart Disease≠ 0.2 (21) 0.1 (12) 
Myocardial Infarction 0.1 (12) 0.1 (7) 
Type 2 Diabetes Mellitus 1.1 (122) 1.1 (102) 
Hypercholesterolaemia 0.02 (2) 0.0 (0) 
 
* Any CVD = Cardiovascular Disease and includes all individual outcomes listed except Hypercholesterolaemia 
and Type 2 Diabetes Mellitus. For this variable, participants were censored after first CVD outcome. 
≠ Coronary Heart Disease includes records of myocardial infarction, angina, unclassified coronary heart 
disease, and heart operations used as treatment for the disease.  
 
6.4.1 Cox Proportional Hazards Regression 
In order to assess the association of pregnancy on the incidence of cardio-metabolic disease, a Cox 
proportional hazards regression was performed. As explained in chapter 5, the analysis was 
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undertaken for the primary outcome of ‘any CVD’, and the secondary outcomes:  myocardial 
infarction (MI), coronary heart disease (CHD), stroke and T2DM. As previously stated, there were 
not enough outcome events to perform the regression for hypercholesterolaemia.  Three models 
were fitted for each outcome; model 1 produced the unadjusted hazard ratio (HR), model 2 the age 
adjusted HR and model 3 HR adjusted for all the baseline covariates of: age at index date, general 
practice, smoking status, BMI and IMD. As there were only two records of hypercholesterolaemia 
in the follow up, this could not be used as a covariate in the analysis, for the other outcomes. None 
of the interaction terms for these covariates yielded statistically significant results, therefore these 
were not included in the final models.  This was likely due to the lack of power from the small 
number of events. In order to maximise the number of participants within the analysis, those with 
missing codes for IMD and BMI were categorised into a ‘missing’ group for each covariate. This 
allowed the outcome data of these participants to be incorporated into the analysis. Table 6.4 
presents the hazard ratio (HR) of incident cardio-metabolic disease in ever pregnant versus never 
pregnant women for each model of the Cox regression. 
Table 6.4  Ever pregnant versus never pregnant risk of cardio-metabolic disease in women aged 15-45 
years*, during a 15 year follow up period between 2000-2015≠ n=20,513. 
 Hazard Ratio (95% Confidence Interval) 
Outcome†: Model 1₸ Model 2₸ Model 3₸ 
Any CVD ¥ 0.83 (0.70-0.97) 1.07 (0.91-1.27) 0.95 (0.78-1.13) 
Myocardial Infarction 0.55 (0.22-1.39) 0.75 (0.28-1.96) 0.90 (0.32-2.54) 
Coronary Heart Disease∞ 0.54 (0.27-1.09) 0.91 (0.43-1.91) 1.12 (0.50-2.48) 
Stroke 0.64 (0.29-1.43) 0.88 (0.38-2.01) 0.83 (0.35-1.99) 
Type 2 Diabetes Mellitus 0.79 (0.60-1.02) 0.98 (0.75-1.28) 0.87 (0.66-1.16) 
* Women were aged 15-45years at the start of follow up. 
≠ Maximum follow up was 15 years with a median follow up of 3.8 years.  
¥ Any CVD = Cardiovascular Disease and includes all individual outcomes listed except 
Hypercholesterolaemia and Type 2 Diabetes Mellitus. For this variable participants were censored after first 
CVD outcome. 
∞ Coronary Heart Disease includes records of myocardial infarction, angina, unclassified coronary heart 
disease, and heart operations used as treatment for the disease. 
† Participants could contribute more than one outcome event except for the Any CVD outcome, where 
women were censored after the first outcome. 
₸ Model 1 = Unadjusted HR. Model 2= Age adjusted. Model 3= Adjusted for: age, smoking status, body mass 
index, index of multiple deprivation and general practice. 
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As can be seen from table 6.4, the unadjusted HRs for each outcome suggest a reduced risk of 
cardio-metabolic disease for the exposed, ever pregnant women. These associations were 
attenuated by adjustment for age but still suggested a reduced risk for exposed women, except for 
the outcome of any CVD, which suggested a slightly increased risk. All the model 3 results, except 
for CHD, suggest that ever pregnancy is protective against cardio-metabolic disease incidence. 
However, these results were not statistically significant, with large confidence intervals (CI) due to 
the low number of outcomes. The results therefore suggest that there is no association between a 
history of pregnancy and the risk of future CVD. 
Table 6.5 displays the risk estimates for the covariates from the model 3 regression for the primary 
outcome of ‘any CVD’.  As can be seen from the table, the risk of CVD differs between practises, 
and is higher in overweight or obese people. The risk of CVD is also higher in people living in 
deprived neighbourhoods (2nd quartile of IMD), older women and in those who have ever smoked.  
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Table 6.5 The effect of covariates within the model 3 Cox regression on the risk of the primary outcome,  
'any cardiovascular disease', in this cohort study, with follow up between 2000 and 2015, n=20,513. 
Model 3 Covariate: 
Hazard Ratio 
(95% Confidence interval): 
p-value: 
Significance at <0.05 
General Practice:   
Practice 1 Reference  
Practice 2 0.70 (0.49-1.01) 0.057 
Practice 3 0.58 (0.41-0.82) 0.002 
Practice 4 0.67 (0.49-0.91) 0.011 
Practice 5 0.73 (0.48-1.11) 0.140 
Practice 6 0.84 (0.60-1.17) 0.295 
Practice 7 0.67 (0.49-0.92) 0.012 
Practice 8 0.68 (0.48-0.96) 0.028 
Practice 9 0.85 (0.57-1.27) 0.426 
IMD Quartile*:   
Most Deprived Reference  
2nd Quartile 1.12 (0.82-1.5) 0.467 
3rd Quartile 0.81 (0.58-1.15) 0.241 
Least Deprived 0.82 (0.57-1.18) 0.281 
Missing 0.23 (0.05-0.97) 0.045 
Body Mass Index:   
Ideal Reference  
Underweight 0.59 (0.28-1.27) 0.178 
Overweight 1.52 (1.23-1.88) <0.001 
Obese 2.72 (2.24-3.31) <0.001 
Missing 0.37 (0.23-0.60) <0.001 
Age at index date≠: 1.10 (1.08-1.11) <0.001 
Ever smoker: 1.23 (1.03-1.47) 0.021 
* IMD = Index of Multiple Deprivation  
≠ Women were aged between 15 and 45 years at the start of follow up 
 
6.4.2 Sensitivity Analysis 
Sensitivity analyses were performed to determine if the categorisation of missing data in the BMI 
covariate and allocation of participants without a smoking code into the non-smokers group, 
affected the results of the Cox regression. As both of these covariates had been statistically 
significant in the original ‘any CVD’ outcome analysis, this regression was repeated with the 
participants with missing data excluded. The results of the sensitivity analyses are presented in 
table 6.6. As can be seen from these results, the exclusion of women with missing data had no effect 
on the HR or statistical significance of the ever pregnant versus never pregnant risk of the primary 
outcome ‘any CVD’. The sensitivity analysis results for the effect of each covariate on the risk of 
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each outcome was not greatly changed. The sensitivity analyses were only performed on the 
primary outcome due to the small number of events in the secondary outcomes. 
Table 6.6 Results of model 3 Cox regression and sensitivity analysis after participants with missing data were 
excluded, for primary and secondary outcomes during a follow up period between 2000 and 2015.  
 
Ever Pregnant versus Never Pregnant 
Hazard Ratio (95% Confidence Interval) 
Outcome: Covariate: Model 3: 
Sensitivity Model 
with missing data 
excluded: 
Any CVD* 
Body Mass Index 0.95 (0.80-1.13) 0.95 (0.79-1.12) 
Ever Smoker 0.95 (0.80-1.13) 0.94 (0.79-1.11) 
*Any CVD = Cardiovascular Disease and includes all individual outcomes listed except Hypercholesterolaemia and Type 2 
Diabetes Mellitus. For this variable, participants were censored after first CVD outcome. 
 
 
 
6.5 Discussion 
The aim of this cohort study was to assess the relationship between parity and cardio-metabolic 
disease in the local population of North Staffordshire using general practice (GP) data from the 
CiPCA database. This discussion summarises the findings of the study as well as discussing the 
notable results. The strengths and limitations of the study are also presented with implications for 
future research.  
6.5.1 Summary of findings 
The cardio-metabolic diseases with the highest period prevalence in the 31,715 women, 
representing the female general population aged 15-45 within the CiPCA database, were 
hypertension at 2.3% and T2DM at 1.1%. Also, 41.4% of the total women were ever smokers and 
22.0% were obese.  
Once the exclusion criteria had been applied to this group a final cohort of 20,513 women was 
formed. There were dissimilarities between the unexposed and exposed groups, most notably the 
proportion of ever smokers was much higher in the exposed compared to the unexposed groups at 
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62% and 37.8% respectively.  There was missing data for the BMI and IMD groups, with the majority 
of this corresponding to the unexposed participants, however, sensitivity analyses proved that this 
did not affect the results of the Cox regression analyses for the primary outcome, ‘any CVD’.  
The results of the Cox regression suggest that after adjustment for risk factors, the risk of 
developing cardio-metabolic disease is equivalent in ever pregnant versus never pregnant women 
(‘any CVD’ HR: 0.95 (0.78-1.13)). Due to the small number of outcomes the CIs were wide and none 
of the ever pregnant versus never pregnant risk estimates were statistically significant. All of the 
risk factors adjusted for in the model 3 ‘any CVD’ regression were statistically significant. 
6.5.2 Notable findings 
The prevalences of cardio-metabolic diseases in this cohort were similar to the female United 
Kingdom (UK) figures for 16-44 year olds, according to GP data collected by the British Heart 
Foundation (BHF), (Townsend et al., 2015). The prevalences of both MI and stroke, in the UK, were 
0.1% for 2011. On the other hand, the prevalence of any CVD in this study, 3.5%, was greater than 
the UK average of 1.9% of 16-44 year old females. However, these figures are not directly 
comparable as the women in this cohort study were aged 15-45 years at their index date and the 
prevalence is over a median of 3.8 years rather than 1 year. The prevalence of obesity was 
comparable in this study population (22.0%) to the English figure for 2013 (24%), although this latter 
figure is for all women over 16 years (Townsend et al., 2015) and so the results are not exactly 
comparable. 
When assessing the baseline characteristics of the study participants there was missing data for 
smoking, BMI and IMD. The majority of the participants with missing codes for these covariates 
were unexposed women. This difference between the groups is likely to be because a woman’s 
smoking status and BMI are required when completing an antenatal booking assessment. 
Therefore, the women who have been pregnant are more likely to have these risk factors recorded. 
As previously explained, the women without a smoking code were classified in the analysis reported 
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here as non-smokers due to the Quality and Outcomes Framework (QOF) recommendation to not 
ask for smoking status after the age of 25 years in non-smokers (NHS Employers, 2014). An 
alternative to this method would have been to use multiple imputation. However, sensitivity 
analysis showed there was no difference in results for the primary outcome, after excluding the 
women without a recorded smoking status. This was also true for the women with missing BMI 
data, and is probably due to the fact that healthcare practitioners are more likely to record the BMI 
of the women at the extreme ends of the BMI scale e.g underweight and obese. Therefore, the 
women with missing data likely represent those of an ideal weight.  
As well as the missing data for the baseline characteristics, there was a clear distinction in the 
smoking status of exposed and unexposed women, with ever smokers comprising 62% and 37.8% 
respectively. When the women with missing data for smoking were excluded there was still a large 
distinction in the prevalence of ever smoking in exposed and unexposed women, with 59.2% and 
40.8% respectively. This does not correspond to the expected prevalences of smoking in parous and 
nulliparous women, which in the pan-European study by Peters et al., (2016) were similar at 21% 
and 25% respectively. Peters et al., only recorded those who were current smokers which is why 
the figures are lower than those for this cohort study which reported ever smokers. However, using 
the Peters et al. study as an example it would be expected that the proportion of ever smokers 
would be similar across the exposed and unexposed groups. A potential reason for this deviation in 
the baseline characteristics could be that there is clear evidence that smoking can be harmful to a 
growing foetus (Mund et al., 2013; Stone, Bailey and Khraisha, 2014). Smoking cessation advice and 
support is therefore given to pregnant women by healthcare professionals (Chamberlain et al., 
2017). Therefore, a combination of repeated questioning and lifestyle advice from healthcare 
professionals and a woman’s desire for smoking cessation services during pregnancy will increase 
the likelihood that a woman will report a smoking habit. Unexposed women would not have 
experienced this period of intense smoking cessation advice and may therefore be less likely to 
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disclose their true smoking status. This could have led to the disproportionate number of ever 
smokers in the exposed group compared to the unexposed.  
All of the risk factors were statistically significant as covariates in the Cox regression for the ‘any 
CVD’ outcome. This demonstrates the clear links between these risk factors and atherosclerosis and 
CVD progression, which have been proven by the Global Burden of Disease study (GBD 2015 Risk 
Factors Collaborators). Also, the trends seen in the covariate results were in keeping with the 
knowledge of these risk factors (Libby and Theroux, 2005; GBD 2015 Risk Factors Collaborators, 
2016; Wilkins et al., 2017), as the risk of an outcome was increased in the higher BMI groups and 
the ever smoker group. For example, compared to an ideal weight, the risk of T2DM incidence was 
HR: 2.9 (1.9-4.3) in the overweight category and HR: 7.6 (5.2-11.0) in the obese category.  
6.5.3 Strengths and limitations 
There are several strengths and limitations of this cohort study, some of which are due to the 
characteristics of GP databases and the assumptions which come with using this recorded data, 
whilst others reflect the specific design of this cohort study.  
A GP is the usual gateway to healthcare in the UK, with all medical conditions, other than 
emergencies, first being reported at this level. GP visits are available free of charge for all under the 
National Health Service  (NHS) in the UK, where 98% of residents are registered with a GP (Herrett 
et al., 2015).  Information regarding the management of diseases within secondary care, is also fed 
back to GP’s to enable continuity of care. Primary care databases therefore provide invaluable 
health data for research, as the records from these consultations depict broad health profiles for 
the specific population served by that GP.  Furthermore, when the records from individual practices 
are compiled into a database, the resulting health data is highly representative of the general UK 
population (Jordan et al., 2007). GP databases are therefore increasingly being used for research, 
for example the CiPCA database has been used for over 30 research papers 
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(www.keele.ac.uk/mrr/publications/), while the Clinical Practice Research Datalink (CPRD) a 
national database, has been used for over 1,800 publications since 1988 (CPRD, 2018).  
The records stored within these databases allow for the follow up of patients over time, without 
the cost of repeated correspondence with participants. Also, the potential for reporting bias, being 
the incorrect recall by a participant of an exposure or outcome event (Sedgwick, 2014), is abolished 
as the conditions and symptoms are coded at the time of presentation. The size of the registered 
population allows for research into rare diseases or studies where the outcome incidence may be 
low, as in this cohort study.  
Since the introduction of the QOF, which is a voluntary reward scheme for general practices based 
on the coding of specific indicators (NHS Employers, 2014), the completeness of coding has 
improved (Herrett et al., 2015). Specific to this study, the percentage of consultations coded from 
the GPs contributing to the CiPCA database was 93% in 2004 (Jordan, Porcheret and Croft, 2004).  
As well as the associated strengths of primary care databases, certain aspects of this specific cohort 
study are noteworthy. Firstly, the CiPCA database is comprised of North Staffordshire practices and 
is therefore an excellent resource for health data from the specific population of Stoke on Trent, 
Newcastle under Lyme and the Staffordshire Moorlands. As this area is in the 10% most deprived 
localities within the UK (Public Health England, 2017b), it was useful to conduct research in this 
location on the incidence of CVD, for which low socioeconomic status is a risk factor (Mackenbach 
et al., 2000; Cubbin et al., 2006). 
The Read codes used to identify the exposure, outcomes and confounders in the study participants, 
were compiled from several previous code lists, and the NHS Clinical Browser, with the duplicates 
removed. These lists were also discussed with Dr Pensée Wu (PW) for clinical expertise in assessing 
the suitability of each code for identifying the required conditions.  Therefore, the final lists are 
likely to contain all of the relevant read codes for each variable, thereby reducing bias from the 
incorrect recording of exposure or outcomes in this study.  
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The GPs which contribute data to the CiPCA database have ongoing training and assessment in 
accurate and complete coding of morbidities, meaning the data provided is of high quality 
(Porcheret et al., 2004). Furthermore, the variables of CHD, smoking status, heart failure, 
hypertension and diabetes mellitus recorded in this study are included in the QOF, therefore GPs 
have an incentive to code these conditions to a high standard (NHS Employers, 2014). This means 
the incidence and prevalence of these variables should closely reflect the true values within the 
population.  
Within the model 3 Cox regression, four risk factors of cardio-metabolic disease were adjusted for: 
age, socioeconomic status (defined by IMD score), BMI and smoking status. This meant the HRs 
produced by the analysis more closely reflected the true, independent relationship between parity 
and cardio-metabolic disease. The age covariate was statistically significant in every outcome 
regression with all of the covariates being statistically significant in the ‘any CVD’ analysis. This 
confirmed the requirement to adjust for these risk factors. This strength in the study improves upon 
five of the cohort studies included in the systematic review, presented in chapter 4, which either 
did not adjust for age (Jacobsen et al., 2011), or adjusted for age only (Colditz et al., 1987; Cooper 
et al., 1999) or adjusted for age and only one other risk factor (Parikh et al., 2010; Gallagher et al., 
2011).  
This study does however present some limitations. Despite the strengths of primary care databases, 
the data is not recorded specifically for research purposes, leading to limitations in its use. Firstly, 
the coding of morbidities is subjective, with the potential for certain codes to be used more than 
others based on the preference of the healthcare professional (Jordan, Porcheret and Croft, 2004). 
Also, during multi-complaint consultations only the most important issues may be coded, whilst 
long standing conditions may not be recorded at every presentation and may only be coded for if 
the treatment changes (Jordan et al., 2007).   These subjective aspects of the recording process 
produce disparities in coding both between and within practices, meaning the quality of coding and 
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use of specific codes across practices may not be directly comparable. This was demonstrated by 
Porcheret et al. (2004) who found a variation in coding completeness of 5% to 97% in seven 
practices, however coding has improved since this paper was published (Herrett et al., 2015).  
Inaccurate or incomplete data coding may also arise due to the inadequate transcription of 
secondary care records onto the primary care coding system, and morbidities being written as free 
text rather than coded in the correct format (Herrett et al., 2015).  Also, the GPs can only code for 
conditions which are consulted for, meaning complaints which do not require medical treatment 
or are not regarded as significant by a patient will not be recorded. For example, a general limitation 
of using GP records is that the availability of over the counter medicines for common ailments will 
reduce the number of patients consulting for these problems. All of these inconsistencies either 
due to the subjective nature of coding or inaccurate and missing codes, may result in the 
underestimation of prevalence and incidence of morbidities in research, both with cross-sectional 
and longitudinal study designs (Jordan et al., 2007). This is built upon the necessary assumption 
that the lack of a Read code is due to the absence of that disease in any particular patient (Herrett 
et al., 2015). 
The most significant weakness in this research study is the short follow up of participants due to 
the lack of sufficient data within the CiPCA database before 2000. Therefore, the longest potential 
follow up was fifteen years which is not in accordance with the disease processes of the study 
outcomes. This is due to a lag effect between the exposure to a risk factor and the development of 
CVD (Yusuf et al., 2001). As explained in the chapter 2, the main pathophysiological process causing 
CVD is atherosclerosis, which is a development of fatty plaques within the arteries over decades 
(Strom and Libby, 2011). This is demonstrated by data collected by the BHF (Townsend et al., 2014) 
which shows the prevalence of both angina and stroke respectively do not surpass 1% of the UK 
population until the age of 55-64 years. As the mean age of the exposed and unexposed women in 
this study at the index date were 28.14 years and 27.69 years respectively, the maximum potential 
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follow up of fifteen years would not have been sufficient. Therefore, the incidence rates of CVD 
reported in the results will be an underestimate of the true value if a longer follow-up had been 
identified. This study can however be used to determine the risk of early onset cardio-metabolic 
disease in exposed and unexposed women.  
Another limitation is that there may have been participants in this study which met the exclusion 
criteria, for example type 1 diabetes mellitus, but due to inconsistent coding of chronic conditions 
at each presentation or due to non-consultation, were not coded for this in the one year preceding 
the study start. These participants would therefore have been incorrectly included within the 
cohort and may have biased results by overestimating the incidence of cardio-metabolic disease.  
Furthermore, the time frame of the study restricted the assessment of exposure status, as women 
may have had pregnancies before 2000 which were not recorded in the CiPCA database. This poses 
several limitations to the research as this may have caused incorrect classification of unexposed 
and exposed women. Firstly, women who had a pregnancy before 2000 and no pregnancies after 
this point would have been assigned into the unexposed group. Women with pre-eclampsia or GDM 
during a pregnancy before 2000 would also have been included in the unexposed group. The 
incidence of an outcome for these women would have been recorded in the unexposed group and 
therefore underestimated the association between pregnancy and cardio-metabolic disease. 
Secondly, women with CVD following a pregnancy which occurred before 2000 would have been 
excluded from the study, as it would have appeared that this CVD preceded their first pregnancy 
after 2000. This exclusion of exposed women with a CVD outcome would have led to an 
underestimate of the relationship between parity and cardio-metabolic disease. Also, due to the 
use of the first pregnancy code as the index date, CVD beginning in pregnancy but after the first 
record would have been classified as an outcome of CVD after pregnancy.  Thirdly, only ever 
pregnant versus never pregnant analysis could be completed as there was insufficient information 
in the coding of pregnancies to determine the parity level of women.  
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As explained in chapter 2, the maternal cardiovascular adaptations are greater during a multiple 
pregnancy compared to a singleton, and the long term effects on the cardiovascular system may be 
increased (Tan and Tan, 2013; Sanghavi and Rutherford, 2014). However, due to incomplete coding 
it was not feasible to determine whether the pregnancies of the exposed group were singleton or 
multiple pregnancies.  As multiple pregnancies could not be adjusted for in the Cox regression, this 
study could not determine if the relationship between pregnancy and cardio-metabolic disease is 
different in multiple pregnancies compared to singletons.  However multiple pregnancies account 
for only 1% of pregnancies (Sagili and Divers, 2007) meaning any potential effect will have been 
small.  
The original proposal for this study was to determine a participant’s ethnicity and incorporate this 
into the analysis, as the systematic review presented in chapter 4, proposed varied CVD risks across 
different ethnicities. However, the completeness of coding of ethnicity within the CiPCA database 
was poor and therefore could not be included as a variable. This is consistent with data from the 
Clinical Practice Research Datalink (CPRD), a national GP database, which only reports an ethnicity 
code for half of patients (Herrett et al., 2015). As a result, this cohort study was unable to examine 
the effect of ethnicity on CVD risk.  
As the majority, 82%, of women in the UK, have at least one child (Office of National Statistics), 
there was not a sufficient number of nulliparous, unexposed women to match two to every one 
parous women by exact age. However, to overcome this, age was adjusted for in the analysis. It 
was also not possible to match all exposed women to 2 unexposed women. 
Due to all of these limitations it is likely that the results of this study, which suggest there is no 
association between a history of pregnancy and cardio-metabolic disease, are an underestimate of 
the true effect of parity on future cardio-metabolic disease. Using data from a national database 
with a longer period of records would overcome many of these limitations. There would have been 
more data available to determine exposure status and longer follow up of patients for outcomes. 
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As this study was a feasibility study, the recommendations for future research in this area are 
explained in chapter 7.  
6.5.4 Conclusion 
The results of this study could suggest there is no association between parity and short term CVD 
outcomes. The study has highlighted the importance of adjusting for risk factors in analyses of this 
kind and presented the strengths and limitations of using GP records in observational research. 
Similar to the conclusions of the systematic review in chapter 4, this study has demonstrated the 
requirement of a follow up duration which suits the population and outcomes of interest. This 
feasibility study can be used to improve the methods of future studies carried out using CPRD or an 
equivalent database with a longer period of available data for follow up.  
In the next chapter, the results of this study and the systematic review presented in chapter 4, will 
be compared to the current published literature on the association of parity with CVD, which was 
not included in the systematic review. Recommendations for future research and clinical practice 
will also be presented.  
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7 Discussion of Research 
The aim of this research was to investigate the relationship between parity and future 
cardiovascular disease (CVD) and to determine if parity is a risk factor for CVD. This was achieved 
by completing a systematic review of the published literature, which was presented in chapters 3 
and 4, and conducting a cohort study using the Consultations in Primary Care Archive (CiPCA) 
database, which was presented in chapters 5 and 6. This discussion will summarise the main 
findings of this research as well as the strengths and limitations. The results will be compared to 
previous publications on the topic. The potential mechanisms through which parity increases the 
risk of CVD will be explored and a conclusion will be reached as to whether parity is a risk factor for 
CVD. The implications this research has on future clinical practice and research will also be 
discussed. 
7.1 Summary of Findings 
The systematic review included eighteen studies in total, with thirteen cohort and five case-control 
studies. Separate meta-analyses of the cohort study results were conducted for the outcomes of 
morbidity or mortality from coronary heart disease (CHD) and from stroke, while the case-control 
studies only assessed the outcome of CHD. Both the CHD and stroke results suggested that the risk 
of CVD is increased from para 4 onwards.  
The cohort study, included the records of 20,513 women from the CiPCA database, aged 15-45 
years at baseline, between 2000 and 2015. There was no association between a history of 
pregnancy and future CVD. However, the covariates of: age, smoking status and body mass index 
(BMI) were all statistically significantly associated with CVD. The study acts as a feasibility study for 
future research into the association of parity with CVD. It provides a template of methods to be 
applied to another database, with a lengthier duration of patient records, to allow a longer follow 
up of participants.  
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There are three main findings of this research.  Firstly, more research is needed to assess the risk 
of CVD in ever parous versus nulliparous women, as both the systematic review and CiPCA cohort 
study found no association. However, the subgroup analysis of the systematic review found that 
studies with an adequate follow up were more likely to find an association. For the purpose of this 
research an adequate follow up was defined as all of the study participants being 55 years and over 
at the end of follow up. Therefore, the results from the ever parous/ever pregnant analyses 
presented here may be an underestimate of the true relationship, due to the short follow up time 
in the CiPCA cohort study and in some of the studies included in the review. This theory is in 
accordance with the increased risk of CHD for ever parous women found in the case-control meta-
analysis.    
The second main finding of this research is that the risk of CVD is not the same for each parity level. 
Therefore, research into the relationship between parity and CVD should not only focus on ever 
parity but also each individual parity level as an exposure. Finally, the results of the meta-analysis 
for stroke demonstrated a ‘J’ shaped trend in risk per parity level. The lowest risk compared to 
nulliparity was at para 2, after which the risk increased with each subsequent pregnancy, with para 
5+ women having a statistically significant increased risk of stroke.  
7.2 Previous Research 
Both the systematic review (see chapter 4) and CiPCA cohort study (see chapter 6) results suggested 
there was no difference in CVD risk between ever parous and nulliparous women. These results are 
similar to the ever parous versus nulliparous risk of all-cause CVD mortality found in the previous 
systematic review (Lv et al., 2015), which suggested a protective effect of parity but with a non-
statistically significant risk estimate. These findings are in contrast with a cross-sectional study by 
Catov et al. (2008), which found a statistically significant increase in stroke risk for ever parous 
women compared to nulliparous, in women whose mean age was 80 years. This study was not 
included in this systematic review (see chapters 3 and 4) as it was a cross-sectional study. The meta-
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analysis of the case-control studies in this systematic review also found a statistically significant 
increased risk of CHD in ever parous women.  Although these studies were not of a cohort design, 
it adds weight to the conclusion that a longer follow up of participants in a cohort study may yield 
statistically significant results for this risk estimate.  
Within the published literature assessing the association between parity and CVD, there is a 
growing body of evidence demonstrating that grand multiparity increases the risk of CVD, as was 
seen in this systematic review. However, this systematic review did not include all published studies 
focussing on the association of parity with CVD, due to the specific exclusion criteria set within the 
protocol. For example, studies which examined composite cardiovascular disease risk, gravidity 
rather than parity, did not have a nulliparous comparison group, or utilised a cross-sectional design, 
were excluded. The following paragraph will compare the results of those excluded studies with 
this systematic review.  
In concordance with this systematic review (see chapter 4), some studies report a ‘J’ shaped 
association of CVD risk with increasing parity (Green, Beral and Moser, 1988; Lawlor et al., 2003; 
Dior et al., 2013; Lv et al., 2015), while others indicate a ‘U’ shaped curve (Koski-Rahikkala et al., 
2006; Catov et al., 2008; Jaffe, Eisenbach and Manor, 2011) or a positive linear association (Ness et 
al., 1993; Kvale, Heuch and Nilssen, 1994; Qureshi et al., 1997; Chang et al., 2011; Kim et al., 2016). 
In contrast to these studies and the systematic review, a minority of studies report a negative linear 
association of risk with increasing parity (Sakauchi, 2007; Jacobs et al., 2012). 
These heterogeneous results are due to large disparities in the study design, population, exposure 
and outcomes of interest in the studies. The exposure of interest in these studies varies between 
gravidity (Ness et al., 1993; Qureshi et al., 1997; Kim et al., 2016), meaning number of pregnancies, 
which was the exposure in the CiPCA cohort study (see chapter 5) and parity, being number of live 
or potentially live births. This means the results are not directly comparable at the lower 
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parity/gravidity levels, as a woman who has suffered three miscarriages would be a para 0 but 
would also be a gravida 3.  
The inclusion of women with miscarriages in para 0 may partly explain the ‘U’ shaped and ‘J’ shaped 
associations reported by studies, in the form of negative health selection (Grundy and Tomassini, 
2005; Jacobs et al., 2012). Women with poor health, for example polycystic ovary syndrome, may 
be unable to conceive or may experience miscarriages, due to the associated subfertility (Lawlor et 
al., 2003; Goodman et al., 2015). Also, due to the underlying medical problem they are at an 
increased risk of CVD (Goodman et al., 2015) compared to women who are healthy enough to 
support several pregnancies (positive health selection). Therefore, the ‘J’ or ‘U’ shaped trends of 
risk per parity level may reflect the increased risk of women who are unable to conceive due to 
health problems, rather than parity bearing a protective effect for women of para 1 or 2. Similar to 
this, the increased risk of CVD attributed to para 1 in some studies may be due to women who had 
a pregnancy complication, such as pre-eclampsia, which are more likely to occur in first pregnancies 
and due to this did not reconceive (Hernández-Díaz, Toh and Cnattingius, 2009). As these 
complications are independent risk factors for CVD, and were not adjusted for in all studies, the 
para 1 women appear to be more at risk of CVD compared to women of para 2. Para 2 women most 
commonly represent the parity at lowest risk of CVD, as was seen in the stroke results in this 
systematic review (see chapter 4).  
Although multiple studies have investigated the association of parity with CVD, the specific 
outcomes used are different between the studies: mortality only, morbidity only, mortality and 
morbidity, CHD only, stroke only, CHD and stroke and composite CVD. The systematic review (see 
chapter 4), showed no substantial difference between the estimated risk of CHD and stroke with 
parity.  The apparent irrelevance of specific CVD outcomes in determining results, may be due to 
the common pathophysiological process of atherosclerosis behind these different diseases.  
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Few of the results reported by the excluded studies are statistically significant, which was similar to 
the studies included in the systematic review. This may be due to the wide parity categories used 
by some, for example Chang et al. (2011) grouped para 0-4 women together, which does not 
account for the varying risks for each of these parities. This was evident in the null results of the 
ever parous analysis in this systematic review (see chapter 4) and CiPCA cohort study (see chapter 
6). Other potential reasons for the non-significant results are inadequate follow up lengths or small 
cohorts leading to a lack of outcome events, which were both limitations of the cohort study 
presented in chapter 6. Also, the results will be subject to confounding as not all of the studies 
completed rigorous adjustment for metabolic and behavioural risk factors.  
Despite the lack of significance for the majority of results on parity level 1-4, the unifying element 
of all of these studies is the increased risk of CVD morbidity in grand multiparous women (para 5+). 
In many studies, including several incorporated in this systematic review (see chapter 4), the risk 
estimate for grand multiparity was statistically significant. This research therefore adds to the 
current evidence supporting the relationship between grand multiparity and an increased risk of 
CVD.  
 
7.3 Strengths and Limitations 
There are specific strengths and limitations of the individual analyses within this thesis which were 
discussed in chapters 4 and 6. The strengths and limitations related to this research as a whole are 
as follows. Firstly, a strength is that the objectives set out at the beginning of this research were 
met, as both a systematic review with meta-analysis and cohort study using the CiPCA database 
were conducted. Another strength of the research is the large number of participants included in 
the systematic review and cohort study. This systematic review was the first to assess the 
relationship between parity and the outcomes of CHD and stroke separately and include both 
morbidity and mortality events from these diseases. The outcomes of CHD and stroke were 
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investigated individually, as these diseases have different pathological causes, which may have led 
to a difference in risk with parity. Also, these diseases account for the majority of CVD disability 
adjusted life years (DALYs) in England (Newton et al., 2015). Therefore, the results accurately 
represent the large burden of CVD within the study populations.  
There are limitations to this research in answering the research question of whether parity is a risk 
factor for CVD. Firstly, due to the lack of accurate pregnancy coding in the CiPCA database, the 
exposure recorded in the cohort study was gravidity rather than parity. Although this will have 
included parous women, the results are not directly comparable to that of the systematic review or 
previous research assessing parity. However, Jacobs et al., (2012) investigated both exposures with 
CVD and found that the trends in risk are similar.  The CiPCA cohort study was unable to assess the 
effect of ethnicity on CVD risk with parity. Therefore, future research should aim to address this. 
Due to the single analysis of ever pregnant versus never pregnant women in the cohort study and 
wide parity categories used in previous research  (Koski-Rahikkala et al., 2006; Chang et al., 2011; 
Dior et al., 2013), there were not sufficient results to fully investigate the risk of CVD for individual 
parity levels, specifically para 3 and 4. Also, there is a potential for incorrect recording of exposure 
or outcomes in the studies in the systematic review, due to poor confirmatory methods, for 
example only using self-reported medical diagnoses.  
Another major limitation of the research is the poor quality of some of the studies included in the 
systematic review and the limitations of the cohort study conducted using the CiPCA database. The 
poor quality arose mainly from the short length of follow up in the studies which pose limitations 
for both younger and older cohorts. A short follow up in younger women will not give adequate 
time for the CVD to manifest, yielding a small number of outcomes, as was the case in the CiPCA 
cohort study (see chapter 6). On the other hand, the initiation of follow up starting later in life 
allows the potential for survival related bias to influence results (Saracci, 2007). This occurs when 
exposed women die earlier in life due to the increased risk of mortality. This means any analysis 
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with a baseline at older age, will only include women who survived and may have been less 
exposed, causing the risk of death in exposed women to be biased towards the null (Saracci, 2007).  
Finally, the results of both the systematic review and cohort study were not fully adjusted for 
confounders. This is because the individual studies in the review all adjusted for different CVD risk 
factors, and due to the insufficient recording of ethnicity and socioeconomic status, among other 
risk factors, in the CiPCA database.  
7.4 Mechanisms for the Effect of Parity on future CVD 
The relationship between parity and CVD is thought to be due to three potential mechanisms. These 
are: the cardio-metabolic effects of pregnancy, the lifestyle factors influenced by raising children 
and the social inequalities which undermine health. The interaction of these three mechanisms are 
displayed in figure 7.1 which was adapted from Magnus et al., (2017).  
 
 
 
 
 
 
 
 
There are several biological theories which have been presented for the association between parity 
and future disease. These include the disposable soma theory which considers a trade-off between 
fertility and life expectancy (Kirkwood, 1977; Lorenzini, Stamato and Sell, 2011). This is due to the 
division of resources, being energy and macronutrients between either maintenance of healthy 
Figure 7.1 Potential mechanisms for the relationship between parity and cardiovascular disease. 
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cells or reproduction. Therefore, multiparous women have reduced their resources available for 
maintenance, allowing development of disease. The theories of positive and negative health 
selection have already been discussed earlier in this chapter. Following on from these theories, the 
concept of reverse causality may affect the relationship between parity and CVD (Szklo and Nieto, 
2014). However, these theories do not focus specifically on CVD development, therefore the 
biological factors discussed in this section will focus on the maternal adaptations to pregnancy 
which have been linked to future CVD.  
7.4.1 Cardio-metabolic Effects of Pregnancy 
The physiological mechanisms through which parity increases the risk of CVD were explained in 
detail in chapter 2. These adaptations have long term effects on the cardiovascular system, for 
example, left ventricular diastolic dysfunction is more common in grand multiparous women than 
all other parity levels (Aggarwal et al., 2017; Keskin et al., 2017). The fluctuations in metabolic 
markers and oxidative stress during pregnancy accelerate atherosclerosis development (Eren et al., 
2013, Skilton et al., 2010). The effects of the maternal adaptations have been shown to increase 
with each subsequent pregnancy (Clapp and Capeless, 1997). This is reflected in the results of the 
systematic review (see chapter 4), as the risk of CHD and stroke increased with parity, however the 
results were not statistically significant after adjustment until para 5+. A recent systematic review 
(Li et al., 2016) determined that grand multiparity is an independent risk factor for T2DM. A 
longitudinal study using record linkage in England and Wales by Grundy and Tomassini (2005) found 
that although the risk of all-cause mortality was greatest in para 5+ women, there was no 
statistically significant difference between para 1-4, which is in concordance with the results from 
this systematic review (see chapter 4). The authors therefore suggest that the effects of subsequent 
pregnancies are not cumulative, but that a mother’s physiology can tolerate the adaptations until 
para 5. At this point a threshold is reached where the consequences of the cardio-metabolic 
adaptations manifest. Although, the results of this systematic review support this hypothesis, this 
threshold may be lower in a woman with underlying health problems.  
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7.4.2 Lifestyle Factors 
Another potential mechanism through which parity mediates the increase in risk of CVD is through 
lifestyle choices which are behavioural risk factors for CVD. The characteristics of women in several 
studies assessing parity and mortality have shown that the prevalence of CVD risk factors such as 
smoking, obesity and low physical activity increase with increasing parity (Lawlor et al., 2003; Koski-
Rahikkala et al., 2006; Catov et al., 2008). This was also apparent in the results of the cohort study 
completed as part of this research, as the preponderance of exposed women were ever smokers, 
accounting for 62%, compared to only 37.8% in the unexposed women. This trend may be due to 
the busy lifestyle associated with raising children and the psychological and financial stress on 
parents (Ross and Mirowsky, 2002; Lee and Ryff, 2016). 
A study by Lawlor et al. (2003) involving 8,538 participants from the British Regional Heart Study 
and the British Women’s Heart and Health Study found that there was a statistically significant 
increase in smoking, obesity and inactivity with increasing parity for women. For example, the 
likelihood of smoking increased by odds ratio (OR) of 1.20 (1.11-1.30) for every increase of parity 
level. Furthermore, only the association with obesity was present in the male participants, where 
the number of children rather than parity was investigated. This raises questions in regard to the 
roles of men and women as parents, as having more children was linked to higher smoking rates 
and lower physical activity in women but not in men. Despite these statistically significant trends 
of CVD risk factors only occurring in women, Lawlor et al. (2003) found that there was not a 
statistically significant difference in risk of CVD between men and women for each number of 
children. As men have not undergone the cardiometabolic adaptations which occur in pregnancy, 
this result suggests that the increase in risk of CVD with parity in women is due to these behavioural 
risk factors rather than the biological effects of pregnancy.  Other studies which propose that 
lifestyle choices are responsible for the link between parity and CVD are Jaffe et al. (2010) and 
Magnus et al. (2017). The latter of which was included in the systematic review presented in chapter 
4.  
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7.4.3 Social Inequalities 
The interaction between parity and socioeconomic status forms the third pathway through which 
the increase in risk of CVD is seen in grand multiparous women. As explained in chapter 2, parity 
increases inversely to socioeconomic status. Women of para 5+ are more likely to have completed 
fewer years of education, have lower income and be unemployed or in routine manual occupations 
than any other parity level (Lawlor et al., 2003; Dior et al., 2013; Office for National Statistics, 2016). 
Socioeconomic status impacts greatly on health as the prevalence of risk factors, such as poor diet 
and smoking, is higher in lower socioeconomic positions (Public Health England, 2017a). 
Data from the 2010 report ‘Fair Society, Healthy Lives’ (The Marmot Review, 2010) show that the 
most deprived people will live shorter lives with more disability from ill health, compared to the 
least deprived. In the United Kingdom (UK), the difference in disability free life expectancy at birth, 
from the richest neighbourhoods compared to the poorest is seventeen years. Furthermore, a 
person with poor health or poor access to childcare may be unable to work and therefore cannot 
progress to higher social positions. This displays the complex nature of the social determinants of 
health and highlights the need to tackle social inequalities to improve the health of society as a 
whole.  
These social inequalities are apparent in the literature addressing parity and CVD (Kington, Lillard 
and Rogowski, 1997; Lawlor et al., 2003; Koski-Rahikkala et al., 2006; Catov et al., 2008; Dior et al., 
2013). In the Lawlor et al. (2003) study the independent adjustment for socioeconomic status 
attenuated the ORs, of CHD risk with increasing parity, more than any other metabolic or 
behavioural risk factor (Age adjusted OR: 1.31 (95% CI 1.18-1.44), Socioeconomic status adjusted 
OR: 1.22 (95% CI 1.10-1.35)). Thus, demonstrating the large weight socioeconomic status bears on 
parity and health outcomes.  
In the Lawlor et al. (2003) study, the percentage of women of low socioeconomic status, as both an 
adult and a child, increased with parity level (p <0.001 and p 0.002 respectively). The social class a 
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woman is born into therefore influences her reproductive patterns and risk of CVD. For example, 
the rate of teenage pregnancies is higher in women of lower socioeconomic status (Lee and Ryff, 
2016; Office for National Statistics, 2016). A systematic review (Rosendaal and Pirkle, 2017) has 
shown that the younger a woman is at her first birth, the higher her risk of CVD. This is due to a 
dynamic interplay of social and physiological factors as discussed above. Younger women gain and 
retain more weight during pregnancy and through the risk of obesity are more likely to develop 
CVD (Rosendaal and Pirkle 2017). Also, a young woman with a child will likely not complete high 
school or further education and is unable to work due to the need for childcare, meaning she will 
likely remain in the low socioeconomic position she was born into throughout adulthood (Lee and 
Ryff, 2016; Rosendaal and Pirkle 2017). This perpetuating cycle of adversity affects every generation 
of a family. Children born to mothers of low socioeconomic status will bear the same shorter 
disability free life expectancy as their mothers. Low socioeconomic status in early childhood has 
been shown to increase the risk of CHD in the future after adjustment for adult socioeconomic 
status and lifestyle factors (Hamil-Luker and O’Rand, 2007).  
The studies in the systematic review (see chapter 4) were adjusted for several behavioural and 
metabolic risk factors as well as socioeconomic status and the para 5+ stroke risk estimate retained 
statistical significance. This suggests that the increased risk of CHD and stroke in para 5+ women is 
due to biological factors. However, not all of the cohort studies adjusted for these CVD risk factors, 
suggesting that a definite conclusion cannot be made from this research. Furthermore, Rosendaal 
and Pirkle (2017) propose that adjusting for metabolic factors such as T2DM and 
hypercholesterolaemia, which form part of the biological pathway between parity and CVD, masks 
the true relationship. Therefore, the adjusted risk ratios (aRR) presented in chapter 4 may be an 
underestimate of the effect parity has on woman’s physiology and CVD risk in later life. Despite the 
statistically significant results after adjustment for socioeconomic status in both the systematic 
review and the Lawlor et al. (2003) study, high parity is clearly associated with social inequalities. 
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Therefore, further research into the association, with the aim of identifying the underlying 
mechanism, is required. 
7.5 Parity as a risk factor for CVD 
The aim of this research was to determine if parity is a risk factor for CVD. Several elements of the 
research compiled in this thesis can be used to answer this question. Firstly, the non-linear 
associations between parity and CVD identified in this systematic review (see chapter 4) and the 
previous published literature have demonstrated that parity should not just be classified as a 
dichotomous exposure. Future research should focus not only on ever parity as an exposure but 
also individual parity levels.  
Although there is not clear evidence for an association between ever parity and CVD, one has been 
identified for para 5+ (grand multiparity). The systematic review in chapter 4, and previous studies 
(Ness et al., 1993; Kvale, Heuch and Nilssen, 1994; Dior et al., 2013) presented a statistically 
significant association between grand multiparity and CVD. The magnitude of this association was 
also noteworthy, with the systematic review in chapter 4 suggesting a 21% increase in stroke risk 
for para 5+ women (aRR 1.21 (95% CI 1.06-1.39)). In addition, as discussed above, due to the 
adjustment for risk factors which are influenced by parity, such as obesity, cholesterol and diabetes, 
the strength and magnitude of study results may be an underestimate of the true relationship. 
However, by adjusting for CVD risk factors, the studies included in this review have illustrated that 
the biological effects of pregnancy reach a threshold effect in grand multiparous women which 
increases their risk of CVD. This biological plausibility adds weight to the association. This research 
therefore suggests that grand multiparity is a risk factor for CVD, however more research is needed 
with a longer follow up of participants to form a definite conclusion.  
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7.6  Future Implications for Research 
This thesis has highlighted several implications for future research into the association between 
parity and CVD. These are derived from the strengths and limitations of this research and those 
identified in the current published literature.  
The main strength of this research is the inclusion of morbidity and mortality from CVD as 
outcomes, as this reflects the true burden of CVD.  This should therefore be continued in future 
studies. However, this systematic review was unable to conduct meta-analyses for morbidity and 
mortality separately, due to a limited number of studies once stratified by CHD and stroke outcome. 
This has also not been achieved by other published studies on this topic. Therefore, it would be 
beneficial for future studies to complete analysis for the risk of composite CVD morbidity and 
mortality separately.  
The main limitation of this research is the short duration of follow up in cohort studies, which does 
not reflect the lag effect between the exposure of parity and development of CVD. However, studies 
which only include an older population of women are susceptible to survival related bias (Saracci, 
2007). Studies which utilised an adequate follow up duration were more likely to find an association 
between parity and CVD. Therefore, to build upon the current knowledge, there is a requirement 
for future studies to begin follow up during women’s childbearing years and continue recording 
outcomes until the death of each participant. As this may not be feasible due to the cost and time 
required to complete such as study, follow up could continue until a defined study end date which 
would allow all participants to have reached 75 years. The age of 75 years would be a reasonable 
end point as death before this is considered to be premature mortality (Townsend et al., 2015). 
Taking into account this long length of follow up required, case-control studies assessing the 
relationship between parity and CVD may be more appropriate in the short term. 
As this research was unable to determine the effect of certain parity levels, specifically para 1, 3 
and 4, it is imperative that each parity level is recorded and analysed in isolation in future research, 
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as the risk of CVD may differ between parity levels. Following this, it is important that future studies 
exclude women with pregnancy complications which are risk factors for CVD, such as pre-eclampsia. 
Also, women with CVD or T2DM before pregnancy should be excluded. These exclusions would 
facilitate a clearer evaluation of the effect parity exerts on the risk of CVD especially in nulliparous 
and primiparous women. By starting follow up during a woman’s reproductive years, the risk of 
recall bias when identifying these exposures will be reduced. However, the risk of recall bias is 
particularly low in research on parity, due to the life-changing nature of the exposure.  
In a future cohort study, the measurement of metabolic risk factors, such as cholesterol level and 
hypertension, as well as behavioural risk factors, for example, BMI and smoking status, should be 
recorded at baseline and at set intervals, as time-varying covariates, during follow up. This would 
allow the investigation of the changes in these risk factors with increasing parity. As Rosendaal and 
Pirkle (2017) suggest that adjusting for these risk factors underestimates the association between 
parity and CVD, presenting serial measurements could add weight to the theory that pregnancy 
causes these deviations in metabolic risk factors. Moreover, adjusting for these risk factors as 
continuous variables rather than categorical, where possible, would reflect the trend in risk, for 
example with increasing cholesterol levels, even within the normal range of results. Potential 
factors to adjust for in future research would include those related to pregnancy: age at first birth, 
history of the pregnancy complications pre-eclampsia, gestational diabetes mellitus (GDM), small 
birth weight and preterm birth as well as history of miscarriage and subfertility. Metabolic risk 
factors should also be adjusted for, including: hypertension, total cholesterol and lipoprotein levels 
and fasting plasma glucose level. The behavioural risk factors which should be adjusted for are: 
smoking, BMI, low physical activity and poor diet. Socioeconomic status should also be adjusted 
for, through measuring the IMD or other measure of socioeconomic status e.g. income or level of 
education. The non-modifiable risk factors of: age, family history of CVD and personal history of 
CVD or diabetes mellitus should also be adjusted for in future research.  
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As these recommendations present time consuming and costly study methods, it would be 
beneficial to conduct a cohort study fulfilling these criteria using electronic health records (EHR) 
from a general practice (GP) database such as the Clinical Practice Research Datalink (CPRD). This 
would facilitate the follow up of participants until death, without large resource implications, as 
well as abolishing recall bias when determining exposure or outcomes events. The methods 
employed in the cohort study presented in chapter 5 could be used to conduct such a study. 
However, as there are limited unexposed women compared to parous women, it would not be 
feasible to match two unexposed women to one woman of each parity level. Therefore, age would 
need to be adjusted for in the statistical analysis. The participants could be identified by selecting 
women from the database and then excluding all women with an exclusion code, as outlined in 
chapter 5. 
In a study that utilises EHR, the index date for all participants could be the date of their 15th birthday. 
As the participants would not be matched, therefore the classification of women into parous and 
nulliparous could occur at the end of follow up. Starting follow up from fifteen years of age, allows 
for an accurate measurement of parity for both ever parity and per parity level. The frequency of 
birth/labour codes on a participant’s record could be used to identify the specific parity level. 
Alternatively, the frequency of pregnancy codes could be used to identify parity level, however this 
would be more complicated, as a woman may have several pregnancy codes recorded during one 
pregnancy. Therefore, a gap of time between clusters of pregnancy codes could be set to determine 
that a new pregnancy has begun. For example, a gap of twleve months between pregnancy codes 
could be used to indicate two separate pregnancies. The participants could be followed up for CVD 
outcomes until death, or at least until their 75th birthday. This is currently not feasible in British 
national databases such as CPRD as the duration of records is not long enough. However, as the 
databases continue to record patient data this will be achievable in the future.  
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As socioeconomic status was strongly associated with both high parity and CVD, it would be 
beneficial to conduct an intergenerational study assessing parity and CVD. However, this could not 
be completed within a GP database as it would require information on years of education attained 
and occupation, which are not recorded in GP consultations. The IMD could not be used as an 
indicator of socioeconomic status in this situation as it is dependent on postcode and is therefore 
not specific to different individuals of one family, living in the same neighbourhood. Promisingly, 
this study could be done using the Multigeneration Register for Sweden (Ekbom, 2011) which has 
information on all people born in Sweden from 1932 onwards and has linkage to parental 
information. This would allow the investigation of the effects of childhood socioeconomic status 
and mother’s parity on the relationship with adult socioeconomic status and reproductive patterns. 
 
7.7 Future Implications for Clinical Practice 
This research has identified two implications for future clinical practice. Firstly, grand multiparity is 
a likely risk factor for CVD and should therefore be considered by healthcare professionals when 
evaluating a woman’s CVD risk. Explaining this risk to women may encourage them to engage in 
healthier lifestyle behaviours, for example smoking cessation. If healthcare professionals recognise 
this increased risk, it may also lead to the earlier instigation of medications for primary prevention 
of CVD. This would assist in the reduction of CVD incidence. The inclusion of grand multiparity in a 
risk assessment tool, such as the QRISK3 (Hippisley-Cox, Coupland and Brindle, 2017), which is part 
of the National Institute for Health and Care Excellence (NICE) Guidelines for CVD prevention (NICE, 
2010), would enable healthcare professionals to recognise this increased risk.  However, more 
studies are needed to confirm the increased risk, as the European Society of Cardiology (Piepoli et 
al., 2016) and American Heart Association (Mosca et al., 2011) do not yet recognise grand 
multiparity as risk factor for CVD, and as such do not recommend the consideration of this exposure 
in CVD risk assessment.  
145 
 
Secondly, this thesis has highlighted relevant literature showing that grand multiparity is associated 
with low socioeconomic status, which influences the health and lifestyle of children born to these 
women. Therefore, healthcare professionals should utilise the increased encounters with grand 
multiparous women during pregnancy, to encourage healthier lifestyle behaviours and signpost to 
social support if required. This is in line with the European Society of Cardiology (Piepoli et al., 2016) 
and American Heart Association (Mosca et al., 2011) guidelines on opportunistic screening for CVD 
risk assessment. This advice could improve the CVD risk of these women as well as their children.  
 
7.8 Final Conclusion 
This thesis has highlighted the importance of research into parity as a risk factor for poor health 
and CVD prevention. The research has explored the association of parity with CVD morbidity and 
mortality through a systematic review of the published literature and a cohort study using an EHR 
database. This facilitated an investigation of CVD risk in ever parous women and per parity level, 
compared to nulliparous women. There are complex interactions between parity and biological, 
social and lifestyle factors, which can determine both reproductive patterns and CVD development. 
This research has identified an increased risk of CVD in grand multiparous women, which should be 
considered by healthcare professionals when assessing a woman’s CVD risk and explained to 
patients to encourage healthy lifestyle behaviours. As the current literature presents conflicting 
results for the trend in risk per parity level, more high quality research is needed in this area, to 
establish the relationship between parity and future CVD.  
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Appendix A 
Arthritis Research UK Primary Care Centre 
Systematic Review Protocol & Support Template 
Version 5, last updated 0ctober 2016 
 
Title of the review 
Is Parity a Risk Factor for Cardiovascular Disease: a 
Systematic Review and Meta-Analysis  
First reviewer Ashleigh Woodland (AW) 
Other reviewers (with 
role/contribution in the 
review) 
Dr Pensée Wu (PW) 
Prof Kelvin Jordan 
Clinical Portfolio Group  
Funding source Part of an MPhil project.  
PROSPERO registration 
number 
 
 
Amendments to the 
protocol 
Addition of an exclusion criteria: Exclude studies if the only 
exposure is number of pregnancies (gravidity). 
 
Due to the time restraints of the review PW was unable to 
extract all of the data from the studies as part of the dual 
extraction.  
Change to the process of data extraction: AW will extract 
data from all the studies and PW will extract from 30% of 
the studies to quality assess AW’s extraction. 
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1. Background to review   
Brief introduction to the subject of the review, including rationale for undertaking the 
review and overall aim 
 
It is known that a women’s cardiovascular system undergoes significant changes during 
pregnancy, to support the developing fetus1. These maternal adaptations increase 
cardiac load and have been shown to affect the cardiac function long term2. Based on 
this knowledge, there have been many studies comparing parity and future 
cardiovascular disease (CVD).  A study by Keskin et al2 found that grand multiparous 
women (>5 pregnancies) had significantly reduced left ventricular diastolic function 
when compared to nulliparous women2. A systematic review by Lv et al3 found that 
parity was inversely proportional to CVD risk until a woman’s fourth live birth and with 
every pregnancy after this the risk of CVD increases. However, this study only looked at 
CVD mortality as a whole, rather than the individual diseases which are included within 
the umbrella term of CVD. The study also had significant heterogeneity of results and 
differences based on the country of origin3.  By carrying out a systematic review and 
meta-analysis, we aim to assess the literature to identify if multiparity is an independent 
risk factor for ischaemic heart disease and cerebrovascular disease. This is because 
the two diseases cause the most mortality and morbidity, compared to all other types of 
CVD4.  The results of this study can be used to inform women of their cardiovascular 
risk when discussing family planning and long term health. As well as allowing health 
professionals to consider parity as a risk factor for cardiovascular disease when 
assessing a woman’s future health.  
1. May L. Cardiac Physiology of Pregnancy. Compr Physiol. 2015 Jul 1;5(3):1325-
44.  DOI: 10.1002/cphy.c140043. Review. PubMed PMID: 26140720. 
2. Keskin M, Avşar Ş, Hayıroğlu Mİ, Keskin T, Börklü EB, Kaya A, Uzun AO, Akyol 
B, Güvenç TS, Kozan Ö. Relation of the Number of Parity to Left Ventricular 
Diastolic Function in Pregnancy. Am J Cardiol. 2017 Jul 1;120(1):154-159.  
DOI: 10.1016/j.amjcard.2017.03.244. Epub 2017 Apr 12. PubMed PMID: 
28479168. 
3. Lv, H. et al. Parity and Cardiovascular Disease Mortality: a Dose-Response 
Meta-Analysis of Cohort Studies. Sci. Rep. 5, 13411; doi: 10.1038/srep13411 
(2015) 
4. Newton JN, Briggs ADM, Murray CJL, Dicker D, Foreman KJ, Wang H, et al. 
Changes in health in England, with analysis by English regions and areas of 
deprivation, 1990–2013: a systematic analysis for the Global Burden of Disease 
Study 2013. The Lancet 2015;386(10010):2257-2274. 
2. Specific objectives/questions the review will address 
Is parity an independent risk factor for cardiovascular disease, specifically for coronary 
heart disease and stroke? 
 
At what number of pregnancies is the risk of developing cardiovascular disease the 
highest/lowest? 
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3. a) Eligibility Criteria for including studies in the review  
If the PICOS format does not fit the research question of interest, please split up the 
question into separate concepts and put one under each heading 
i. Population, or participants 
and conditions of interest 
Adult women, aged 15 years and over 
ii. Interventions/Exposure/item 
of interest 
Parity  
iii. Comparisons or control 
groups, if any 
Adult nulliparous women, aged 15 years and 
over 
iv. Outcomes of interest 
 
Morbidity and mortality from coronary heart 
disease (CHD) and stroke 
CHD includes angina, myocardial infarction 
and unclassified CHD 
Stroke includes hemorrhagic and ischaemic 
stroke and transient ischaemic attack 
v. Setting 
No restriction  
vi. Study designs 
Cohort studies and case-control studies 
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3. b) Criteria for excluding studies not covered in inclusion criteria  
Any specific populations excluded, date range, language, whether abstracts or full text 
available, etc 
Exclude studies if they are not case-control or cohort studies. 
Exclude studies where the study participants had cardiovascular disease before 
or during pregnancy and puerperium e.g. pre-existing hypertension or 
pregnancy-induced hypertension.   
Exclude studies if they do not compare multiparous women with nulliparous 
women. Some studies have different groups of patients e.g. 1-2 pregnancies, 3-5 
pregnancies. These studies can be included as long as there is a nulliparous 
group. 
Exclude studies that give composite outcomes for men and women together.  
Exclude a study if the exposure of parity is not analysed separately from other 
exposures.  
Exclude a study if the outcome reporting is not either crude numbers (sufficient 
to calculate risk) or most adjusted results in form of risk ratio, relative risk, 
hazard ratio, odds ratio, etc. 
Exclude a study if the exposure is number of pregnancies (gravidity).  
 
4. Search methods 
Electronic databases 
& websites 
Please list all databases 
that are to be searched 
and include the interface 
(eg NHS HDAS, EBSCO, 
OVID etc) and date ranges 
searched for each. 
 
The databases to be searched are: EMBASE and 
MEDLINE through Ovid and CINAHL through EBSCO. 
 
Articles will be searched from inception of database to 
present. 
 
Other methods used 
for identifying 
relevant research  
ie contacting experts and 
reference checking, 
citation tracking 
The reference lists of included studies will be searched 
for any relevant articles to include. 
 
Journals hand 
searched 
If any are to be hand 
searched, please list which 
journals and date 
searched from, including a 
rationale.  
Due to time restraints of this systematic review, 
journals will not be hand searched. 
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5. Methods of review 
How will search results 
be managed & 
documented? 
ie which reference 
management software, 
how duplicates dealt 
with 
The search results will be exported into Refworks to 
remove the duplicates and be screened by study title. 
The studies which are included after the title screen 
will be exported into Covidence for the abstract and 
full text screening.   
Selection process 
Number of reviewers, 
how agreements to be 
reached and 
disagreements dealt 
with, etc. 
There will be one reviewer AW during the initial 
selection using titles only. Then there will be two 
reviewers AW & PW for the selection using abstracts 
and full text. If there is a disagreement between 
reviewers then a decision will be made based on 
discussion. However, PW will make the final decision. 
Quality assessment 
Tools or checklists 
used with references 
or URLs, was this 
piloted? Is it to be 
carried out at same 
time as data 
extraction? 
The Newcastle- Ottawa Quality Assessment Scale 
(Wells et al., 2014) will be used for quality assessment 
as follows: 
1. Is the exposed population representative of the 
general population. 
2. Is the exposed cohort similar to the non-exposed 
cohort? 
3. How is the exposure ascertained? 
4. Is the outcome of interest present at the beginning 
of the study?  
5. Comparability of cohort?  
6. How reliable is the ascertainment of the outcome? 
7. How long is the follow up? 
8. What is the attrition rate? 
The scale has been used in previous publications by 
PW. The scale has been piloted on several possible 
studies to be included in this review.  
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How is data to be 
extracted? 
What information is to 
be collected on each 
included study? If 
databases or forms on 
Word or Excel are 
used, were these 
piloted and how is this 
recorded and by how 
many reviewers? 
The data to be extracted from each paper will be: 
Main author, year of publication, country of study, 
study design, number of exposure and control 
participants, age range of participants, categories of 
parity, the outcome risk, length of follow up, % 
participants lost to follow up and what confounders the 
results have been adjusted for.  
The outcomes listed below will be extracted from the 
data. The outcome reporting must be either crude 
numbers (sufficient to calculate risk) or most adjusted 
results in form of risk ratio, relative risk, hazard ratio, 
odds ratio, etc. 
The forms which will be used to record the data in 
Excel have been trialled on several studies which may 
be included in this review.  
AW will extract data from all the studies and PW will 
extract from 30% of the studies to quality assess AW’s 
extraction. 
Outcomes to be 
extracted & 
hierarchy/priority 
of measures 
In order of preference:  
Morbidity from CHD and stroke. Meaning receiving a 
diagnosis of either of these diseases. 
Mortality from CHD and stroke. Meaning the cause of 
death being identified as one of these diseases. 
Narrative synthesis 
Details of what 
methods, how 
synthesis will be done 
and by whom. Is the 
Narrative Synthesis 
Framework to be 
used? 
 
We plan to conduct a thorough meta-analysis which 
will be complemented with a brief narrative synthesis. 
We will tabulate the main characteristics of each study 
to begin the synthesis as well as writing an overall 
description of the included studies.  
As we are analysing the results separately for CHD 
and stroke the synthesis will focus on the results of a 
few studies at a time which are all recording the same 
disease outcome. If there are not enough studies 
looking at the same disease outcome then the 
narrative synthesis will describe the cardiovascular 
disease risk as a whole involving all of the studies.  
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Meta-analysis  
Details of what and 
how analysis and 
testing will be done. If 
no meta-analysis is to 
be conducted, please 
give reason. 
We aim to complete a meta-analysis for each disease 
outcome (CHD and stroke). However, if there are not 
enough studies to allow this, we will instead complete a 
meta-analysis for the composite cardiovascular risk 
using all of the outcomes together.  
We will use RevMan version 5.3.5 (Nordic Cochrane 
Center) to conduct random-effects meta-analysis using 
the inverse variance method for pooling log risk ratios. 
We will use random effects because the preliminary 
searches showed studies which were conducted in a 
wide range of settings and in different populations. 
Where possible, we will pool adjusted risk estimates 
from primary studies and if the data is not available, we 
will use raw data to calculate unadjusted risk 
estimates. We will complete a meta-analyses for the 
ever parous versus nulliparous results and the per 
parity level versus nulliparous risk of each disease 
outcome.  
Will the overall strength 
of evidence be assessed? 
If so, how?  
ie GRADE? 
As most of the studies will be cohort or case control 
studies, they will all be observational evidence and of a 
similar strength of evidence using the GRADE score. 
We therefore do not plan to assess the strength of the 
evidence of the included studies.  
 
6. Presentation of results 
Outputs from review  
Papers and target 
journals, conference 
presentations, reports, 
etc 
This systematic review will be forming part of an MPhil 
dissertation.  
The target journal for publication is Circulation: 
Cardiovascular Quality and Outcomes. 
 
7. Timeline for review – when do you aim to complete each stage of the review 
Protocol   
Literature searching 2 weeks 
Quality appraisal 2 weeks 
Data extraction 2 weeks 
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Synthesis 2 months 
Writing up 2 months 
 
Support – please state if advice/training or required at each stage 
SR overview  
Protocol development  
Literature searching Will require assistance with literature search 
Quality appraisal  
Data Extraction  
Synthesis  
Writing up  
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Appendix B 
 
Final Search Strategy: MEDLINE 
 
1 pregnan*  
2 multipar*.ti,ab.  
3 parity.ti,ab.  
4 parous.ti,ab.  
5 Parity/  
6 gravidity.ti,ab.  
7 Gravidity/  
8 live birth*.ti,ab.  
9 or/1-8  
10 angina.ti,ab.  
11 myocardial infarct*.ti,ab.  
12 MI.ti,ab.  
13 (myocard* adj5 isch?emi*).ti,ab.  
14 isch?emic heart disease.ti,ab.  
15 IHD.ti,ab.  
16 heart attack*.ti,ab.  
17 (coronary adj4 disease).ti,ab.  
18 acute coronary syndrom*.ti,ab.  
19 ACS.ti,ab.  
20 exp Myocardial Ischemia/  
21 stroke*.ti,ab.  
22 cerebral infarct*.ti,ab.  
23 cerebrovascular disease.ti,ab.  
24 cerebrovascular accident*.ti,ab.  
25 cerebrovascular event*.ti,ab.  
26 CVA.ti,ab.  
27 exp Stroke/  
28 cardiovascular diseas*.ti,ab.  
29 CVD.ti,ab.  
30 cardiovascular outcome*.ti,ab.  
31 Cardiovascular Diseases/  
32 or/10-31  
33 exp Epidemiology/  
34 exp Epidemiologic Methods/  
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35 epidemiology.fs.  
36 etiology.fs.  
37 risk*.ti,ab.  
38 Risk Factors/  
39 cohort*.ti,ab.  
40 predict*.ti,ab.  
41 or/33-40  
42 9 and 32 and 41  
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Appendix C 
Headings within data extraction table for the cohort studies in the systematic review. 
Study Characteristics 
First Author - Surname, Initial e.g Jones, A 
Year - Year of publication 
Country of Study - Countries where participants were followed up 
Study Design - cohort or case control 
Name of Trial or Cohort - If a cohort e.g. Framingham Heart Study was used to collect data. If 
individual study with no name put N/A 
 
Participant Characteristics 
Total number of participants - If a study included men and women, only give total number of women 
in study 
Number of Exposed Women - Total number of parous women included 
Number of Unexposed Women - Total number of nulliparous women included 
Categories of Parity - What levels of parity are used?   E.g. 1-2,  3-5, >5 etc. 
Number of Participants per Parity Level - Give number of participants per parity level. If not stated in 
paper put ? 
Age of Unexposed - Mean age ± SD nulliparous women 
Age of Exposed - Mean age ± SD parous women 
 
Study Methods & Quality Assessment using Newcastle Ottawa Scale 
Selection of Exposed – How were parous participants selected? 
Representativeness – How representative were the exposed group to the general population? Please 
see extra guidance for NOS 
Exposure Confirmation – How was the level of parity for each participant ascertained? See extra 
guidance for NOS 
Selection of Unexposed – How were nulliparous participants selected? See extra guidance for NOS 
Matching – How were the participants matched? If not matched put N/A if not stated put ? 
Temporality – Was there a demonstration that the outcome of interest was not present at start of 
study?  Yes/No 
Length of Follow Up – How long were the participants followed up for? Cohort studies only 
Adequate Follow Up? – Was follow up long enough for outcomes ot occur?  Yes/No 
Attrition Rate – How many participants were lost to follow up? See extra guidance for NOS 
Outcomes – Give all outcomes recorded in order of priority 
Outcome Definition – What were the definitions of outcomes if stated e.g. mortality or morbidity 
Outcome Confirmation - How was the presence of outcomes confirmed?  See guidance for NOS 
 
Results 
Crude Numbers Exposed – Give crude number of outcomes in parous women. If stated e.g 1/10 that 
developed CVD. Give for each outcome in same order as previously. If not stated put ? 
Crude Numbers Unexposed – Give crude number of outcomes in nulliparous women if stated.  Give 
for each outcome in same order as previously.  If not stated put ? 
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Unadjusted Ratio – Can be risk, hazard or odds ratio. Give for each outcome with 95% confidence 
interval. 
Adjusted Ratio – Can be risk, hazard or odds ratio for each outcome. Give with 95% confidence 
interval. Choose most adjusted result. 
Confounders – Which confounders were adjusted for in the analysis? 
 
Any additional comments about the study which do not fit into these boxes 
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Headings within data extraction table for the case-control studies in the systematic review. 
Study Characteristics 
First Author - Surname, Initial e.g Jones, A 
Year - Year of publication 
Country of Study - Countries where participants were followed up 
Study Design - cohort or case control 
Name of Trial or Cohort - If a cohort e.g. Framingham Heart Study was used to collect data. If 
individual study with no name put N/A 
 
Participant Characteristics 
Total number of participants - If a study included men and women, only give total number of women 
in study 
Number of cases - Total number of cases included 
Number of controls - Total number of controls women included 
Categories of Parity - What levels of parity are used?   E.g. 1-2,  3-5, >5 etc. 
Number of Participants per Parity Level - Give number of participants per parity level. If not stated in 
paper put ? 
Age of Controls - Mean age ± SD  
Age of Cases - Mean age ± SD 
 
Study Methods & Quality Assessment using Newcastle Ottawa Scale 
Outcomes – Give all outcomes recorded in order of priority 
Outcome Definition – What were the definitions of outcomes if stated e.g. mortality or morbidity 
Selection of cases – How were participants selected? 
Outcome Confirmation - How was the presence of outcomes confirmed?  See guidance for NOS 
Representativeness – How representative were the cases to the general population? Please see extra 
guidance for NOS 
Selection of Unexposed – How were controls selected? See extra guidance for NOS 
Matching – How were the controls matched to cases? If not matched put N/A if not stated put ? 
Definition of controls – Were the controls free from the outcomes of interest? See NOS guidance  
Exposure definition – What was the exposure e.g. number of children, number of live births etc. 
Exposure Confirmation – How was the level of parity for each participant ascertained? See extra 
guidance for NOS 
Ascertainment of Exposure – Was the method of exposure ascertainment the same for cases and 
controls. See extra guidance for NOS 
Non-response Rate– How many participants did not respond for exposure ascertainment? See extra 
guidance for NOS 
 
Results 
Crude Numbers Cases – Give crude number of exposed cases out of all cases. If stated e.g 1/10 that 
developed CVD. Give for each outcome in same order as previously. If not stated put ? 
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Crude Numbers Controls– Give crude number of exposed controls out of all controls. If stated.  Give 
for each outcome in same order as previously.  If not stated put ? 
Unadjusted Ratio – Can be risk, hazard or odds ratio for each outcome. Give with 95% confidence 
interval. 
Adjusted Ratio – Can be risk, hazard or odds ratio for each outcome. Give with 95% confidence 
interval. Choose most adjusted result. 
Confounders – Which confounders were adjusted for in the analysis? 
Any additional comments about the study which do not fit into these boxes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
175 
 
Appendix D 
Wells, G. et al. (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised 
studies in meta- analyses, The Ottawa Hospital Research Institute. Available at: 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (Accessed: 28 June 2018). 
NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
CASE CONTROL STUDIES 
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection 
and Exposure categories. A maximum of two stars can be given for Comparability. 
 
Selection 
1) Is the case definition adequate? 
a) yes, with independent validation  
b) yes, eg record linkage or based on self reports 
c) no description 
2) Representativeness of the cases 
a) consecutive or obviously representative series of cases   
b) potential for selection biases or not stated 
3) Selection of Controls 
a) community controls  
b) hospital controls 
c) no description 
4) Definition of Controls 
a) no history of disease (endpoint)  
b) no description of source 
Comparability 
1) Comparability of cases and controls on the basis of the design or analysis 
a) study controls for _______________  (Select the most important factor.)   
b) study controls for any additional factor   (This criteria could be modified to indicate specific                   
control for a second important factor.) 
Exposure 
1) Ascertainment of exposure 
a) secure record (eg surgical records)  
b) structured interview where blind to case/control status  
c) interview not blinded to case/control status 
d) written self report or medical record only 
e) no description 
2) Same method of ascertainment for cases and controls 
a) yes  
b) no 
3) Non-Response rate 
a) same rate for both groups  
b) non respondents described 
c) rate different and no designation 
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NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
COHORT STUDIES 
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection 
and Outcome categories. A maximum of two stars can be given for Comparability 
 
Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average _______________ (describe) in the community   
b) somewhat representative of the average ______________ in the community  
c) selected group of users eg nurses, volunteers 
d) no description of the derivation of the cohort 
2) Selection of the non exposed cohort 
a) drawn from the same community as the exposed cohort  
b) drawn from a different source 
c) no description of the derivation of the non exposed cohort  
3) Ascertainment of exposure 
a) secure record (eg surgical records)  
b) structured interview  
c) written self report 
d) no description 
4) Demonstration that outcome of interest was not present at start of study 
a) yes  
b) no 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for _____________ (select the most important factor)  
b) study controls for any additional factor   (This criteria could be modified to indicate specific                   
control for a second important factor.)  
Outcome 
1) Assessment of outcome  
a) independent blind assessment   
b) record linkage  
c) self report  
d) no description 
2) Was follow-up long enough for outcomes to occur 
a) yes (select an adequate follow up period for outcome of interest)  
b) no 
3) Adequacy of follow up of cohorts 
 a) complete follow up - all subjects accounted for   
b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select an                     
adequate %) follow up, or description provided of those lost)  
c) follow up rate < ____% (select an adequate %) and no description of those lost 
d) no statement 
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Appendix E 
 
Blank table for the quality assessment of cohort studies included in the systematic review, using the Newcastle-Ottawa Scale. 
Study ID: Selection Comparability Exposure 
Surname, 
Year 
Is the case 
definition 
adequate? 
Representa-
tiveness of 
the cases 
Selection 
of controls 
Definition 
of 
controls 
Total 
number 
of Stars 
(max. 4) 
Confounders 
adjusted for in 
the design or 
analysis* 
Total 
number 
of stars 
(max. 2) 
Ascertainment 
of exposure 
Same method 
of 
ascertainment 
for cases and 
controls? 
Non-
response 
rate 
Total 
number 
of stars 
(max. 3) 
 
 
Blank table for the quality assessment of case-control studies included in the systematic review, using the Newcastle-Ottawa Scale.  
Study ID Selection Comparability Outcome 
Surname, 
Year 
Representativen-
ess of the exposed 
cohort 
Selection 
of non-
exposed 
Ascertainment 
of exposure 
Tempora-
lity in 
results 
Total 
number 
of stars 
(max. 4) 
Confounders 
adjusted for 
in analysis 
Total 
number 
of stars 
(max. 2) 
Assessment 
of outcome 
Was 
follow up 
long 
enough? 
Particip-
ants lost 
to follow 
up 
Total 
number 
of stars 
(max. 3) 
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Appendix F 
Highest level exposure Read codes used in cohort study. All daughter codes were included. 
Pregnancy 
 
13H8.00 Illegitimate pregnancy 
13H7 Unwanted pregnancy 
13Hd.00 Teenage pregnancy 
13S..00 Pregnancy benefits 
1541 H/O: stillbirth 
1544 H/O: ectopic pregnancy 
1547 H/O: medical termination of pregnancy 
13SZ.00 PREGNANCY BENEFIT NOS 
2684 O/E - VE - gravid uterus 
14Y0.00 Born by caesarean section 
14Y1.00 Born by forceps delivery 
14Y2.00 Born by elective caesarean section 
14Y3.00 Born by normal vaginal delivery 
14Y4.00 Born by breech delivery 
14Y5.00 Born by ventouse delivery 
14Y6.00 Born by emergency caesarean section 
271.. O/E - gravid uterus size 
2723 O/E - oblique lie 
2724 O/E - transverse lie 
271B.00 O/E - fundal size = dates 
271Z.00 O/E - GRAVID UTERUS SIZE NOS 
2722 O/E - breech presentation 
44Cy Serum pregnancy associated plasma protein-A MoM measurement 
4453 Serum pregnancy test positive 
4654 URINE PREGNANCY TEST POSITIVE 
584.. Fetal U-S scan 
615C.00 IUD failure - pregnant 
615C.11 PREGNANT, IUD FAILURE 
615H.00 Breast feeding problem 
6166 Pregnant, diaphragm failure 
6174 Pregnant, sheath failure 
62… PATIENT PREGNANT 
63… Birth details 
64 Bottle fed at birth 
640 Breast fed at birth 
648..11 Baby length centiles 
6556 Pertussis vaccination in pregnancy 
65560 Pertussis vacc in pregnancy given by other healthcre providr 
66AX.00 Diabetes: shared care in pregnancy - diabetol and obstet 
67A2 Diet in pregnancy advice 
67A3 Pregnancy smoking advice 
180 
 
67A4 Pregnancy exercise advice 
67A5 Pregnancy alcohol advice 
67A6 Drugs in pregnancy advice 
67A7 Pregnancy dental advice 
67AE Folic acid advice in first trimester of pregnancy 
67B..00 Ante-natal relaxation classes 
7F… Obstetric operations 
7N61100 [SO]Gravid uterus 
7N61111 [SO]Delivered uterus 
7N61200 [SO]Fetus 
7N61300 [SO]Placenta 
7N61400 [SO]Amniotic membrane 
851..00 Haemorrhage control by packing 
851Z.00 Haemorr. control by pack NOS 
8B68.00 Pregnancy prophylactic therapy 
8B7..11 Pregnancy vitamin/iron prophyl 
8B74.00 IRON SUPPLEMENT IN PREGNANCY 
8HHf Refer to early pregnancy unit 
8IEc Pertussis vaccination in pregnancy declined 
8B75.00 Vitamin supplement - pregnancy 
8M6..00 REQUESTS PREGNANCY TERMINATION 
942 Medical cert. of still-birth 
9Ea0.00 Risk life pregnant woman greater than if pregnancy terminatd 
9G7 Notification of birth 
9kv Pertussis vaccinatn progrme pregnant women enhan srvce admin 
9mK Pertussis vaccination in pregnancy invitation 
9mK0 Pertussis vaccination in pregnancy invitation first letter 
9mK1 Pertussis vaccination in pregnancy invitation second letter 
9mK2 Pertussis vaccination in pregnancy invitation third letter 
9Nif Did not attend pertussis vaccination in pregnancy 
9NkN Seen in early pregnancy unit 
H472.00 Asp pneumonitis due to anaesthesia during labour and deliv 
L.... COMPLICATIONS OF PREGNANCY, CHILDBIRTH AND THE 
PUERPERIUM 
L030000 Delivery of viable fetus in abdominal pregnancy 
L08.. Failed attempted abortion 
L0A.. Failed attempted abortion 
L1… PREGNANCY COMPLICATIONS 
L2… RISK FACTORS IN PREGNANCY 
L3… Complications occurring during labour and delivery 
L4… Complications of the puerperium 
L5… Maternal care for fetus 
Ly… COMPLICATIONS OF PREGNANCY,CHILDBIRTH OR THE 
PUERPERIUM OS 
Lz… Complications of pregnancy,childbirth and the puerperium NOS 
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M240500 ALOPECIA OF PREGNANCY 
M290300 CHLOASMA GRAVIDARUM 
Q01..00 Fetus/neonate affected by maternal complication of pregnancy 
Q021.00 Fetus/neonate affect other placental separation/haemorrhage 
Q022200 Fetus or neonate affected by placental insufficiency 
Q030.00 Fetus or neonate affected by breech delivery and extraction 
Q030.11 Fetus affected by breech delivery 
Q031.00 Fetus/neonate affected by malposition/disproportion-delivery 
Q031.11 Fetus affected by malpresentation during delivery 
Q031400 Fetus or neonate affected by transverse lie in labour/deliv 
Q031y00 Fetus/neonate affected malpos/malpres/disprop - lab/deliv OS 
Q032.00 Fetus or neonate affected by forceps delivery 
Q033.00 Fetus or neonate affected by vacuum extraction delivery 
Q034.00 Fetus or neonate affected by caesarean section 
Q100.00 Fetus small-for-dates, without mention of malnutrition 
Q100.11 Fetus small-for-dates (SFD), without mention of malnutrition 
Q101.00 Fetus small-for-dates with signs of malnutrition 
Q101.11 Fetus small-for-dates (SFD) with signs of malnutrition 
Q10z.00 Fetal growth retardation NOS 
Q10z.11 Intrauterine growth retardation 
Q11.. Short gestation and unspecified low birthweight problems 
Q12.. Disorders relating to long gestation and high birthweight 
Q13.. Light for gestational age 
Q212.00 Liveborn with prelabour fetal distress 
Q213.00 Liveborn with labour fetal distress 
Q214.00 Liveborn with fetal distress, unspecified 
Q21z.00 Liveborn with birth asphyxia NOS 
Q432.00 Preterm delivery associated jaundice 
Q44..00 Perinatal endocrine and metabolic problems 
Q44z.00 Perinatal endocrine or metabolic problem NOS 
Q48D [X] Stillbirth 
Q4z-5 Stillbirth NEC 
Qyu1000 [X]Other low birth weight 
Qyu1100 [X]Other preterm infants 
Qyu1200 heavy for gestational age infants 
Z1H4.00 Pain relief in labour 
Z2… Pregnancy, childbirth and puerperium observations 
ZC2CB00 Dietary advice for gestational diabetes 
ZV13900 [V]PH comp of pregnancy, childbirth and the puerperium 
ZV22.00 [V]Normal pregnancy 
ZV23.00 [V]High-risk pregnancy supervision 
ZV24000 [V]Examination immediately after delivery 
ZV27.00 [V]Outcome of delivery 
ZV3..00 [V]Healthy liveborn infants according to type of birth 
ZV4J000 [V]PROBLEMS RELATED TO UNWANTED PREGNANCY 
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ZV61800 [V]ILLEGITIMATE PREGNANCY 
ZV61900 [V]Other unwanted pregnancy 
ZVu2300 [X]Supervision of other normal pregnancy 
ZVu2400 [X]Supervision of preg with oth poor reprod obstet history 
ZVu2500 [X]Supervision of other high-risk pregnancies 
DEGRADE_EVENT_1730_
48 
Patient pregnant 
EMISREQ|4654 Urine pregnancy test positive 
EMISREQ|62 Patient pregnant 
L04.. Spontaneous abortion 
L04..11 Miscarriage 
1542 H/O: miscarriage 
L02..00 Missed Abortion 
L02..11 Missed Miscarriage 
L02..12 Silent Miscarriage 
6755 Post miscarriage counseling 
L044..00 Inevitable abortion incomplete 
L044..11 Inevitable miscarriage incomplete 
L045..00 Inevitable abortion complete 
L045..11 Inevitable miscarriage complete 
L043..00 Inevitable abortion unspecified 
L043..11 Inevitable miscarriage unspecified 
1543 H/O: abortion 
1543..11 H/O: termination 
L0312 Tubal abortion 
L07..00 Unspecified abortion 
6776 Preg. termination counselling 
6776..11 Abortion counselling 
6776..13 Termination counselling 
6776..12 TOP counselling 
L05..00 Legally induced abortion 
L05..11 Elective abortion 
L05..13 Therapeutic abortion 
L05..12 Termination of pregnancy 
L06..00 Illegally induced abortion 
L06..11 Criminal abortion 
L06..12 Self-induced abortion 
956..00 HSA1-therap. abort. green form 
L097.00 Readmission for abortive pregnancy (NHS Codes) 
L097.11 Readmission for retained products of conception 
7E08800 Dilation andf curettage removal of missed abortion 
L09..00 Complications following abortion and ectopic and molar 
pregnancies 
L09..11 Complications following abortion and ectopic and molar 
pregnancies 
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8Cg..00 Pregnancy termination care 
7E086.00 Termination of pregnancy NEC 
8M6..00 Requests pregnancy termination 
7E08400 Suction termination of pregnancy 
7E08411 Vacuum termination of pregnancy 
9Ea.00 Reason for termiantion of pregnancy 
L051700 Incomplete medical abortion 
L051711 Incomplete termination of pregnancy 
8HHV.00 Referral for termination of pregnancy 
389B.00 Assessment for termination of pregnancy 
7E06600 Hysterotomy and termination of pregnancy 
8Hh3.00 Self referral to termination of pregnancy service 
7E07100 Curettage of products of conception from uterus 
7E07111 Curettage of term pregnancy NEC 
7E07112 Curettage of retained products of conception 
7E07113 Curettage of uterus for termination of pregnancy 
7E07114 Curettage of uterus for termination of pregnancy NEC 
Q48G.00 Complication of termination of pregnancy, affecting fetus newborn 
7E08500 Dilation of cervix and extraction termination of pregnancy 
7E07000 Dilation of cervix uteri and curettage for termination of pregnancy 
7E07011 Dilation of cervix uteri and curettage for termination of pregnancy 
7E07012 Dilation cerv & curettage RPC 
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Appendix G 
Highest level outcome Read codes used in cohort study. All daughter codes were included. 
Myocardial Infarction  
G30.. Acute myocardial infarction 
G35.. Subsequent myocardial infarction 
G36.. Certain current complications following acute myocardial infarction 
G38.. Postoperative myocardial infarction 
G501. Post infarction pericarditis 
323.. ECG: myocardial infarction (excl. 3231. ECG: no myocardial infarction & 3232. ECG: 
old myocardial infarction) 
889A. Diabetes mellitus insulin-glucose infusion in acute myocardial infarction 
G3115 Acute coronary syndrome 
G31y1 Microinfarction of heart 
G344.00 Silent myocardial infarction 
Gyu34 [X]Acute transmural myocardial infarction of unspecified site 
Gyu35 [X]Subsequent myocardial infarction of other sites 
Gyu36 [X]Subsequent myocardial infarction of unspecified site 
G32.. Old myocardial infarction 
322.. ECG: myocardial ischaemia   
Stroke (or just use G6… Cerebrovascular disease plus non G6 codes below) 
G61.. Intracerebral haemorrhage 
G610. Cortical haemorrhage 
G611. Internal capsule haemorrhage 
G612. Basal nucleus haemorrhage 
G613. Cerebellar haemorrhage 
G614. Pontine haemorrhage 
G615. Bulbar haemorrhage 
G616. External capsule haemorrhage 
G617. Intracerebral haemorrhage, intraventricular 
G618. Intracerebral haemorrhage, multiple localized 
G61X. Intracerebral haemorrhage in hemisphere, unspecified 
G61X0 Left sided intracerebral haemorrhage, unspecified 
G61X1 Right sided intracerebral haemorrhage, unspecified 
G61z. Intracerebral haemorrhage NOS  
G63y1 Cerebral infarction due to embolism of precerebral arteries 
G64z. Cerebral infarction NOS 
G64z0 Brainstem infarction 
G64z1 Wallenberg syndrome 
G64z2 Left sided cerebral infarction 
G64z3 Right sided cerebral infarction 
G64z4 Infarction of basal ganglia 
G66.. Stroke and cerebrovascular accident unspecified 
G660. Middle cerebral artery syndrome 
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G661. Anterior cerebral artery syndrome 
G662. Posterior cerebral artery syndrome 
G663. Brain stem stroke syndrome 
G664. Cerebellar stroke syndrome 
G665. Pure motor lacunar syndrome 
G666. Pure sensory lacunar syndrome 
G667. Left sided CVA 
G668. Right sided CVA 
G677. Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction 
G6770 Occlusion and stenosis of middle cerebral artery 
G6771 Occlusion and stenosis of anterior cerebral artery 
G6772 Occlusion and stenosis of posterior cerebral artery 
G6773 Occlusion and stenosis of cerebellar arteries 
G6774 Occlusion and stenosis of multiple and bilateral cerebral arteries 
G683. Sequelae of cerebral infarction 
G6W.. Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries 
G6X.. Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries 
G6z.. Cerebrovascular disease NOS 
G63y0 Cerebral infarct due to thrombosis of precerebral arteries 
Gyu6. [X]Cerebrovascular diseases 
G60.. Subarachnoid haemorrhage 
G68.. Late effects of cerebrovascular disease 
1M4.. Central post-stroke pain 
E0324 Acute confusional state; of cerebrovascular origin 
E0334 Subacute confusional state; of cerebrovascular origin   
Hypertensive disease 
G2... Hypertensive disease 
662P0 Hypertension 9 month review 
9OI.. Hypertension monitoring admin.   
Angina 
 
662K. Angina control 
G31.. Other acute and subacute IHD 
G3111 Unstable angina 
G3112 Angina at rest 
G3113 Refractory angina 
G3114 Worsening angina 
G33.. Angina pectoris   
Heart failure 
G58.. Heart failure 
1O1.. Heart failure confirmed 
8B29. Cardiac failure therapy 
8CeC. Preferred place of care for next exacerbation heart failure 
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8CL3. Heart failure care plan discussed with patient 
8CMK. Has heart failure management plan 
8CMW8 Heart failure clinical pathway 
8H2S. Admit heart failure emergency 
G5yy9 Left ventricular systolic dysfunction 
G5yyA Left ventricular diastolic dysfunction 
585f. Echocardiogram shows left ventricular systolic dysfunction 
585g. Echocardiogram shows left ventricular diastolic dysfunction   
Ischaemic Heart Disease 
G3… Ischaemic heart disease 
G34.. Other chronic IHD 
Gyu3 [X]Ischaemic heart diseases   
Other Heart disease (not included elsewhere) OR broad G…. Circulatory disease 
G5… Other forms of heart disease 
G7… Arterial, arteriole and capillary disease 
G8… Vein, lymphatic and circulatory diseases NOS 
Gyu7. [X]Diseases of arteries, arterioles and capillaries   
Procedures 
7A4.. Iliac and femoral artery operations 
7A1.. Aorta operations 
792 Coronary artery operations 
79... Heart operations 
7A... Artery and vein operations   
Hypercholesterolaemia: 
Xa9As Hypercholesterolaemia 
X40Wz Primary Hypercholesterolaemia 
XaYQB Dietary surveillance in hypercholesterolaemia 
X40X6 Secondary hypercholesterolaemia 
X40X0 Polygenic hypercholesterolaemia 
XaX3u Possible familial hypercholesterolaemia 
C320y Other specified pure hypercholesterolaemia 
  
Type 2 Diabetes Mellitus 
C10 Diabetes 
66A.. Diabetes monitoring 
9OL.. Diabetes monitoring admin. 
1434 H/O Diabetes Mellitus 
6872 Diabetes mellitus screen 
9NM0. Attending diabetes clinic 
XaZq8 Pre-diabetes 
R102. Glucose tolerance test abnormal 
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Appendix H 
All Read codes for confounders in the cohort study. 
Smoking  
137..00 Tobacco consumption 
137..11 Smoker - amount smoked 
1372 Trivial smoker - < 1 cig/day 
1372.11 Occasional smoker 
1373 Light smoker - 1-9 cigs/day 
1374 Moderate smoker - 10-19 cigs/d 
1375 Heavy smoker - 20-39 cigs/day 
1376 Very heavy smoker - 40+cigs/d 
1377 Ex-trivial smoker (<1/day) 
1378 Ex-light smoker (1-9/day) 
1379 Ex-moderate smoker (10-19/day) 
137a.00 Pipe tobacco consumption 
137b.00 Ready to stop smoking 
137c.00 Thinking about stopping smoking 
137d.00 Not interested in stopping smoking 
137e.00 Smoking restarted 
137F.00 Ex-smoker - amount unknown 
137G.00 Trying to give up smoking 
137H.00 Pipe smoker 
137I.00 Passive smoker 
137j.00 Ex-cigarette smoker 
137K.00 Stopped smoking 
137K000 Recently stopped smoking 
137l.00 Ex roll-up cigarette smoker 
137m.00 Failed attempt to stop smoking 
137N.00 Ex pipe smoker 
137O.00 Ex cigar smoker 
137P.00 Cigarette smoker 
137P.11 Smoker 
137Q.00 Smoking started 
137Q.11 Smoking restarted 
137R.00 Current smoker 
137S.00 Ex smoker 
137T.00 Date ceased smoking 
137V.00 Smoking reduced 
137W.00 Chews tobacco 
137X.00 Cigarette consumption 
137Y.00 Cigar consumption 
137Z.00 Tobacco consumption NOS 
8CAL.00 Smoking cessation advice 
8H7i.00 Referral to smoking cessation advisor 
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8HkQ.00 Referral to NHS stop smoking service 
8HTK.00 Referral to stop-smoking clinic 
8IAj.00 Smoking cessation advice declined 
9km..00 Ex-smoker annual review - enhanced services administration 
9km..11 Ex-smoker annual review 
9ko..00 Current smoker annual review - enhanced services admin 
9ko..11 Current smoker annual review 
9NS0200 Referral for smoking cessation service offered 
13p..00 Smoking cessation milestones 
13p0.00 Negotiated date for cessation of smoking 
13p1.00 Smoking status at 4 weeks 
13p2.00 Smoking status between 4 and 52 weeks 
13p3.00 Smoking status at 52 weeks 
13p4.00 Smoking free weeks 
13p5.00 Smoking cessation programme start date 
13p5000 Practice based smoking cessation programme start date 
13p6.00 Carbon monoxide reading at 4 weeks 
13p7.00 Smoking status at 12 weeks 
13p8.00 Lost to smoking cessation follow-up 
38DH.00 Fagerstrom test for nicotine dependence 
6791 Health ed. - smoking 
67H6.00 Brief intervention for smoking cessation 
745H.00 Smoking cessation therapy 
745H000 Nicotine replacement therapy using nicotine patches 
745H100 Nicotine replacement therapy using nicotine gum 
745H200 Nicotine replacement therapy using nicotine inhalator 
745H300 Nicotine replacement therapy using nicotine lozenges 
745H400 Smoking cessation drug therapy 
745Hy00 Other specified smoking cessation therapy 
745Hz00 Smoking cessation therapy NOS 
8B2B.00 Nicotine replacement therapy 
8B3f.00 Nicotine replacement therapy provided free 
8B3Y.00 Over the counter nicotine replacement therapy 
8BP3.00 Nicotine replacement therapy provided by community pharmacis 
8CAg.00 Smoking cessation advice provided by community pharmacist 
8CdB.00 Stop smoking service opportunity signposted 
8HBM.00 Stop smoking face to face follow-up 
8HBP.00 Smoking cessation 12 week follow-up 
8I2I.00 Nicotine replacement therapy contraindicated 
8I2J.00 Bupropion contraindicated 
9N2k.00 Seen by smoking cessation advisor 
E023.00 Nicotine withdrawal 
E251.00 Tobacco dependence 
E251000 Tobacco dependence; unspecified 
E251100 Tobacco dependence; continuous 
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E251300 Tobacco dependence in remission 
E251z00 Tobacco dependence NOS 
ZG23300 Advice on smoking 
ZRaM.00 Motives for smoking scale 
ZRao.00 Occasions for smoking scale 
ZRBm200 Fagerstrom test for nicotine dependence 
ZRBm211 FTND - Fagerstrom test for nicotine dependence 
ZRh4.00 Reasons for smoking scale 
ZRh4.11 RFS - Reasons for smoking scale 
ZV11600 [V]Personal history of tobacco abuse 
ZV4K000 [V]Tobacco use 
ZV6D800 [V]Tobacco abuse counselling 
Body Mass Index 
22A..00 O/E - weight 
22A1.00 O/E - weight > 20% below ideal 
22A2.00 O/E -weight 10-20% below ideal 
22A3.00 O/E - weight within 10% ideal 
22A4.00 O/E - weight 10-20% over ideal 
22A4.11 O/E - overweight 
22A5.00 O/E - weight > 20% over ideal 
22A5.11 O/E - obese 
22A6.00 O/E - Underweight 
22K..00 Body Mass Index 
22K1.00 Body Mass Index normal K/M2 
22K2.00 Body Mass Index high K/M2 
22K3.00 Body Mass Index low K/M2 
22K4.00 Body mass index index 25-29 - overweight 
22K5.00 Body mass index 30+ - obesity 
22K6.00 Body mass index less than 20 
22K7.00 Body mass index 40+ - severely obese 
22K8.00 Body mass index 20-24 - normal 
22Z..00 Height and Weight 
229.. Height 
 
